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Background: Atopic dermatitis (AD) is a common chronic inflammatory skin 
disease, which significantly impairs patients’ quality of life. A typical AD feature 
is colonisation and infection of the skin with Staphylococcus aureus, which 
leads to loss of commensal staphylococci (Staphylococcus epidermidis) from 
the skin. Although S. epidermidis and S. aureus have many similarities, S. 
aureus is a major cause of skin infections, unlike S. epidermidis, which is 
abundant in normal skin. The balance between S. epidermidis and S. aureus 
is disturbed in AD and there is increasing evidence that microbial dysbiosis is 
associated with AD pathogenesis. 
Hypothesis: Skin cells respond differently to commensal staphylococci (S. 
epidermidis) and bacteria associated with skin infections, such as S. aureus. 
Results: Cell-suspensions and filter-sterilised supernatants of most S. aureus 
strains induced human-beta-defensin (HBD)-3 production in cultured 
keratinocytes and skin equivalents, measured by enzyme-linked 
immunosorbent assay (ELISA), whereas S. epidermidis and a minority of S. 
aureus strains did not. The S. aureus factor(s) responsible for the HBD-3 
induction were found to be heat-stable and likely proteinaceous. Candidate S. 
aureus proteins were identified using ion-exchange chromatography and 
mass spectrometry and their HBD-3-inducing capacity was tested. Phenotypic 
characterisation indicated compounds that may favour S. epidermidis over S. 
aureus growth. 
Discussion: S. epidermidis and S. aureus have a different effect on HBD-3 
induction in keratinocytes. This suggests that the skin has evolved an effective 
defence strategy against S. aureus (HBD-3 production) and a means of 
triggering this response specifically to non-commensal staphylococci by 
detecting a cell component unique to S. aureus. AD patients have increased 
susceptibility to S. aureus infection. If disruption of the skin microbial balance 
is proven to be able to trigger AD, or if restoration of skin flora can resolve AD, 
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The chapters of this thesis describe the background, the methods and the 
experiments performed in order to study the effects of S. aureus and S. 
epidermidis on keratinocytes, with a view to understanding AD. Based on the 
results from the experimental work, this thesis draws conclusions and makes 
suggestions for future work. 
Chapter 1 (Introduction) describes AD and summarises the key points relevant 
to this project, as well as the project aims and achievements. 
Chapter 2 (Materials and methods) lists the bacterial strains, skin cells and 
compounds used in the project, as well as the experimental approaches that 
were taken. 
Chapter 3 (Production of AMPs in keratinocytes in response to S. aureus and 
S. epidermidis) reports on differences in the effects of S. aureus and S. 
epidermidis on the production of AMPs by keratinocytes. 
Chapter 4 [Nature of the S. aureus HBD-3-inducing factor(s)] describes 
experimental approaches used in an attempt to identify S. aureus factor(s) 
that could potentially account for the induction of HBD-3 in keratinocytes. 
Chapter 5 (Defining conditions to rectify staphylococcal dysbiosis: a 
preliminary evaluation of differing growth requirements for S. aureus and S. 
epidermidis) aims to identify conditions that favour the growth of S. 
epidermidis over S. aureus. 
Chapter 6 (Conclusions) summarises the conclusions drawn from the 
experiments performed in this project and makes suggestions for future 
experimental work, in order to better understand the role of skin microbiome 
and S. aureus in the pathogenesis of AD.  
Chapter 7 (References) lists the citations mentioned throughout this thesis. 
Chapter 8 (Appendices and supplemental material) includes additional 





1.1. The skin 
Human skin is exposed to the environment and represents a barrier organ with 
an important defence role against external pathogens (Boer et al., 2016). It 
has antimicrobial, antioxidant and mechanical functions and it also controls 
permeability of molecules and skin hydration (Elias, 2008). It consists of three 
layers: the epidermis, the dermis and the hypodermis (Yousef et al., 2019). 
The layers of the epidermis, starting from the outermost, are the stratum 
corneum, stratum lucidum (only in palms and soles), stratum granulosum, 
stratum spinosum and stratum basale (Figure 1-1) (Yousef et al., 2019). More 
than 90% of epidermal cells are keratinocytes (Eckhart et al., 2013). They are 
the main cells of the skin barrier and also participate in immune defence 
(Eyerich et al., 2018; Coates et al., 2018). The epidermis also contains 
melanocytes, Langerhans cells and Merkel cells (Figure 1-1) (Proksch et al., 
2008; Elias, 2007; Lim et al., 2013; Gilbert, 2000; James et al., 2005; Eady 
and Pope, 2004; Yousef et al., 2019). 
Keratinocytes of the stratum basale migrate and differentiate to form the other 
epidermal layers. During keratinocyte differentiation, keratinocyte stem cells 
in the stratum basale, which are attached to the basement membrane 
(extracellular matrix), produce transient amplifying suprabasal cells not 
attached to the membrane (Pincelli and Marconi, 2010; Dahl, 2012; Jones and 
Watt, 1993). These cells exit the cell cycle and start to migrate towards the 
upper epidermal layers (Simpson et al., 2011). Keratinocytes in the stratum 
spinosum are polyhedral with large nuclei. Langerhans cells, polar lipids, 
glycosphingolipids, free sterols, phospholipids and catabolic enzymes are 
also found in the stratum spinosum. Keratinocytes are attached together with 
desmosomes in both the stratum basale and spinosum (Mauldin and Peters-
Kennedy, 2016; Yousef et al., 2019). Keratin filaments anchor the 
keratinocytes to the desmosomes and provide mechanical strength. Keratins 
5 and 14 expressed in the stratum basale are replaced by keratins 1 and 10 
in the stratum spinosum (Fuchs, 1993). Keratinocytes in the stratum 




profilaggrin and loricrin. Filaggrin induces aggregation of keratin and formation 
of a cornified cell envelope underneath the plasma membrane (Candi et al., 
2005). Lipids accumulate inside lamellar bodies (Wikramanayake et al., 2014). 
Tight junction proteins (e.g. claudins and occludins) form a barrier between 
keratinocytes in the stratum granulosum and regulate the passage of solutes 
(Mauldin and Peters-Kennedy, 2016; Gonzalezmariscal, 2003; Anderson and 
Van Itallie, 2009; Brandner et al., 2015). During terminal differentiation, 
keratinocytes turn into corneocytes, when their nucleus, plasma membrane 
and cellular organelles disintegrate (Eckhart et al., 2013). Transglutaminase, 
which is calcium-activated, links involucrin, loricrin and small proline-rich 
proteins in an insoluble cell envelope (Candi et al., 2001), whereas the polar 
lipids of keratinocytes are converted into non-polar molecules, forming a lipid 
barrier (ceramides and fatty acids) around corneocytes (Elias, 1983; Kalinin 
et al., 2002). Therefore, the stratum corneum consists of anucleate 
corneocytes attached together with corneodesmosomes and surrounded by a 
cornified envelope, water-retaining keratin proteins and lipid layers. 
Corneocytes produce lamellar bodies, which secrete AMPs, fatty acids, 
cholesterol, sphingosine and ceramides and form the lipid matrix and 
proteases (Mauldin and Peters-Kennedy, 2016; Coates et al., 2014). Finally, 
during desquamation, the outermost corneocytes are shed (Wikramanayake 
et al., 2014). The stratum corneum is the outermost skin barrier, whereas tight 
junctions seal adjacent keratinocytes in the stratum granulosum, providing a 






Figure 1-1: The layers of the human epidermis 
The picture shows the epidermal layers, their components and the direction of cell 
migration [image from (Coates et al., 2014)]. 
 
The dermis, located between the epidermis and the hypodermis, consists of 
the papillary (outermost) and the reticular (inner) layers and it is composed of 
mesenchymal cells that produce the extracellular matrix (collagen, elastic 
fibres), as well as hair follicles, glands, vessels, macrophages, dendritic cells, 
mast cells and lymphocytes (Eady and Pope, 2004; Marks and Miller, 2006; 
James et al., 2005). 
The hypodermis consists mainly of adipose cells, which provide insulation and 
mechanical protection to the underlying tissues and organs (Suarato et al., 
2018; Gurtner et al., 2008; Ahn and Kaptchuk, 2011). 
Pigmented skin shows structural differences compared to white skin. The 
concentration of melanin in pigmented skin melanosomes is twice as high as 
in white skin. Darker skin also has large melanosomes that contain more 
melanin and have a lower degradation rate. Melanin content offers protection 
against ultraviolet (UV) radiation and skin aging (Iozumi et al., 1993; Vashi et 
al., 2016). Although the thickness of the stratum corneum is similar in both 




layers and is more compact against mechanical and chemical challenge 
(Rawlings, 2006). Moreover, its spontaneous desquamation is 2.5 times 
greater compared to white skin, due to a difference in the composition of the 
intercellular lipids. Pigmented skin has lower levels of ceramides, which are 
important for skin moisturisation and may explain the fact that water loss in 
pigmented skin is up to 2.7 times greater compared to white skin, leading to 
increased skin dryness (Berardesca and Maibach, 1988; Wan et al., 2014; 
Coderch et al., 2003; Sugino et al., 1993; Richards et al., 2003). 
 
 
1.2. Atopic dermatitis: general background 
Atopic dermatitis (AD) is an inflammatory skin disease, characterised by 
immune system dysregulation and an impaired skin barrier. The prevalence 
of AD is rising, affecting the quality of life of more than 20% of children and 
around 3-10% of adults worldwide (Kolb and Ferrer-Bruker, 2019; Nutten, 
2015; Leung and Bieber, 2003). Genetic predisposition and environmental 
factors can both affect the initiation and course of AD (Thomsen, 2014), which 
is characterised by periods of relapses and remissions. Acute AD usually 
presents with lesions characterised by erythema, oozing, excoriation and 
oedema due to the formation of papules and vesicles. In chronic AD, the 
lesions can also be pigmented and lichenified (Figure 1-2) (Leung and Bieber, 
2003; Thomsen, 2014; Correale et al., 1999; Bieber, 2010). A hallmark of AD 
is intense pruritus, which can result in excoriations, impairment of the skin 
barrier integrity and infections. Pruritus can cause sleep loss and, along with 
skin lesions, it can lead to significant psychosocial conditions (Nutten, 2015; 
Absolon et al., 2003; Barnetson and Rogers, 2002; Leung and Bieber, 2003; 





(a)   (b)  
Figure 1-2: Skin lesions in AD  
Erythema, oedema, excoriation and vesicles are usually present from the acute stage 
of AD (a). In subacute and chronic AD, lichenification and hyperpigmentation can also 
appear (b) (Thomsen, 2014; Correale et al., 1999; Bieber, 2010) [images a and b 
adapted from (iStock.com/defun) and (Bridgett et al., 1996) respectively]. 
 
The diagnosis of AD is mainly clinical and largely based on the Hanifin-Rajka 
diagnostic criteria that have been used worldwide in clinical trials and in the 
diagnosis of AD (Hanifin and Rajka, 1980; Lee, 2016; Schram et al., 2011). 
AD is a chronic condition and to date no permanent cure has been found; the 
available therapeutic approaches focus on the control of symptoms and 
infections and avoidance of potential triggering factors. The mainstay of 
treatment is application of moisturisers and topical glucocorticosteroids 
(Yarbrough et al., 2013; Leung, 2003; Van Zuuren et al., 2017). Emollients 
improve skin moisturisation and skin barrier integrity (Giam et al., 2016; Hon 
and Leung, 2013; Hon et al., 2013; Varothai et al., 2013). Topical anti-
inflammatory agents such as calcineurin inhibitors (tacrolimus, pimecrolimus) 
and corticosteroids (hydrocortisone) inhibit mediator release from skin-
resident and skin-infiltrating cells, such as T-cells (Carr, 2013; Stuetz et al., 
2006; Norris, 2005; Atherton, 2003). Systemic treatments include oral 
glucocorticosteroids (prednisolone) and immunomodulatory drugs 
(calcineurin inhibitors, methotrexate) (Simon and Bieber, 2014; Megna et al., 
2016). The use of biologic drugs, such as the monoclonal antibody dupilumab 
that binds to the IL-4 receptor-α and inhibits IL-4 and IL-13 signalling, is a 
promising and more disease-specific approach (Megna et al., 2016). In 
chronic AD, UV therapy can be beneficial (Majoie et al., 2009). Finally, 
antibiotics are often prescribed against infection. Although they have 
significant short-term benefits (Wohl et al., 2015), they are not recommended 




the development of antibiotic-resistant strains (Błażewicz et al., 2017; Gilani 
et al., 2005; Friedman and Goldman, 2011; Rayner and Munckhof, 2005; 
Chambers and Deleo, 2009; Dethlefsen et al., 2008; Cogen et al., 2008; 
Kobayashi et al., 2015). 
 
 
1.3. Atopic dermatitis: pathogenesis 
Genetic predisposition, environmental factors, skin barrier dysfunction and 
alterations in the immune response have been implicated in the pathogenesis 
of AD (McPherson, 2016; Thomsen, 2014). The skin microbiome has also 
been show to play a role (Lebwohl et al., 2013; Baker, 2006; Salava and 
Lauerma, 2014), although the pathway of transition from the normal skin flora 
to a microbial imbalance and its effect on AD pathogenesis is not yet fully 
elucidated (Yamazaki et al., 2017; Paller et al., 2019). These factors will be 
analysed in more detail in the following sections. 
 
1.3.1. Genetic factors of AD 
As regards genetic background, the association of AD with various single 
nucleotide polymorphisms and gene mutations has been studied. Filaggrin is 
an important structural protein of the skin, with filaggrin mutations significantly 
affecting skin barrier integrity and hydration and increasing the risk of 
developing AD (O'Regan et al., 2008; Zaniboni et al., 2016; Leung, 2013; 
Palmer et al., 2006; Janssens et al., 2012; Elias et al., 2008; Milani, 2016). Up 
to 50% of AD patients carry filaggrin null mutations (Brown and Irwin-Mclean, 
2009). The R510X and 2282del4 filaggrin null mutations, found in 9% of the 
European population, highly predispose to AD (Palmer et al., 2006), whereas 
filaggrin gene mutations in pigmented skin are 6 times less common 
compared to white skin (Brunner and Guttman-Yassky, 2019). The 
high-affinity immunoglobulin E receptor (FcεRI) is expressed mostly in 
dendritic and mast cells (Park et al., 2011). Polymorphisms in the β chain of 




degranulation (Cookson and Moffatt, 2002). The serine protease inhibitor 
Kazal-type 5 (SPINK5) gene regulates skin barrier formation. Mutations in the 
SPINK5 gene leading to premature termination codons are found in 
Netherton’s disease, which is characterised by severe AD lesions and 
increased immunoglobulin (Ig) E serum levels (Agarwal et al., 2014; Tartaglia-
Polcini et al., 2006; Bitoun et al., 2002). A functional mutation of the “regulated 
on activation normal T-cell expressed and secreted” (RANTES/CCL5) gene 
has been associated with AD, leading to increased gene expression and 
chemokine-induced eosinophil migration (Kato et al., 2006; Nickel et al., 
2000). Furthermore, interleukin (IL)-4 and IL-13 act through their receptors 
IL-4R and IL-13R, which both have the IL-4Rα chain and activate the factor 
“signal transducer and activator of transcription 6” (STAT6), leading to 
production of T-helper (Th) 2 cytokines and IgE. Previous studies report an 
association between nucleotide polymorphisms that can alter their expression 
levels and AD. Two single nucleotide polymorphisms in the IL-13 gene 
(rs3091307 and rs20541) and two in the IL-13Rα1 receptor (rs2265753 and 
rs2254672) are associated with AD (Namkung et al., 2011; Leung et al., 2003; 
Shirakawa et al., 2000). Lastly, mutations of the genes encoding toll-like 
receptor (TLR) 2 and nucleotide-binding oligomerisation domain (NOD) 2 can 
increase AD severity (Ahmad-Nejad et al., 2004; Jiao et al., 2015; Macaluso 
et al., 2007; Wong et al., 2016). 
 
1.3.2. Environmental factors of AD 
Environmental factors have been also found to play a role in AD pathogenesis 
(McPherson, 2016; Thomsen, 2014). Skin dryness, infections (S. aureus), 
extreme climatic conditions (temperature, humidity, CO2, precipitation), 
exposure to aero-allergens (pollen, house dust mite) and serum-specific IgE 
sensitisation can trigger or exacerbate AD (Leung and Bieber, 2003; 
Schneider et al., 2013; Langan and Irvine, 2013; Silverberg et al., 2013; 
Harrop et al., 2007; Sheffield et al., 2011). 
IgE sensitisation is important in AD (Tanaka, 1994). Pre-school AD is 




2017). Also, patients with severe AD react to a larger panel of environmental 
allergens (such as house dust mite and pollen) than patients with moderate 
AD and have increased levels of S. aureus-specific IgE antibodies 
(Mittermann et al., 2016). 
Socio-economic factors also affect AD. The prevalence of AD decreases with 
increasing age and shows a female-to-male preponderance (1.3 to 1) (Hatta 
et al., 2016; Herd et al., 1996; Fennessy et al., 2000). Moreover, AD is more 
frequent in urban areas, people with a family history of atopy, a higher level of 
education and socio-economic status, or coming from smaller families 
(Sybilski et al., 2015; Shaw et al., 2011; Girolomoni et al., 2003; National 
Collaborating Centre for Women's and Children's Health, 2007). Anxiety and 
psychological stress can upregulate the release of neuromediators from 
sensory nerves, which affect the immune response and the skin barrier and 
may consequently exacerbate AD (Adams et al., 2005; Suárez et al., 2012; 
Cacioppo et al., 1998). Also, the prevalence of AD in the population with 
pigmented skin has been found to be 1.2-1.7 times higher compared to the 
Caucasian population (Kaufman et al., 2018; Fu et al., 2014; Shaw et al., 
2011). 
The “hygiene hypothesis”, according to which there is less exposure to 
infections and allergens in early childhood due to lifestyle habits, has been 
postulated to play a role in the increasing AD prevalence (Baker, 2006; 
Williams et al., 1994). 
 
1.3.3. The skin barrier in AD 
The skin barrier is implicated in the pathogenesis of AD (McPherson, 2016). 
This section will analyse the lipid matrix and filaggrin protein, found in the 
stratum corneum, which are essential components of the skin barrier (Van 
Smeden and Bouwstra, 2016; McAleer and Irvine, 2013) and the pH of the 






 Lipid matrix 
The epidermis acts as a barrier against external pathogens and regulates skin 
hydration. Low relative humidity and high salt concentration are important for 
skin barrier integrity (De Goffau et al., 2009; Elias, 1983). Corneocytes in the 
stratum corneum are embedded in a lipid matrix arranged in “stacked bilayers” 
consisting of cholesterol, fatty acids and ceramides (Landmann, 1988; Hatta 
et al., 2006). 
Omega-ω-6 and ω-3 are the main polyunsaturated fatty acids. They are 
structural components of cell membranes and an energy source. They also 
regulate cell membrane enzymes and properties and produce inflammatory 
regulators (leukotrienes-cytokines) (Stillwell and Wassall, 2003; Rakesh and 
Yung-Sheng, 2006). Delta (Δ) 5, 6 and 9 desaturases catalyse the fatty acid 
formation (Nakamura and Nara, 2004). Linoleic and arachidonic acids are the 
most common ω-6 polyunsaturated fatty acids in human skin (Trumbo et al., 
2002; Nakamura and Nara, 2004; Chapkin et al., 1986; Ziboh et al., 2000). 
Gamma-linolenic acid (γ-linolenic acid) is produced from linoleic acid by Δ6-
desaturase and it modulates matrix proteins that participate in inflammation 
(Rakesh and Yung-Sheng, 2006). In AD, linoleic acid increases and γ-linolenic 
and arachidonic acids decrease (Calder and Burdge, 2012; Calder and Miles, 
2000; Manku et al., 1984). This polyunsaturated fatty acid imbalance could be 
caused by Δ6-desaturase dysfunction (Horrobin and Manku, 1990) or by 
increased use of arachidonic acid in AD inflammation (Calder, 2006). 
Ceramides are composed of a sphingoid base (e.g. sphingosine) and a fatty 
acid and constitute up to 50% of the stratum corneum lipids. Changes in 
ceramide levels are correlated with skin barrier dysfunction and AD severity 
but not with filaggrin gene mutations (Janssens et al., 2012; Smeden et al., 
2014). Sphingosine, which is potent against S. aureus, is reduced in AD 
(Parsons et al., 2012; Arikawa et al., 2002; Pruett et al., 2008; Imokawa and 
Ishida, 2014).  
The skin barrier in AD is affected in both lesional and non-lesional skin 
(Proksch et al., 2006; Kelleher et al., 2015). An imbalance of the skin barrier 
components disrupts skin barrier integrity and increases water loss and 





Filaggrin is the major structural protein of the stratum corneum, essential for 
the skin barrier integrity (McAleer and Irvine, 2013). The final protein is formed 
after cleavage of the profilaggrin protein, during the terminal epidermal 
differentiation and binds to keratin filaments, leading to the formation of a 
keratin matrix (Palmer et al., 2006; Sandilands et al., 2009). Cis-urocanic acid 
(cis-UCA), a filaggrin breakdown product, which contributes to skin 
moisturisation and pH balance, has immunoregulatory function (Ye et al., 
2014; Hart et al., 2002; Noonan and De Fabo, 1992; Sandilands et al., 2009) 
and can also inhibit S. aureus colonisation (Miajlovic et al., 2010).  
Filaggrin expression is downregulated in AD skin. This is more prominent in 
lesional AD skin compared to non-lesional (Pellerin et al., 2013; Howell et al., 
2009). Filaggrin gene expression and cis-UCA can be downregulated in AD, 
even without a loss-of-function mutation, as Th2 cytokines (IL-4, IL-13), which 
are increased in AD, can downregulate filaggrin expression in keratinocytes 
(Kezic et al., 2011; Palmer et al., 2006). Also, keratinocytes exposed to IL-22 
and IL-25 have reduced filaggrin expression (Niebuhr et al., 2010; Gutowska-
Owsiak et al., 2011; Deleuran et al., 2012). Moreover, IL-17, IL-31 and IL-33 
can downregulate filaggrin expression (Seltmann et al., 2015; Gutowska-
Owsiak et al., 2012; Van Drongelen et al., 2014). 
Along with filaggrin, IL-4 and IL-22 can also downregulate claudins, involucrin 
and loricrin proteins (Lee et al., 2014; Sehra et al., 2010; Gruber et al., 2015; 
Howell et al., 2009; Rabeony et al., 2014). The IL-17α cytokine was also found 
to downregulate not only filaggrin but also other skin barrier molecules, such 
as claudins (Eyerich et al., 2009; Niebuhr et al., 2011a; Toda et al., 2003; 
Gutowska-Owsiak et al., 2012; McAleer and Irvine, 2013). The reduced 
expression of filaggrin and cis-UCA in AD can increase the susceptibility to S. 
aureus (Kezic et al., 2011; Miajlovic et al., 2010; Van Drongelen et al., 2014). 
 
 Skin pH 
The pH of normal skin is between 4 and 6. The acidic environment of the skin 




acids, lamellar bodies and filaggrin breakdown products contribute to the 
acidic pH of the skin (Chan and Mauro, 2011; O'Regan et al., 2008). In an 
acidic skin pH, lipid synthesis and the activity of proteases responsible for the 
stratum corneum desquamation are optimal. Moreover, many AMPs are more 
potent, increasing the skin’s defence against external pathogens. In such 
conditions, the growth and virulence of pathogens such as S. aureus are 
reduced (Panther and Jacob, 2015; Malik et al., 2016; Proksch, 2018). Acidic 
pH reduces the rate of S. aureus colonisation and the production of immune 
evasion proteins (clumping factor B, fibronectin binding protein A) (Miajlovic 
et al., 2010). The pH of the skin in AD increases (Eberlein-Konig et al., 2000; 
Seidenari and Giusti, 1995). Filaggrin gene mutations and downregulation of 
filaggrin and AMP production by Th2 cytokines are responsible for the pH 
increase (Proksch et al., 2008; Kezic et al., 2011; Howell et al., 2009; 
Chieosilapatham et al., 2017). The pH of non-lesional AD skin is higher than 
normal skin, while the pH of lesional AD skin is even higher (Panther and 
Jacob, 2015; Tauber et al., 2016). The changes in the skin barrier in AD 
compared to healthy skin are shown in Figure 1-3.  
 
 
 Pathogens & Allergens      Pathogens & Allergens 
  
  Pruritus Disrupted barrier 
   
   Intact barrier  ↑pH & water loss                   
     
  Normal hydration →                                                                          skin lipid imbalance 
 ←↓ keratinocyte adhesion 
  ←↑ protease activity 
 ←↓ AMP production*            
 
   Healthy skin              Atopic skin  
 
Figure 1-3: The skin barrier in normal and AD skin 
The imbalance of skin lipids in AD, as well as the decrease in tight junction and 
cornified envelope proteins can affect the pH, hydration and integrity of the skin 
barrier. The increased pH alters the activity of proteases and the synthesis of lipids 
and AMPs. All these changes facilitate allergen penetration (Calder and Burdge, 
2012; Di Nardo et al., 1998; Palmer et al., 2006; Gruber et al., 2015; Bao et al., 2016; 
Panther and Jacob, 2015; Clausen et al., 2018). 




1.3.4. The immune response in AD 
The host immune response is also implicated in AD pathogenesis (Gavrilova, 
2018; McPherson, 2016). The following section will describe the pattern 
recognition receptors (PRRs), which are important for skin defence and are 
expressed in keratinocytes, as well as the pathways by which keratinocytes 
activated by pathogens can induce expression of cytokines and AMPs (Lai 
and Gallo, 2008; Kuo et al., 2013). 
 
 Pattern recognition receptors (PRRs) 
The immune system is divided into the innate immune system, which is 
mediated by PRRs and pathogen-associated molecular patterns (PAMPs) 
and the adaptive immune system, which is mediated by somatically generated 
receptors of T-cells and B-cells. The PRRs are highly conserved molecules 
but not antigen-specific, whereas the receptors of adaptive immunity are 
formed in order to recognise a specific antigen (cell-mediated via 
antigen-specific T-cell receptors and humoral via immunoglobulins) (Iwasaki 
and Medzhitov, 2004; Clark and Kupper, 2005; Miller, 2008; De Benedetto et 
al., 2009). Both the innate and the adaptive immune systems are implicated 
in AD (Biedermann et al., 2015; De Benedetto et al., 2009). 
The types of PRRs of the innate immune system are TLRs, NOD-like 
receptors (NLRs), C-type lectin receptors (CLRs) and the cytoplasmic proteins 
retinoic acid-inducible gene-I-like receptors (RLRs) (Thompson et al., 2011). 
The most studied receptors are TLRs (De Benedetto et al., 2009), which are 
glycoproteins expressed in various cells, such as keratinocytes, dendritic 
cells, B-cells, T-cells, mast cells, macrophages and fibroblasts. Each cell type 
has different TLRs. The TLRs recognise PAMPs, such as lipopolysaccharides 
and other pathogen components. Binding of TLRs to PAMPs leads to 
activation of the nuclear factor kappa-light-chain-enhancer of activated B-cells 
(NF-κB) pathway and of immune responses such as phagocyte activation, 
cytokine and AMP release and regulation of serine protease inhibitors. So far, 
10 TLRs have been described, which recognise different PAMPs. Some are 




others are intracellular and recognise PAMPs that have entered the cells 
(Miller and Modlin, 2007; Miller, 2008; Clark and Kupper, 2005; Sugimoto et 
al., 2017; Takeuchi and Akira, 2010; Kawai and Akira, 2007b). 
Binding of TLRs to PAMPs can activate the adaptive immune response, by 
activation of dendritic cells through the NF-κB pathway, leading to antigen 
presentation and subsequent T-cell stimulation. Depending on signals 
provided along with the antigen presentation, naive T-cells can be polarised 
to Th1, Th2 or T-regulatory cells (Miller, 2008; Miller and Modlin, 2007; Iwasaki 
and Medzhitov, 2004; Clark and Kupper, 2005; Medzhitov, 2001; Medzhitov 
and Janeway, 2000). 
TLRs can activate the myeloid differentiation factor 88 and “IL-1-receptor 
associated kinases and TNF-receptor-associated” factors, leading to 
activation of mitogen-activated protein kinases (MAPK) and janus kinases 
(JAK), as well as NF-κB and activator protein (AP) 1 and subsequently induce 
inflammatory cytokine release (Miller, 2008; Kawai and Akira, 2007b). Also, 
TLRs can activate NF-κΒ through the “toll/IL-1 receptor domain-containing 
adaptor-inducing IFN-beta (β)” (TRIF) dependent pathway (Kawai and Akira, 
2007a). Polymorphisms of TLRs have been found in AD patients (mainly TLR2 
and TLR9) and have been associated with increased susceptibility to S. 
aureus and other infections (Miller, 2008). 
The NOD1 and NOD2 receptors are cytoplasmic NLRs that recognise 
bacterial peptidoglycans, activate NF-κB and induce cytokine release. Since 
both TLRs and NODs recognise bacterial peptidoglycans, they have 
synergistic action (Takeuchi and Akira, 2010). Mutations of TLR2 and NOD2 
genes can increase the AD severity through the p38 MAPK, the NF-κB and 
the extracellular signal-regulated kinase pathway and eosinophil and basophil 
activation (Ahmad-Nejad et al., 2004; Jiao et al., 2015; Macaluso et al., 2007; 
Wong et al., 2016). 
 
 Cytokines 
Cytokines are signalling proteins, which play a role in the immune response 




growth by regulating keratinocyte proliferation and differentiation (Cameron 
and Kelvin, 2013; Hanel et al., 2013; Coondoo, 2011; Nedoszytko et al., 
2014). Types of cytokines include chemokines, interferons (IFN), interleukins, 
lymphokines and tumour necrosis factors (TNF) (Turner et al., 2014; Dinarello, 
2007; Ferreira et al., 2019). In the skin they are secreted by keratinocytes, 
Langerhans cells, mast cells, macrophages, neutrophils, T-cells, B-cells and 
other cell types. They are produced upon stimulation, rather than being stored 
in cells and act mostly at the local level (Nedoszytko et al., 2014), although 
prolonged action of stimulus can lead to increased cytokine production and 
release in blood circulation, affecting distant body areas. Their signalling 
function is exerted through the corresponding receptors that are expressed on 
the target cells (Coondoo, 2011). 
Many cytokines have been found to play an important role in AD. The hallmark 
of AD is an increase of T-cells polarised along the Th2 pathway, resulting in 
overexpression of Th2 cytokines (IL-4, IL-5 and IL-13). The T-cell infiltration is 
induced by chemoattractant factors and reaches the epidermal compartment. 
Keratinocytes are important cytokine producers and direct various T-cell 
subsets into the skin (Homey and Zlotnik, 1999; Rawlings and Harding, 2004). 
Both IL-4 and IL-13 are increased in AD and act through the IL-4Rα receptor 
expressed on target cells. They promote CCL26 production in keratinocytes 
and activate T-cells, B-cells, macrophages and other cells, leading to Th2 
differentiation, IgE production by B-cells and increased infiltration of mast cells 
and eosinophils. They inhibit keratinocyte differentiation through STAT3 and 
promote cytokine production through STAT6. They also downregulate TNF-α- 
and IFN-γ-mediated production of the AMPs HBD-2 and HBD-3, through 
STAT6 activation (Albanesi et al., 2007; Amano et al., 2015). IFN-γ regulates 
cytokine production, increases pathogen recognition and antigen presentation 
and activates monocytes, macrophages, natural killer cells and apoptotic 
mechanisms (Schroder et al., 2004; Mühl and Pfeilschifter, 2003; Hata and 
Gallo, 2008). TNF-α promotes macrophage activation and nitric oxide 
production, thus increasing the antibacterial potency (Silva et al., 1995; 
Bekker et al., 2001). Downregulation of TNF-α and IFN-γ in AD can increase 
the susceptibility to S. aureus (Liu et al., 2018; Campbell and Kemp, 1997; 




Also, IL-5 promotes Th2 differentiation and the production of IgE, eosinophils 
and mast cells (Brandt and Sivaprasad, 2011; Matsunaga and Yamauchi, 
2016; Kagami et al., 2005; Paller et al., 2017). Pruritic symptoms in AD can 
be attributed to IL-31, which interacts with skin neurons expressing the IL-31 
receptor A and causing itch (Cevikbas et al., 2014; Meng et al., 2018). 
Cytokines IL-25, IL-33 and thymic stromal lymphopoietin (TSLP) promote the 
Th2 response by activating Th2-producing cells or through dendritic cell 
activation (Brandt and Sivaprasad, 2011; Wang and Liu, 2009; Saenz et al., 
2010; Deleuran et al., 2012). Activated dendritic cells produce various 
cytokines, such as CCL-17, CCL-18 and CCL-22 and promote the Th2 
response. The CCL-17 and CCL-22 cytokines are AD markers that promote 
the Th2 response through binding to the C-C chemokine receptors (CCR) type 
4 and 8 (Brandt and Sivaprasad, 2011; Novak, 2012; Leung et al., 2003; Kubo 
et al., 2017; Nakazato et al., 2008; Kimura et al., 2014; Inngjerdingen et al., 
2000; Lu et al., 2016). Also, CCL-27 acts through CCR-10 and attracts 
cutaneous lymphocyte-associated antigen (CLA)+ memory T-cells (Homey et 
al., 2000; Chen et al., 2006; Kubo et al., 2017). The T-cells are directed into 
the skin by means of skin-homing receptors CLA (cutaneous lymphocyte 
antigen) (Homey et al., 2006; Pivarcsi and Homey, 2005; Lee and Hwang, 
2012). Lastly, the levels of IL-36γ cytokine are significantly increased in 
psoriatic lesions compared to AD, which makes this cytokine a marker of 
differentiation between the two inflammatory conditions (Berekmeri et al., 
2018). 
There are differences in the immune response in acute and chronic AD. Acute 
AD is characterised by a Th2-mediated response. The increased Th2-cytokine 
expression (IL-4, IL-5 and IL-13) leads to a systemic increase of eosinophils 
and IgE levels (Yamanaka and Mizutani, 2011; Brandt and Sivaprasad, 2011; 
Wittmann et al., 2014). The Th22 and Th17 responses are also upregulated in 
acute AD (Brunner et al., 2017). Chronic AD displays a shift from Th2/Th17 
towards Th1 and T-regulatory cells (Su et al., 2017; Peng and Novak, 2015), 
whereas Th22 cells are also upregulated (Gittler et al., 2012; Eyerich and 
Eyerich, 2015). 
Atopic skin is more frequently colonised by S. aureus than healthy skin 




leads to more severe disease, higher T-cell expression with a greater Th2/Th1 
ratio, production of AD cytokines such as IL-22 and TSLP and increased 
allergen sensitisation and skin barrier disruption (Wedi et al., 2002; Simpson 
et al., 2018; Nakatsuji et al., 2016). Also, the effect of S. aureus alpha (α) toxin 
on keratinocytes is increased by Th2 cytokines, whereas S. aureus enterotoxin 
B promotes IL-31 production (Baviera et al., 2015). Pruritus triggered by IL-31 
can lead to scratching, disturbance of the skin barrier and further cytokine 
release. As a result, skin fibronectin and laminin are more exposed to S. 
aureus cells, which bind to them. Also, IL-4 induces production of adhesin and 
fibronectin by fibroblasts, enhancing S. aureus binding and downregulates the 
production of AMPs that are potent against S. aureus (Nowicka and 
Grywalska, 2018; Meng et al., 2018; Simanski et al., 2013). 
 
 Antimicrobial peptides 
The expression of AMPs such as HBD-2, HBD-3, cathelicidin LL-37, 
calprotectin (S100A8/S100A9), psoriasin (S100A7), RNAase7 and dermcidin 
by keratinocytes, neutrophils and other cells plays a significant role in the skin 
defence against pathogens (Zhang and Gallo, 2016; Schauber and Gallo, 
2008; Pfalzgraff et al., 2018; Mahlapuu et al., 2016). Investigation of their role 
in AD is important because, compared to other inflammatory diseases, their 
levels do not seem to correspond to the degree of AD inflammation, resulting 
in increased susceptibility of AD patients to pathogen colonisation, mainly with 
S. aureus (Hata and Gallo, 2008; Ong et al., 2002; Nomura et al., 2003b; Lin 
et al., 2007). Upregulation of the AMPs takes place mainly in the outermost 
epidermis (Stoitzner et al., 1999; Percoco et al., 2013; Menzies and Kenoyer, 
2005). Calprotectin, HBD-2, HBD-3 and psoriasin are produced upon 
stimulation. Cathelicidin LL-37 and RNase7 are both constitutively produced 
and induced upon inflammation, whereas dermcidin is constitutively produced 
and non-inducible (Heilborn et al., 2003; Zhang and Gallo, 2016; Rieg et al., 
2004; Schittek, 2012; Schittek et al., 2001; Otto, 2010; Alowami et al., 2003; 
Ross and Herzberg, 2001). Their antimicrobial mechanisms against 
pathogens include disruption of the cell wall or membrane, protein inhibition 




promote keratinocyte differentiation, cytokine production and chemotaxis 
(Clausen et al., 2016; Harder and Schröder, 2005). Moreover, HBD-3 can 
increase the expression of claudins, suggesting that AMPs may also improve 
the skin barrier integrity in addition to their antimicrobial properties 
(Kiatsurayanon et al., 2014). 
Production of HBDs and LL-37 by keratinocytes in AD is of great interest, due 
to their potency against S. aureus (Ong et al., 2002; Midorikawa et al., 2003; 
Menzies and Kenoyer, 2005; Joly et al., 2004). 
 
Cathelicidin LL-37 
The only human cathelicidin, LL-37, is expressed in immune cells, mast cells 
and epithelial cells. Initially, it is encoded as an inactive precursor (hCAP18) 
and is then cleaved in its active form in the skin by proteases kallikrein 5 and 
kallikrein 7 (Van Der Does et al., 2012; Sorensen et al., 2001; Yamasaki et al., 
2006). LL-37 is constitutively expressed in neutrophils, whereas it is inducible 
in keratinocytes upon inflammation. In normal skin and non-stimulated 
keratinocytes the LL-37 levels are below the detection limit (Heilborn et al., 
2003; Frohm et al., 1997; Love et al., 2012; Cowland et al., 1995; Dorschner 
et al., 2001; Kim et al., 2005; Schauber et al., 2006; Van Der Does et al., 2012; 
Schauber et al., 2007). LL-37 is induced after exposure to pathogens through 
PRRs, or to endogenous cytokines. Vitamin D can also induce LL-37 
production in the skin (Love et al., 2012; Nell et al., 2004; Xhindoli et al., 2016). 
Cathelicidin LL-37 has broad antimicrobial activity against Gram-positive and 
Gram-negative bacteria, fungi and viruses. Apart from its pore-forming 
capacity, it can interact with membrane or secreted pathogenic factors or 
factors released from damaged host cells and reduce their ability to induce 
inflammatory effects. It is also a chemoattractant for neutrophils, eosinophils, 
T-cells and mast cells and has immunoregulatory function. Moreover it can 
induce keratinocyte migration through the epidermal growth factor receptor 
(EGFR) and cytokine production in keratinocytes through G-protein coupled 
receptor and EGFR (Xhindoli et al., 2016; Turner et al., 1998; Vandamme et 
al., 2012; Murakami et al., 2002; Tjabringa et al., 2006; Beaumont et al., 2013; 





HBDs are small cationic AMPs expressed in keratinocytes and other epithelial 
cells (oral mucosa, urogenital, gastrointestinal and respiratory tract), as well 
as some leukocytes (neutrophils) (Flaherty, 2012; Mathews et al., 1999; 
Oppenheim et al., 2003; Harder et al., 2001; Harder et al., 1997). They are 
located in the epidermis and have broad-spectrum antimicrobial activity 
(Simanski et al., 2014; Falconer et al., 2001; Ganz, 2003). 
HBD-2 and HBD-3 levels are low in normal conditions and increase upon 
stimulation, whereas HBD-1 is constantly produced by keratinocytes rather 
than being induced by cytokines or bacteria and its levels decrease in AD 
compared to healthy subjects (Harder and Schröder, 2005; Gambichler et al., 
2006). The functions of HBD-2 and HBD-3 have been studied in more detail 
(Harder et al., 2001; Harder et al., 1997). Keratinocytes produce HBD-2 and 
HBD-3 upon exposure to pathogens via PRRs and endogenous cytokines 
(IL-1α, IL-17, IL-22, IL-1β, TNF-α, IL-17A/IFN-γ). Both HBD-2 and HBD-3 
exert their activity through pore formation in membranes (Weinberg et al., 
2012; Taylor et al., 2008; Duclohier, 1994). They can also induce further 
cytokine production and keratinocyte differentiation and recruit dendritic and 
T-cells through the CCR-6 receptor, therefore linking the innate and the 
adaptive immune systems (Yang et al., 1999; Oppenheim et al., 2003; 
Simanski et al., 2013; Dinulos et al., 2003; Mathews et al., 1999; Harder et al., 
2000; Harder et al., 1997; Harder et al., 2004; Liu et al., 2002; Niyonsaba et 
al., 2006; Hata and Gallo, 2008; Harder et al., 2001). 
Even though HBD-2 and HBD-3 belong to the same family, their induction 
pathways may not be identical. Various studies have been conducted using 
different stimulants and testing different pathways. The results are not always 
consistent, suggesting that different factors can trigger different pathways. 
The NF-κB and MAPK/AP-1 pathways mediate pathogen-induced HBD-2 
expression in epithelial cells (Wehkamp et al., 2004; Hertz et al., 2003; 
Steubesand et al., 2009), as well as HBD-2 induction in keratinocytes upon 
stimulation with Pseudomonas aeruginosa and IL-1β (Wehkamp et al., 2006). 
Another study found c-Jun N-terminal kinase (JNK) and p38 MAPK pathways 




al., 2002). It has been reported that both commensal and pathogenic bacteria 
may induce HBD-2 production in keratinocytes through JNK and p38 MAPK 
pathways but the induction by commensal bacteria may not involve NF-κB, 
suggesting that different bacterial components may initially bind to the same 
TLRs but then trigger different pathways (Chung and Dale, 2004). 
HBD-3 induction in keratinocytes (by S. aureus and lipoteichoic acid) and 
other epithelial cells, such as oral mucosa, is mediated through TLR2 
receptor, p38 MAPK pathway and AP-1 transcription factor, whereas there is 
no indication of HBD-3 binding to NF-κB (Inthasin et al., 2018; Menzies and 
Kenoyer, 2006; Peng Jia et al., 2001; Steubesand et al., 2009; Sechet et al., 
2018). Although most studies do not report a role for NF-κB in HBD-3 induction 
(Menzies and Kenoyer, 2006; Peng Jia et al., 2001; Steubesand et al., 2009; 
Sechet et al., 2018), one study found that HBD-3 was induced by live S. 
aureus through NF-κB, whereas HBD-3 induction by secreted S. aureus 
factors was independent of NF-κB (Wanke et al., 2011). It seems that NF-κB 
may not play a major role in HBD-3 induction compared to HBD-2, however, 
more research is needed. Clearly, there are indications of differences in the 
induction pathways of HBD-2 and HBD-3, which are also affected by the 
nature of the bacterial species. 
 
Antimicrobial activity of AMPs 
The HBD-2 defensin is more potent against Gram-negative bacteria, rather 
than Gram-positive, whereas the effect of HBD-3 and LL-37 on S. aureus and 
other Gram-positive bacteria is greater than the effect of HBD-2 (Schröder and 
Harder, 1999; Harder et al., 2000; Chung and Dale, 2004; Joly et al., 2004). 
The fact that HBD-3 is more potent against S. aureus than HBD-2 may be 
attributed to the increased positive charge of HBD-3 compared with HBD-2, 
which can counterbalance the reduced acidity of S. aureus surface compared 
to Gram-negative bacteria (Schibli et al., 2002; Dhople et al., 2006; Harder et 
al., 2001; Jung et al., 2011). As an increased resistance of methicillin resistant 
S. aureus (MRSA) strains to LL-37 compared to HBD-3 has been reported, 
HBD-3 may be more effective against S. aureus infections (Ouhara et al., 




limited compared to S. epidermidis and that both S. epidermidis and S. aureus 
recognise LL-37, whereas only S. epidermidis recognises HBD-3 (Joo and 
Otto, 2015). Nevertheless, HBDs and LL-37 can have a synergistic effect 
against S. aureus (Harder et al., 2001; Chen et al., 2005; Midorikawa et al., 
2003; Wanke et al., 2011). 
Calprotectin is mainly induced by Gram-negative bacteria but is potent against 
both Gram-positive and Gram-negative bacteria (Brandtzaeg et al., 1995; 
Abtin et al., 2010; Steinbakk et al., 1990; Van Crombruggen et al., 2016). Both 
RNase7 (Simanski et al., 2010; Harder and Schröder, 2002; Rademacher et 
al., 2016; Torrent et al., 2010) and dermcidin have broad antimicrobial activity 
against Gram-positive and Gram-negative bacteria (Senyürek et al., 2009; 
Josefson, 2001). Although psoriasin can be induced by S. aureus, it is mostly 
effective against Gram-negative bacteria (Garreis et al., 2011; Gläser et al., 
2005). 
 
Changes in AMP levels in AD 
Most AMPs increase in inflammatory conditions. Research has been 
conducted regarding the role of AMPs in the immune response and changes 
in their levels in inflammatory conditions, such as AD and psoriasis (Schröder 
et al., 2006). Increased levels of HBD-2, HBD-3, LL-37, calprotectin, psoriasin 
and RNase7 have been found in AD and psoriatic lesions, however, their 
increase in AD is lower than in psoriasis (Figure 1-4) (Clausen et al., 2018; 
Harder et al., 2010; Clausen et al., 2016; Jin et al., 2014; Schonthaler et al., 
2013). Dermcidin, which is constitutively expressed in normal skin, is reduced 
in AD (Rieg et al., 2005; Rieg et al., 2004). The relative AMP deficiency in AD 
favours S. aureus growth (Nakatsuji et al., 2017; Nowicka and Grywalska, 
2018).  
The levels of AMPs (HBD-2, HBD-3, LL-37, psoriasin) are increased ιn 
lesional AD skin compared to non-lesional and healthy skin (Clausen et al., 
2018; Clausen et al., 2016). In contrast to the Th1 axis and neutrophil 
infiltration in psoriasis, the Th2 axis in AD inhibits filaggrin production and AMP 
expression by keratinocytes through the STAT6 signalling cytokines IL-4 and 




2016; Howell et al., 2005; Howell et al., 2006b; Albanesi et al., 2007; Nomura 
et al., 2003b; Takeda et al., 1996). 
 
Healthy skin   Atopic skin   Psoriatic skin 
(basal levels)  (intermediate levels)  (high levels) 
HBD-2    ↑ HBD-2    ↑↑ HBD-2 
HBD-3    ↑ HBD-3    ↑↑ HBD-3 
LL-37    ↑ LL-37     ↑↑ LL-37 
Calprotectin   ↑ Calprotectin    ↑↑ Calprotectin 
Psoriasin   ↑ Psoriasin    ↑↑ Psoriasin 
Dermcidin   ↓ Dermcidin     ? Dermcidin 
RNase7    ↑ RNase7    ↑↑ RNase7 





Figure 1-4: AMP expression in healthy, AD and psoriatic skin 
All AMPs except dermcidin are increased in AD and psoriasis compared to healthy 
skin. AMP expression is higher in psoriasis than in AD. Expression of dermcidin is 
reduced in AD (Shiohara, 2011; Heilborn et al., 2003; Ross and Herzberg, 2001; 
Clausen et al., 2016). 
 
As S. aureus is the most common bacterium found in the skin of the majority 
of AD patients and is often implicated in infection (Baldry et al., 2018; Danby, 
2017; Tong et al., 2015; Bouvet et al., 2017), the potency of the main 
cutaneous AMPs against staphylococci, as well as changes in their levels in 






Table 1-1: The most common AMPs which are potent against S. aureus 














Increased, but lower 
than in psoriasis 
(inhibited by 
IL-4/IL-13 in AD) 
(Hata and Gallo, 2008; Yang et al., 
2001; Niyonsaba et al., 2006; Liu et al., 
2002; Harder et al., 2001; Harder et al., 
2004; Harder et al., 1997; Harder et al., 
2010; Ong et al., 2002; Harder et al., 
2000; Mathews et al., 1999; Dinulos et 
al., 2003; Simanski et al., 2013; Gläser 
















Increased, but lower 
than in psoriasis 
(inhibited by 
IL-4/IL-13 in AD) 
(Kisich et al., 2008; Schibli et al., 2002; 
Harder et al., 2001; Schröder, 2011; 
Simanski et al., 2013; Hata and Gallo, 
2008; Yang et al., 2001; Niyonsaba et 
al., 2006; Liu et al., 2002; Harder et al., 
2004; Harder and Schröder, 2002; Sass 




















Increased, but lower 
than in psoriasis 
(due to increased 
IL-4/IL-13 & reduced 
Vitamin D3 in AD); 
similar in non-
lesional AD & 
healthy skin 
(Schauber et al., 2007; Vandamme et 
al., 2012; Murakami et al., 2002; Ong et 
al., 2002; Mallbris et al., 2010; Wang et 
al., 2004; Reinholz et al., 2012; Howell 
et al., 2006b; Jeng et al., 2009; 








Table 1-1 (Continued) 







IFN-γ, TNF-α, IL-1, 
bacteria 
Sequesters zinc, 




Increased, but lower 
than in psoriasis 
(inhibited by 
IL-4/IL-13 in AD) 
(Mørk et al., 2003; Ganz and Lehrer, 
1997; Corbin et al., 2008; Liang et al., 
2006; Hansson et al., 2014; Yui et al., 
2003; Kelly et al., 1989; Aochi et al., 
2011; Semprini et al., 2002; Broome et 











Increased, but lower 
than in psoriasis 
(inhibited by 
IL-4/IL-13 in AD) 
(Gläser et al., 2005; Gläser et al., 2009; 
Broome et al., 2003; Michalek et al., 
2009; Harder et al., 2010; Simanski et 
al., 2013; Alowami et al., 2003; Cunden 
















Decreased in AD 
(Niyonsaba et al., 2009; Lai et al., 2007; 
Rieg et al., 2005; Rieg et al., 2004; 
Schittek, 2012; Schittek et al., 2001; 














Increased in AD 
lesional skin; 
similar in non-
lesional AD & 
healthy skin 
(Simanski et al., 2013; Harder and 
Schröder, 2005; Harder and Schröder, 
2002; Harder et al., 2010; Harder et al., 




1.3.5. The skin microbiome 
The skin microbiome is associated with AD pathogenesis, although its role 
has not been fully elucidated yet (Paller et al., 2019; Lee et al., 2018). The 
skin microbiome refers to the diverse milieu of bacteria, fungi and viruses that 
colonise the skin. Most of them are skin commensals, which do not harm the 
host and protect their colonies and subsequently the skin from colonisation by 
pathogens. The normal skin flora consists mainly of S. epidermidis and other 
coagulase-negative staphylococci, whereas S. aureus prevalence is around 
5% (Otto, 2010; Cogen et al., 2008; Williams et al., 1990). Different sites of 
the body are colonised by different microbial populations, depending on the 
characteristics of the area. Colonisation by pathogens affects the balance and 
reduces the diversity of the skin microbiome. Imbalance of the skin microbial 
flora has been linked to diseases (Byrd et al., 2018; Findley and Grice, 2014). 
Both commensals and pathogens affect the immune response and the 
production of AMPs (Wanke et al., 2011; Chung and Dale, 2004; Lai et al., 
2010; Chung and Dale, 2008). 
 
 Skin commensals – S. epidermidis 
Skin flora plays an important role in skin defence not only directly through 
colonisation resistance, whereby skin commensals inhibit colonisation of the 
skin by pathogens (e.g. by producing antimicrobials) but also indirectly by 
affecting keratinocyte functions, enhancing innate immune activity and 
inducing T-regulatory cells and cytokine production (Prescott et al., 2017; 
Zipperer et al., 2016; Nakatsuji et al., 2017; Hannigan and Grice, 2013). 
Although the skin flora composition depends on various factors such as 
gender, age, site of the body, the immune system, lifestyle and environment, 
staphylococci, corynebacteria and propionibacteria represent more than 60% 
of the skin bacteria (Scharschmidt and Fischbach, 2013; Grice and Segre, 
2011; Grice et al., 2009; Yamazaki et al., 2017). Moist body sites, such as 
creases, are mainly colonised by staphylococci and corynebacteria, 
sebaceous areas by staphylococci and propionibacteria and dry areas by 




Grice and Segre, 2011). Malassezia is the most common species of the fungal 
flora (up to 80%), found mainly in sebaceous areas (Gao et al., 2010; Paulino 
et al., 2008; Findley and Grice, 2014). The bacterial flora is the largest 
proportion of the total normal skin microbiome (Oh et al., 2014; Rodrigues-
Hoffmann, 2017; Gao et al., 2010; Huffnagle and Noverr, 2013). The 
interactions between host and skin flora have been examined in most detail 
for Staphylococcus epidermidis (Cogen et al., 2008). Most skin commensals 
are opportunistic pathogens, meaning they only cause infection under specific 
conditions (Price et al., 2017; Cogen et al., 2010a; Lai et al., 2010). 
The most abundant commensal on normal skin and mucosal surfaces is S. 
epidermidis, which comprises more than 90% of the aerobic microbial flora 
(Prescott et al., 2017; Otto, 2009; Otto, 2012). It has a predominantly 
mutualistic relationship with the host as it competes against other bacteria 
(e.g. S. aureus) by producing bacteriocins (antibacterial peptides) such as 
lantibiotics (epidermin, epilancin-K7, staphylococcin-1580), thus preventing 
pathogen colonisation (Otto, 2009; Iwase et al., 2010; Cogen et al., 2008; 
Peschel and Götz, 1996; Bierbaum et al., 1996). More specifically, S. 
epidermidis acts against S. aureus by producing phenol-soluble modulins 
(PSM) δ and γ, which disrupt lipid membranes and Esp-serine protease, which 
increases the HBD-2 activity against S. aureus biofilms (Vandecandelaere et 
al., 2014; Iwase et al., 2010; Cogen et al., 2010b). 
S. epidermidis is generally characterised by low virulence. Biofilm formation is 
considered its most important virulence factor (Otto, 2009; Kocianova et al., 
2005; Vuong and Otto, 2002). During biofilm formation, bacterial cells attach 
to a surface and then more groups of bacteria accumulate and form a multi-
layered structure. These structures can detach from a surface and spread to 
neighbouring surfaces. This procedure is mediated through a variety of 
molecules, such as polysaccharide intercellular adhesins and other surface 
proteins. In addition to their role in biofilm formation, molecules such as 
poly-γ-glutamic acid also offer protection from host defence mechanisms (e.g. 
AMPs and neutrophils) and external pathogens (Sabaté-Brescó et al., 2017; 
Li et al., 2005; McKenney et al., 2000; Cogen et al., 2008; Otto, 2009; 
Kocianova et al., 2005). Adhesion of S. epidermidis to host molecules such as 




wall-anchored proteins (adhesins) (Sabaté-Brescó et al., 2017; Arrecubieta et 
al., 2007; Brennan et al., 2009; Arciola et al., 2003). 
The accessory gene regulator (Agr) quorum sensing system of S. epidermidis 
detects the expression of an autoinducing peptide (AIP) produced during cell 
growth. In increased colony densities it promotes the expression of PSMβs, 
which detach S. epidermidis biofilms from a surface and promotes 
colonisation to other areas. The S. epidermidis Agr system also produces 
pheromones, which inhibit the Agr system of other bacteria (Boles and 
Horswill, 2008; Olson et al., 2014; Otto, 2001; Otto et al., 2001; Otto et al., 
1999).  
Despite the harmonic interaction with the host, S. epidermidis can become 
pathogenic under specific conditions, such as in presence of medical devices, 
in immunocompromised patients and in neonates. Biofilm formation is the 
main cause of its pathogenicity and production of virulence factors such as 
PSMs is kept low, in accordance with the commensal nature of S. epidermidis 
(Otto, 2012; Namvar et al., 2014; Dong and Speer, 2014; Sabaté-Brescó et 
al., 2017; Büttner et al., 2015). 
In conclusion, S. epidermidis as a skin commensal can protect human host 
from external pathogens. Reduction of S. epidermidis skin colonies (e.g. with 
antibiotics) can disrupt the skin microbial balance (Cogen et al., 2008). 
 
 Skin pathogens – S. aureus 
Pathogens are microorganisms that live at the expense of a host and cause 
disease (Walter et al., 2002). While S. aureus is rarely found on healthy skin, 
it is one of the most common causes of systemic, skin, soft-tissue and 
respiratory tract infections (Lowy, 1998; Moreillon et al., 1995; Cogen et al., 
2008). However, persistent nasal carriage of S. aureus in healthy people can 
reach up to 30% (Zanger et al., 2011; Sakr et al., 2018). 
In order to protect itself from the host, S. aureus has developed a variety of 
mechanisms, including epithelial barrier disruption, inhibition of AMPs and 




(Iwatsuki et al., 2006). Growth and toxin production of S. aureus are optimal 
at 37°C and pH 7.0 (Wirtanen and Salo, 2016). The virulence factors produced 
by S. aureus are either secreted or surface-associated and include 
superantigens (enterotoxins A-C, toxic shock syndrome toxin-1), cytotoxins 
(hemolysins α-δ), enzymes (proteases, lipases, nucleases) and surface 
proteins (fibronectin-binding proteins). The main mechanisms that S. aureus 
has developed against the host have been identified (Table 1-2) (Iwatsuki et 
al., 2006; Foster, 2005; Lyon and Novick, 2004). S. aureus superantigens are 
produced by more than 70% of S. aureus strains (Bröker et al., 2016; Becker 
et al., 2003). They are exotoxins that bridge the major histocompatibility 
complex and the variable region of the T-cell receptor β chain, leading to 
polyclonal T-cell activation. This results in massive production of inflammatory 
mediators. As there are only around 25 types of variable region of T-cell 
receptor β chain and the S. aureus superantigens bind to more than one type 
of β chain, they can activate up to 25% of T-cells, whereas specific binding to 
the major histocompatibility complex of other antigens activates less than 
0.01% of T-cells (Fraser and John, 2016; Llewelyn and Cohen, 2002; Leung 
et al., 1995). 
 
Table 1-2: S. aureus protective mechanisms against host 
Factor Function 
Exfoliative toxins 
Disrupt cell-to-cell cohesion; allow staphylococci to 
spread on the skin (Iwatsuki et al., 2006; Cogen et al., 
2008) 
Enterotoxins A-C & toxic 
shock syndrome toxin-1 
Cause T-cell activation; inhibit eosinophil apoptosis  
(Iwatsuki et al., 2006; Cogen et al., 2008; Wedi et al., 
2002) 
Agr system 
Regulates toxin & biofilm production (Traber et al., 
2008) 
Chemotaxis inhibitory 
protein of staphylococci 
Affects neutrophil chemotaxis (De Haas et al., 2004) 
Extracellular adherence 
protein 
Inhibits leucocyte recruitment & extravasation 
(Chavakis et al., 2002) 
α-toxin 
Damages cell membranes & causes apoptosis of 
B-cells, T-cells & monocytes; affects signalling 
between innate & adaptive system, leading to T-cell 
activation (Otto, 2014; Nygaard et al., 2012; Niebuhr 





The Agr quorum sensing system of S. aureus consists of both secreted and 
surface proteins and regulates the S. aureus virulence (Traber et al., 2008; 
Wang and Tom, 2016). The AIPs produced by S. aureus cells provide positive 
feedback to the Agr system. During late-log and stationary phases, when cell 
densities are increased, the Agr system is activated leading to inhibition of 
biofilm formation and secretion of virulence factors (Pollitt et al., 2014; 
Thoendel et al., 2011; Novick, 2003; Carnes et al., 2010; Qazi et al., 2001). In 
contrast, in low cell densities (with consequent low AIP production) or in a 
high-glucose environment the Agr system is repressed, leading to increased 
biofilm formation and reduced production of virulence factors (Boles and 
Horswill, 2008). Mutations of the Agr system result in increased biofilm 
production (Vuong et al., 2000; Pollitt et al., 2014; Kielian et al., 2001). 
 
 Phenol-soluble modulins (PSMs) 
PSMs are amphipathic, α-helical peptides produced by staphylococci and play 
an important role in their virulence (Cheung et al., 2014). Based on their 
length, PSMs are divided in α-type (20-25 amino-acids) and β-type (43-45 
amino-acids). Most α-type PSMs have a neutral or positive charge, whereas 
β-type PSMs have a negative charge (Cheung et al., 2014). It has been found 
that S. aureus produces PSMα1-PSMα4, PSMβ1, PSMβ2 and δ-toxin 
(PSMγ), (Wang et al., 2007; Cheung et al., 2014), whereas S. epidermidis 
produces PSMα, PSMβ1, PSMβ2, PSMδ, PSMε, and δ-toxin (Cheung et al., 
2014; Mehlin et al., 1999; Vuong et al., 2004b; Yao et al., 2005). The PSMβs 
and δ-toxin are similar between S. aureus and S. epidermidis (Cheung et al., 
2014). 
At micromolar concentrations, PSMs disrupt the membranes of host cells, 
leading to cell-lysis, whereas at nanomolar concentrations they induce 
neutrophil recruitment by binding to the formyl peptide receptor 2 of the 
immune cells, leading to chemokine release (Berube et al., 2014; Kretschmer 
et al., 2010; Cheung et al., 2014; Cogen et al., 2010a; Syed et al., 2015; Giese 
et al., 2011). PSMs also contribute to biofilm detachment and to bacterial 
expansion and colonisation (Periasamy et al., 2012; Dastgheyb et al., 2015). 




PSM production by commensal and pathogenic bacteria (Le and Otto, 2015; 
Cheung et al., 2014; Queck et al., 2008; Vuong et al., 2004a). Although S. 
epidermidis can produce cytolytic PSMs (PSMδ), it usually produces less 
aggressive forms (PSMβs). In contrast, S. aureus produces more cytolytic 
PSMαs and less PSMβs (Cheung et al., 2010; Otto, 2009; Wang et al., 2011; 
Wang et al., 2007). The capacity of S. epidermidis to lyse neutrophils is 
reduced compared to S. aureus. In contrast to S. aureus strains that produce 
highly cytolytic PSMαs, S. epidermidis evades neutrophil killing with passive 
methods such as extracellular polymers that inhibit the uptake of S. 
epidermidis by neutrophils, biofilm formation, the SepA protease and the Aps 
AMP sensor. This indicates that, when it comes to host colonisation, S. 
epidermidis has a more passive profile compared to S. aureus (Cheung et al., 
2010; Otto, 2009; Wang et al., 2011; Wang et al., 2007). 
Although δ-toxin is similar between S. epidermidis and S. aureus, S. 
epidermidis δ-toxin can bind to AMPs (HBD-2, HBD-3, LL-37) and increase 
their antimicrobial activity, unlike S. aureus δ-toxin (Cogen et al., 2010a). S. 
epidermidis PSMδ and δ-toxin have shown similarities in the structure and 
mode of action to LL-37. In addition, they can help maintain the normal skin 
flora, as they are potent mainly against pathogens such as S. aureus (Cogen 
et al., 2010b). 
 
 The skin microbiome in AD 
The skin microbiome plays an important role in AD pathogenesis (Paller et al., 
2019; Lee et al., 2018; Salava and Lauerma, 2014). In AD the susceptibility to 
external pathogens is increased (Hata and Gallo, 2008) and the microbial 
diversity is decreased (Nakatsuji et al., 2017; Salava and Lauerma, 2014; 
Kong et al., 2012). Pathogen colonisation is facilitated by changes that take 
place during AD, such as the defective skin barrier and the shift in skin immune 
response (Th2 axis, AMP deficiency) (Nowicka and Grywalska, 2018; 
Tomczak et al., 2019). The predominant pathogen in AD is S. aureus (Figure 
1-5), followed by β-hemolytic Streptococci (Chiu et al., 2009; David and 
Cambridge, 1986), whereas S. epidermidis populations are reduced (Higaki 




be implicated in the pathogenesis of AD, where specific IgE sensitisation of 
Malassezia allergen is commonly found (Glatz et al., 2017; Gaitanis et al., 
2013; Rodrigues-Hoffmann, 2017; Harada et al., 2015; Kekki et al., 2013). 
Also, AD increases the predisposition to herpes simplex virus-1 and vaccinia 
virus (Kim et al., 2013). 
 
 
Figure 1-5: S. aureus adherence in normal and AD skin 
Adherence of S. aureus (arrows) is observed mainly in the stratum corneum and is 
increased in AD compared to normal skin [image from (Cho et al., 2001)]. 
 
In lesional AD skin, S. aureus prevalence is around 91%, whereas coagulase-
negative staphylococci are the second most prevalent (9%) (Baldry et al., 
2018; Danby, 2017; Abeck and Mempel, 1998; Aly et al., 1977). In 
non-lesional AD skin, the prevalence of coagulase-negative staphylococci is 
around 60% and of S. aureus about 30% (Aly et al., 1977). Moreover, S. 
aureus is more abundant in acute than in chronic AD lesions (Leyden et al., 
1974; Kong et al., 2012). The S. aureus densities in lesional AD skin may 
exceed 107 organisms/cm2 and in non-lesional AD skin are around 103-104 
organisms/cm2 (Aly et al., 1977; Leyden et al., 1974; Zollner et al., 2000; Tomi 
et al., 2005; Williams et al., 1990; Kong et al., 2012; Di Domenico et al., 2018). 
The dysfunctional skin barrier in AD and the increased Th2 cytokines, which 
downregulate AMPs, along with S. aureus virulence factors promote S. aureus 
colonisation (Kisich et al., 2008; Miajlovic et al., 2010). Prevalence of S. 
aureus in anterior nares of AD patients is significantly higher than in healthy 
people and nasal colonisation can contribute to further colonisation of AD skin 




Around 30% to 60% of S. aureus strains on AD skin secrete superantigens 
(Breuer et al., 2002; Breuer et al., 2000; Bunikowski et al., 2000). Colonisation 
with S. aureus and mainly toxin-producing strains is positively correlated with 
AD severity (Nowicka and Grywalska, 2018; Tomczak et al., 2019). 
Enterotoxins produced by S. aureus can increase the skin reaction to common 
allergens in AD patients (Langer et al., 2007). S. aureus α-toxin promotes Th17 
and Th1 cell activation and IFN-γ production, leading to chronification of AD 
(Wichmann et al., 2009; Breuer et al., 2004; Breuer et al., 2005; Niebuhr et 
al., 2011a; Tauber et al., 2016). 
Patients with AD can develop specific sensitisation and IgE responses to S. 
aureus superantigens (McAleer and Irvine, 2013; Llewelyn and Cohen, 2002; 
Tomi et al., 2005; Zollner et al., 2000; Bunikowski et al., 2000). Treatment 
against S. aureus in AD patients even without clinical signs of superinfection 
can improve the disease. Nevertheless, eradication of S. aureus is not 
possible and recolonisation can be seen after 1-2 months, indicating the need 
for a more effective and long-term treatment (Breuer et al., 2002; Huang et al., 
2009; Gong et al., 2006; Machura et al., 2008; Ryan et al., 2013). 
There is a significant overuse of topical and systemic antibiotics in particular 
in primary care, which has increased the prevalence of S. aureus resistant 
strains (Błażewicz et al., 2017; Llor and Bjerrum, 2014; Ventola, 2015; 
Shallcross and Davies, 2014). Increased resistance of S. aureus strains in AD 
patients mainly to fusidic acid but also to methicillin and other antibiotics 
compared to healthy people has been reported (Harkins et al., 2018; Jung et 
al., 2015; Park et al., 2016). Moreover, antibiotics also act against S. 
epidermidis and other bacteria of the normal skin flora, leading to reduced 
microbial diversity and increased S. aureus colonisation after the antibiotic 
treatment, which suggests that antibiotics fail to restore the microbial balance 
and the proper recolonisation of the skin (Kobayashi et al., 2015; Friedman 
and Goldman, 2011; Gilani et al., 2005; SanMiguel et al., 2017). A systematic 
review emphasised the importance of S. aureus on AD course and the need 
for further research regarding the association of S. aureus with AD 





1.4. The project 
1.4.1. Project background 
Pathogenesis of AD 
Genetic predisposition, environmental factors, skin barrier, immune response 
and skin microbiome are all implicated in the pathogenesis of AD (Table 1-3). 
Nevertheless, it has not yet been elucidated which factor is the driving cause 
of AD and which factors are secondary (McPherson, 2016; Salava and 
Lauerma, 2014; Thomsen, 2014). Deeper understanding of the contribution of 
these factors to AD will support the development of more targeted and 
effective treatments for patients (McPherson, 2016). 
Two main hypotheses regarding AD pathogenesis have been proposed 
(Figure 1-6). The “inside-outside” theory describes the immune system 
dysregulation, including a shift towards a predominance of Th2 responses, a 
weakening of the skin barrier under the influence of IL-4, IL-13, IL-33 and a 
switch of the antibody production of the IgE isotype (class switch) with the 
development of specific IgE against innocuous antigens (Brüssow, 2016; Elias 
et al., 2008; Boguniewicz and Leung, 2006; Ong et al., 2002; Cork et al., 
2009). The “outside-inside” theory claims that a defective skin barrier allows 
pathogens to penetrate the skin and trigger a deregulated immune response 
(Brüssow, 2016; Elias et al., 2008). The “outside-inside” pathway can cause 
immune system dysregulation (“inside-outside” theory), leading to a vicious 











Table 1-3: Summary of the factors implicated in AD pathogenesis 
Pathogenesis of AD 
Genetic factors 
- Filaggrin gene mutations 
- FcεRI gene polymorphisms 
- SPINK5 gene mutations 
- CCL5 gene mutations 
- IL-13 & IL-13Rα1 single   
  nucleotide polymorphisms 
- TLR2 & NOD2 gene mutations 
→ affect skin barrier integrity & hydration 
→ mast cell degranulation 
→ ↑ IgE 
→ ↑ eosinophil migration 
→ ↑ IgE 
 
→ ↑ cytokines & eosinophils 
Environmental factors 
socio-economic factors, skin 
dryness, infection, extreme climatic 
conditions, aero-allergens, specific 
IgE sensitisation (S. aureus 
superantigens) 
→ affect skin barrier integrity 
     & pathogen penetration 
Skin barrier 
- ↑ cholesterol & linoleic acid  
  ↓ tight junction & cornified cell    
  envelope proteins, ceramides,  
  γ-linolenic & arachidonic acids 
 
- ↓ cis-UCA & sphingosine 
 
- ↑ pH 
 
 
→ affect skin barrier integrity 
 
 
→ ↓ skin antimicrobial activity 
 
→ affects activity of proteases, AMPs, lipid    
     synthesis & pathogen colonisation 
Immune response 







- downregulation of AMPs 
(compared to inflammation degree) 
→ ↑ Th2 cytokines, Th2 cells, mast cells   
     ↑ eosinophils, IgE 
     ↓ keratinocyte differentiation, filaggrin, 
     cis-UCA, loricrin, involucrin 
     changes in lipid composition & ↑ pH 
     ↑ adhesin, fibronectin, S. aureus binding 
→ ↑ pathogen colonisation 
 
Skin microbiome 
- ↓ skin commensals (S.   
  epidermidis) & microbial diversity 
 




- S. aureus superantigens 
→ ↑ pathogen colonisation 
 
→ ↑ T-cell expression with greater Th2/Th1   
     ratio, cytokine production (IL-22, TSLP,  
     IL-31) & allergen sensitisation, pruritus &  
     skin barrier disruption 
 
→ T-cell activation & ↑ cytokine production 
 
References: Genetic factors (Palmer et al., 2006; Cookson and Moffatt, 2002; 
Tartaglia-Polcini et al., 2006; Bitoun et al., 2002; Kato et al., 2006; Namkung et al., 
2011; Ahmad-Nejad et al., 2004; Wong et al., 2016); Environmental factors (Leung 




2013; Harrop et al., 2007; Sheffield et al., 2011; Sybilski et al., 2015; Shaw et al., 
2011; Zollner et al., 2000; Bunikowski et al., 2000); Skin barrier (Calder and Burdge, 
2012; Di Nardo et al., 1998; Imokawa et al., 1991; Arikawa et al., 2002; Kezic et al., 
2011; Palmer et al., 2006; Gruber et al., 2015; Bao et al., 2016; Panther and Jacob, 
2015; Miajlovic et al., 2010); Immune response (Ahmad-Nejad et al., 2004; Wong et 
al., 2016; Albanesi et al., 2007; Amano et al., 2015; Nomura et al., 2003b); Skin 
microbiome (Kong et al., 2012; Chiu et al., 2009; Higaki et al., 1999; Wedi et al., 
2002; Simpson et al., 2018; Nakatsuji et al., 2016; Baviera et al., 2015; Wichmann et 
al., 2009) 
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Figure 1-6: Inside-outside and outside-inside theory 
a. “Inside-outside” theory: When allergens come in contact with dendritic cells, they 
induce their migration to the dermis and promote cytokine production. A 
predisposition to elevated Th2 cells can lead to increased Th2 cytokine production (IL-
4, IL-5, IL-13). Allergen presentation by dendritic cells in the context of Th2 cytokines 
also induces the production of allergen-specific IgE from B-cells, which activates 
mast cells and induces inflammatory molecules. The inflammation compromises the 
skin barrier. b. “Outside-inside” theory: Skin barrier defects allow allergens to 
penetrate the skin and trigger inflammatory mediators (Th2 cells and Th2 cytokines) 
(Cork et al., 2009; Brüssow, 2016; Elias et al., 2008). 
 
Microbial dysbiosis and medical conditions 
There is a growing body of literature, which suggests that microbial dysbiosis 
is implicated in a broad range of medical conditions (Carding et al., 2015; 




dysbiosis of the gut microbiome may play a role in the pathogenesis of 
intestinal diseases (Olivares et al., 2015; De Palma et al., 2010; Krogius-
Kurikka et al., 2009; Miquel et al., 2013), metabolic disorders (Larsen et al., 
2010; Ley et al., 2006; Vrieze et al., 2012), disorders of the central nervous 
system (Hsiao et al., 2013; Desbonnet et al., 2010; Neufeld et al., 2011) and 
autoimmune conditions (Mu et al., 2017). Oral microbial dysbiosis has also 
been found to play a role in oral infections and systemic conditions 
(Sudhakara et al., 2018; Van Der Meulen et al., 2016). Although more 
research is needed regarding the exact role of the microbiome in these 
disorders, several studies have noticed that there is an increased prevalence 
of microbial dysbiosis in people affected with such conditions and that 
restoration of the microbial flora may improve the symptoms (Walker et al., 
2011; Carding et al., 2015; Belizário et al., 2018). 
 
Microbial dysbiosis and AD 
The defective skin barrier and immune system dysregulation in AD are 
associated with skin microbial imbalance and S. aureus colonisation, which is 
the most common pathogen in AD, although their correlation is not clear yet 
(Chiu et al., 2009; Harder et al., 2010; Rieg et al., 2005; Paller et al., 2019; 
Lee et al., 2018). 
Whether or not there is a causative relationship between S. aureus and AD, 
needs to be investigated. Research results are conflicting. Studies have 
reported that imbalance of skin microbial flora may precede the development 
of AD (Kennedy et al., 2017) and that restoration of the skin microbial balance 
in AD exacerbations precedes the improvement of AD lesions (Kong et al., 
2012). Skin microbial dysbiosis characterised by increased S. aureus 
colonisation, has been also shown to trigger atopic-like inflammation in mice 
(Kobayashi et al., 2015). However, other researchers failed to show that 
treatment of S. aureus can improve AD (Bath-Hextall et al., 2010). 
Furthermore, even though S. aureus and S. epidermidis belong to the same 
genus and have many similarities (Méric et al., 2015), they have different 
effects on the skin. This is also supported by the fact that normal skin flora 




(Otto, 2010; Cogen et al., 2008; Williams et al., 1990), whereas in AD S. 
aureus prevalence is more than 90% (Baldry et al., 2018; Chiu et al., 2009; 
David and Cambridge, 1986). Therefore, this fact raises the question of 
whether skin has developed specific mechanisms that maintain S. aureus 
colonisation low in normal skin and whether defects in these mechanisms lead 
to microbial dysbiosis and increased S. aureus colonisation, which may 
potentially trigger AD. Most scientific research investigates the role of S. 
aureus in AD by performing studies involving AD patients (Totte et al., 2016). 
This project involved both S. epidermidis and S. aureus, focused on the role 
of S. aureus at the cellular level and investigated differences in the effects of 
S. aureus and S. epidermidis on keratinocytes, with a view to understanding 
the role of S. aureus in the pathogenesis of AD. 
 
1.4.2. Hypothesis, aims and achievements of the project 
Hypothesis: S. epidermidis, which is a skin commensal and S. aureus, which 
is associated with skin infections, trigger different responses in keratinocytes 
and differential induction of AMPs. An atopic environment can alter the 
response of keratinocytes to S. aureus. 
Aims: The main aim of the project was to investigate the interaction of 
staphylococci with skin cells, focusing on the AMP production by 
keratinocytes, when exposed to S. aureus and S. epidermidis. A second aim 
was to identify compounds that favour the growth of S. epidermidis over S. 
aureus. 
Achievements: 
a. S. aureus but not S. epidermidis induces HBD-3 production in 
keratinocytes 
b. Induction of HBD-2 and LL-37 production in keratinocytes by S. aureus 
and S. epidermidis is similar 
c. The factor(s) produced by S. aureus responsible for the HBD-3 





2. Materials and methods 
2.1. Materials 
Manufacturers/suppliers of materials used in this study are indicated within 




2.2. Staphylococci used in this study 
The S. aureus and S. epidermidis strains used in this project are shown in 
Table 2-1. 
Two presumptive S. epidermidis strains were self-isolated from the forearm 
by members of the laboratory of Dr Alex O'Neill, by plating swabs onto 
mannitol-salt agar (Sigma-Aldrich). The individuals from which the strains 
were isolated had no skin disease or other chronic condition. The identity of 
these strains was confirmed as S. epidermidis by amplification of the RNA 
polymerase β subunit (rpoB) by polymerase chain reaction (PCR) and DNA 
sequencing (analysed in chapter 2.2.2.3) (Drancourt and Raoult, 2002) and 
named SE3 and SE9, respectively. 
The NRS strains and the S. aureus USA300 mutant strains from the Nebraska 
Transposon Mutant Library (NTML) were obtained from the Network on 
Antimicrobial Resistance in S. aureus (NARSA) repository (BEI Resources, 
c2019). The MOS strains are a mix of hospital-associated, community-
associated and livestock-associated S. aureus strains, collected and pre-
characterised during the MOSAR project by the MOSAR trial investigators 
group (Lee et al., 2013; Kime et al., 2019). The S. aureus WC003 and WC006 
strains were purchased from Woundchek. 
All other staphylococci used in this project are part of a collection held in the 





Table 2-1: Staphylococcal strains used in this project 
(a)              S. epidermidis  
Strain Comments Source/Reference 
NCTC11047 Isolated from human nose 
(Public Health England), 
(Banner et al., 2007)  
NCTC6513 Isolated from human nose 
(Public Health England), (Sanyal 
and Greenwood, 1993),  
7765746 Methicillin resistant strain (Laboratory of Dr Alex O’Neill)  
SE3 Isolated from healthy skin (Current project) 
SE9 Isolated from healthy skin (Current project) 
   
(b) S. aureus  
Strain Comments Source/Reference 
USA300 
Highly virulent clinical isolate, 
methicillin resistant, implicated in 
recurrent skin infections 
(Azarian et al., 2016; Fey et 
al., 2013; Boyle-Vavra and 
Daum, 2007) 
SH1000 
Common laboratory strain with well 
characterised virulent repertoire, used 
in cutaneous infections studies 
(O’Neill, 2010), (Horsburgh 
et al., 2002; O’Neill, 2010; 
Clarke et al., 2007) 
UAMS-1 Biofilm forming clinical isolate 
(Savage et al., 2013a; Sassi 
et al., 2015) 
WC003 V8 protease positive clinical isolate (Woundchek) 
WC006 V8 protease positive clinical isolate (Woundchek) 
WV1 
SH1000 variant with loss-of-function 
sigB gene mutation (deletion of 650-
770 sigB nucleotides), increased agr 
function, highly proteolytic, unable to 
form biofilms 
(Savage et al., 2013b) 
LPV1 
SH1000 variant loss of agr function 
due to agrA missense mutation, 
biofilm forming, deficient in colony 
spreading 
(Savage et al., 2013b) 
CS6-
EEFIC* 
AD clone, implicated in impetigo, fusB 
gene, resistant to fucidic acid 
(O'Neill et al., 2007a; 
Pereira, 2014) 
805 
AD clones, fusC gene, resistant to 
fucidic acid 








NRS720 Methicillin resistant clinical isolate (BEI Resources, c2019) 










Table 2-1 (Continued) 
(b) S. aureus  
Strain Comments Source/Reference 
MOS283 
Methicillin resistant clinical isolates 
 
(Lee et al., 2013; 














   
(c) S. aureus USA300 mutants ***  
Strain Name Gene description Accession number 
NE24 secretory antigen precursor SsaA (ssaA) SAUSA300_2503 
NE33 
LPXTG-motif cell wall surface anchor 
family protein 
SAUSA300_2589 
NE67 immunodominant antigen B (isaB) SAUSA300_2573 
NE460 autolysin (atl) SAUSA300_0955 





NE925 superantigen-like protein 7 SAUSA300_0401 
NE987 secretory antigen precursor SsaA (ssaA) SAUSA300_2249 
NE1035 secretory antigen precursor SsaA (ssaA) SAUSA300_2253 
NE1109 RNA polymerase sigma factor SigB (rpoF) SAUSA300_2022 
NE1241 thermonuclease (nuc) SAUSA300_1222 
NE1289 SdrD protein (sdrD) SAUSA300_0547 
NE1408 
phiSLT ORF 87-like protein, putative DNA-
binding protein 
SAUSA300_1430 
NE1532 accessory gene regulator protein A (agrA) SAUSA300_1992 
NE1544 
glycerophosphoryl diester 
phosphodiesterase family protein 
SAUSA300_1020 
* Epidemic European Fusidic acid-resistant Impetigo Clone 
** Intermediate‐level minimum inhibitory concentration (MIC) to the glycopeptide 
drugs vancomycin and teicoplanin 




2.2.1. Culturing staphylococcal strains 
All staphylococcal strains were stored in cryovials (Thermo-Fisher Scientific) 
at -80°C as glycerol stocks, with 20% (w/v) glycerol (Sigma-Aldrich). 
According to the needs of each experiment, the staphylococcal strains were 
propagated using either Mueller-Hinton agar/broth II (MHA-II/MHB-II, Oxoid) 
or tryptone soy agar/broth (TSA/TSB, Oxoid). 
In order to culture S. aureus strains, TSA or MHA-II agar plates were prepared 
(Sarstedt). For the NTML strains, agar was supplemented with 10 µg/mL 
erythromycin (Sigma-Aldrich). Strains were streaked for individual colonies 
from glycerol stocks using a 1 µL-inoculating loop (Sarstedt). The plates were 
incubated overnight (18 h) in a static incubator at 37oC and then stored at 4oC. 
Aliquots of 9 mL TSB or MHB-II were inoculated with individual colonies and 
incubated at 37oC for 18 h with vigorous aeration. 
 
2.2.2. Verifying the identity of staphylococcal species 
 Gram staining and pastorex test 
In order to verify the identity of staphylococci, Gram staining and coagulase 
tests were performed for the previously identified staphylococcal strains that 
were used in this project (Table 2-1). Crystal violet, Lugol's iodine, carbol 
fuchsin (Pro Lab Diagnostics) and acetone (Sigma-Aldrich) were used during 
Gram staining (Matheson, 1999). In order to identify whether a strain is 
coagulase-positive or coagulase-negative, the pastorex test (Bio-rad) was 
used according to the manufacturer’s protocol (Appendices and supplemental 
material, 8.2). 
 
 Susceptibility testing – minimum inhibitory concentration (MIC) 
determination 
In order to evaluate the susceptibility of staphylococcal strains to antimicrobial 
molecules, the MIC protocol was followed according to the Clinical and 
Laboratory Standards Institute (CLSI) guidelines (Cockerill et al., 2012) 




for MICs are shown in Table 2-2. All compounds were purchased from Sigma-
Aldrich, except arachidonic acid (Biovision). 
 
Table 2-2: Peptides and fatty acids used in this project 







































80% acetic acid 
   
* DMSO: dimethyl sulfoxide 
 
 PCR amplification and DNA sequencing1 
Genomic DNA isolation of the staphylococcal strains was performed with the 
PurElute Bacterial Genomic Kit (EdgeBio) in general accordance with the 
manufacturer’s instructions. However, following resuspension of the cell pellet 
in spheroblast buffer, lysostaphin was added at a final concentration of ~ 0.1 
mg/mL and held at 37°C for 30 min to facilitate cell lysis. Post-isolation, DNA 
concentration was measured by UV spectrophotometry at 260 nm using a 
P300 nanophotometer (Implen). The purity of the DNA (absence of protein 
and salt/solvent contaminants) was determined from the absorbance ratios at 
260 nm / 280 nm and 260 nm / 230 nm, respectively (Sambrook and Russell, 
2001). 
                                            
1PCR amplification-DNA sequencing was performed by Dr Liam Sharkey, 




For PCR, oligonucleotide primers were synthesised by Eurofins (Appendices 
and supplemental material, 8.3), resuspended in 10 mM Tris-Cl (pH 8.5) to a 
final concentration of 100 pmol/μL and stored at -20°C. PCRs were performed 
in a Techne-TC-3000 thermal cycler (Bibby Scientific) with Q5 High-Fidelity 
DNA Polymerase (New England Biolabs). Each reaction was composed of 1 
X Q5 reaction buffer, 200 µM dNTPs (Promega), 0.5 µM forward primer, 0.5 
µM reverse primer, 10 ng genomic DNA, and 0.02 U/µL Q5 polymerase. 
Reactions were run for 30 cycles of 98C for 10 s, 61C for 20 s and 72C for 
20 s. Primer annealing temperatures were calculated using the NEB-Tm 
calculator (New England Biolabs, c2019). 
PCR products were analysed by electrophoresis through a 1.2% (w/v) 
agarose gel in tris-acetate-ethylenediaminetetraacetic acid (TAE) buffer 
(Thermo-Fisher Scientific) and 4 μL of SYBR Safe DNA stain (10,000X 
concentrate in DMSO, Thermo-Fisher Scientific) at 90 volts for 30 min. The 
DNA from the PCR reactions was purified using a QIAquick PCR Purification 
Kit (Qiagen), according to manufacturer’s instructions and DNA sequencing 
was performed on the purified PCR product (Genewiz-Sanger sequencing, 
Beckman-Coulter Genomics). The sequences were subsequently searched 
against the National Center for Biotechnology Information (NCBI) genomic 
database using the Basic Local Alignment Search Tool (BLAST) algorithm 
(Altschul et al., 1990; Altschul et al., 1997). 
 
2.2.3. Phenotype microarrays 
After confirming their identity, S. aureus USA300, S. aureus CS6-EEFIC, S. 
epidermidis NCTC11047 and S. epidermidis NCTC6513 were sent to Biolog 
for phenotypic characterisation. The strains were tested using 10 phenotype 
microarray (PM) panels designed to interrogate metabolic pathways along 
with ionic, osmotic and pH effects (PM-1 to PM-10), and 10 panels to assess 
the sensitivity to various antimicrobials with different mechanisms of action 
(PM-12 to PM-20). A patented redox technology with cell respiration 
(nicotinamide adenine dinucleotide production) as a universal reporter was 




2.3. Skin cells 
2.3.1. Growth media 
Primary normal human epidermal keratinocytes (isolated from single adult 
donors) and dermal fibroblasts (isolated from adult skin) were purchased from 
PromoCell. All cells used were between passages 3 and 5. The HaCaT cells 
(a human aneuploid immortal keratinocyte cell line from adult skin) were 
obtained from the laboratory of Dr Wittmann, University of Leeds. 
Both HaCaT cells and fibroblasts were cultured in Dulbecco's modified Eagle 
medium (DMEM) with 1 g/L glucose and sodium pyruvate, supplemented with 
10% (v/v) heat inactivated fetal bovine serum (FBS, Gibco, Thermo-Fisher 
Scientific) and 1% (v/v) penicillin-streptomycin (PenStrep 10,000 U/mL, Gibco, 
Thermo-Fisher Scientific). The primary keratinocytes were cultured in 
keratinocyte growth medium (KGM, PromoCell) supplemented with 0.004% 
(v/v) bovine pituitary extract, 0.125 ng/mL recombinant human epidermal 
growth factor, 5 μg/mL recombinant human insulin, 0.33 μg/mL 
hydrocortisone, 0.39 μg/mL epinephrine, 10 μg/mL recombinant human 
transferrin and 0.06 mM CaCl2 (all products were from PromoCell). 
 
2.3.2. Storage and thawing of skin cells 
In order to freeze cells, a suspension with around 1 million cells was harvested 
by centrifugation at 400 x g for 3 min to remove the growth medium. The cell 
pellet was resuspended in 1 mL freezing medium (PromoCell) and stored 
overnight at -80oC in a freezing container (Thermo-Fisher Scientific). The cells 
were then transferred to the liquid nitrogen tank for long-term storage. 
In order to thaw cells, the cryovial obtained from the liquid nitrogen tank was 
thawed in a 37oC waterbath and the suspension was transferred into a T75 or 
a T150 flask (Corning, Appleton Woods) containing the appropriate medium, 
as described above. For the T75 flasks, 15 mL of medium was used, whereas 
for the T150 flasks, 20 mL of medium was used. Cells were incubated at 37oC 
with 5% CO2 and medium was changed every 2-3 days. When the flasks were 




2.3.3. Skin cell passage 
Primary keratinocytes 
The growth medium from the flask was aspirated and the cells were washed 
twice with 10 mL of phosphate buffered saline (PBS, Gibco, Thermo-Fisher 
Scientific). Then, 5 mL of 0.02% versene-ethylenediaminetetraacetic acid 
(EDTA, Thermo-Fisher Scientific) was added and the flask was incubated at 
37oC with 5% CO2, until the majority of cells appeared to detach from each 
other (~ 3 min). The versene-EDTA was aspirated and 3 mL of 0.05% trypsin-
EDTA (Thermo-Fisher Scientific) was added to the flask. Cells were then 
incubated again at 37oC with 5% CO2 until the majority of cells appeared to 
detach from the flask (~ 3 min) and trypsin was then inactivated by addition of 
3 mL of trypsin-neutralising solution (TNS, Lonza). 
 
HaCaT cells and fibroblasts 
The growth medium from the flask was aspirated and the cells were washed 
twice with 10 mL of PBS. Then, 5 mL of 0.05% trypsin-EDTA was used for the 
T150 flask and 3 mL for the T75 flask. The flask was incubated at 37oC with 
5% CO2, until the majority of cells appeared to detach from each other (round 
up) and from the flask (~ 6-10 min). An equal volume of DMEM containing 
10% (v/v) FBS and 1% (v/v) PenStrep was used to inactivate the trypsin (5 
mL for the T150 flask and 3 mL for the T75 flask). 
 
Final steps for all cell types 
For all cell types, the suspension was transferred into a 50 mL-falcon tube 
(Corning, Appleton Woods). Cells were harvested by centrifugation at 400 x g 
for 3 min. The supernatant was then removed and the cell pellet resuspended 
in 10 mL of growth medium. In order to define the number of cells in the 
suspension, 10 µL of this suspension was mixed with an equal volume of 
trypan blue dye (Sigma-Aldrich) and introduced into a Hawksley 
hemocytometer (Camlab) with a cover slip (Thermo-Fisher Scientific). After 




cells were seeded onto 24-well plates (25,000 cells in 0.5 mL of medium in 
each well, Appleton Woods) and were incubated at 37oC with 5% CO2. When 
the confluence reached 70-80% (170,000 cells per well approximately), the 
plates were stimulated (usually within 1-3 days). 
 
2.3.4. Stimulation of skin monolayers 
About 30 min before stimulation, the medium in the wells of the HaCaT 
cultures was replaced with serum-free DMEM (DMEM with 1% PenStrep) and 
the medium in the wells of the primary keratinocyte cultures with KGM not 
containing epidermal growth factor and hydrocortisone. The 24-well plates 
were then stimulated with whole cultures (~ 107 CFU) or filter-sterilised 
supernatants (at a final dilution ratio of 1:50 in DMEM or KGM, unless stated 
otherwise) and incubated at 37oC with 5% CO2 (for 20 h when staphylococcal 
cells were added and for 24 h when only supernatant was added). As S. 
aureus densities in atopic skin were found to be around 107 CFU/cm2 (Leyden 
et al., 1974), this number of bacteria was chosen in order to approximate the 
staphylococcal densities of inflamed skin. As controls, one well was left non-
stimulated (DMEM or KGM), whereas TSB staphylococcal growth medium 
was added to another well. The suspensions were collected in 1.5 mL 
collection tubes (Eppendorf) and cleared by centrifugation at 500 x g for 5 min, 
to remove cell debris. These supernatants were then stored at -20oC. 
In order to create atopic-like conditions, HaCaT monolayers were incubated 
with 10, 20 and 50 ng/mL of recombinant IL-4 (Peprotech) for 1 h, prior to 
staphylococcal stimulation. 
Lastly, a protease inhibitor cocktail (PIC) from Sigma-Aldrich was used to 
block proteolytic activity of S. aureus supernatant. 
 
2.3.5. 3D skin equivalent models 
The 3D skin equivalent models were produced by Dr Adewonuola Alase, post-




University Hospital, Leeds, UK), according to the “Vienna Model” (Seltmann 
et al., 2015; Mildner et al., 2006; Gschwandtner et al., 2013). Approximately 
20,000 fibroblasts and 200,000 keratinocytes were seeded per cell culture 
insert (3 µm pore size, Corning, Appleton Woods). During stimulation, the 
surface of the skin equivalent was pierced with a 21 g needle (Terumo). Skin 
equivalents were stimulated with ~ 106 CFU of S. aureus USA300 or S. 
epidermidis NCTC6513, resuspended in PBS and incubated for 16 h at 37oC 
with 5% CO2. PBS without bacterial cells was added to skin equivalents as a 
negative control. The culture medium was collected, cleared by centrifugation 
at 500 x g for 5 min and stored at -20oC. 
 
 
2.4. Enzyme-linked immunosorbent assays (ELISA) 
In order to measure the levels of the AMPs produced by skin cells when 
stimulated with staphylococci, enzyme-linked immunoassays (ELISA) were 
used. Compared to Western Blot, the ELISA test has shown better sensitivity 
and reproducibility and lower variability and has been widely used in similar 
experiments (Pempkowiak, 2001; Oh et al., 2017; Ommori et al., 2013). 
Sandwich ELISA assays were chosen. In these assays, two antibodies are 
used, which bind to different sites of the antigen and provide higher sensitivity 
and specificity compared to direct ELISA (Jordan, 2000). Initially, the plate 
was coated with the capture antibody. The sample was added, followed by the 
detection antibody. An enzyme-linked secondary antibody then bound to the 
detection antibody. Lastly, the substrate was added, and was converted by 
the enzyme to a detectable form (Cox et al., 2004). 
The HBD-2 and HBD-3 ELISA kits were from Peprotech, whereas the human 
IL-8 ELISA kit was from Biolegend. The LL-37 ELISA kit was from Hycult 
Biotech. The manufacturer’s protocol was followed in each case. The 
detection limit for the HBD-2 ELISA is 31.25 pg/mL, for the HBD-3 ELISA is 





2.5. Toxi-light assay 
The ToxiLight™ Non-destructive Cytotoxicity BioAssay Kit (Lonza) was used 
in order to define the toxicity of staphylococcal supernatants towards skin 
cells. The kit measures the activity of adenylate kinase, a protein released into 
the supernatant when cells die (Olsson et al., 1983; Crouch et al., 1993). 
After collection of the supernatants, remaining cells were lysed using Triton 
X-100 (Sigma-Alrich), in order to determine the adenylate kinase which was 
contained in living cells (not released into the supernatant). Briefly, plates 
were washed with 200 µL of PBS followed by addition of 100 µL of 10% (v/v) 
Triton X-100 in PBS in each of the 24 wells. The plate was incubated at room 
temperature with shaking for 20 min. Lysates were centrifuged at 16,000 x g 
for 1 min. All supernatants and lysates were stored in 1.5 mL Eppendorf tubes 
at -20oC. The Toxilight protocol was followed according to the manufacturer’s 
instructions. Duplicate determinations were performed on each sample. For 
each plate, 10 mL assay buffer was added to the vial containing the lyophilised 
adenylate kinase detection reagent which was equilibrated at room 
temperature for at least 15 min. The samples were loaded into a 96-well plate 
(Appleton Woods) in duplicates (20 µL of the supernatants or 10 µL of the 
lysates – 1:2 dilution) and then 100 µL of the assay buffer was added to each 
well. The luminescence was determined for each well with 1 s intervals, using 
the Mithras Microplate Reader (Berthold Technologies) and the Microwin 
programme (Berthold Technologies). Toxicity was measured by dividing the 
luminescence value for the supernatant by the sum of the luminescence 
values for the supernatant and the lysate. 
 
 
2.6. Protein inactivation 
2.6.1. Heat inactivation 
Supernatant from S. aureus overnight TSB culture was incubated at 100oC for 
10 min in a thermocycler and then filter-sterilised using a 0.22 µm Millex-GP 




2.6.2. Proteinase K treatment 
Proteinase K (PrK) was purchased from Sigma-Aldrich. Supernatants from S. 
aureus SH1000 (SA) were incubated in a thermocycler for 1 h at 37oC with 
33.3 µg/mL PrK non-heated (SA-PrK) or heated at 100oC for 10 min (SA + 
PrK-heat). As controls, an aliquot of SA-PrK was heated at 100oC for 10 min 
after incubation [(SA+PrK)-heat] to deactivate PrK and also SA was incubated 
at 37oC for 1 h (SA37). HaCaT monolayers were stimulated with these 
samples (maximum PrK concentration in HaCaT monolayers: 0.999 µg/mL). 
 
 
2.7. The SdrD and IsaB proteins 
In an attempt to produce the SdrD protein, Lactococcus lactis expressing sdrD 
was obtained from the Research Group of Host-Microbe Interactions, 
Department of Medical Biology, Faculty of Health Sciences, UiT, The Arctic 
University of Norway (Askarian et al., 2017). Lactococcal wild-type strains, 
strains with an empty vector (pMG36e) and with a vector containing the sdrD 
insert were cultured in M17 medium (Sigma-Aldrich) supplemented with 0.5% 
(w/v) glucose and 0.5% (w/v) sucrose (Sigma-Aldrich), according to the 
recommendation of the research group that produced the mutant strains. For 
the strains that carried the plasmid, media was also supplemented with 10 
µg/mL erythromycin (Sigma-Aldrich) to ensure plasmid maintenance. Both 
agar plates and broth cultures were incubated at 30oC for 18 h (with vigorous 
aeration for broth cultures). 
In order to investigate the effect of IsaB protein on skin cells, recombinant IsaB 







2.8. Fractionation and characterisation of 
staphylococcal supernatant 
2.8.1. Ion-exchange chromatography 
S. aureus SH1000 was propagated in TSB overnight at 37oC with vigorous 
aeration. The following day, 4 mL of the culture was added to 800 mL TSB, 
which was then incubated for 18 h at 37oC with vigorous aeration. The cells 
were then harvested via centrifugation at 5000 x g for 20 min. The supernatant 
was collected and 1 M filter-sterilised 2-(N-morpholino)ethanesulfonic acid 
(MES) buffer (Sigma-Aldrich) was added in order to obtain a final 
concentration of 50 mM. The pH was adjusted to 5.5 and the supernatant was 
filter-sterilised. Then, 600 mL of this S. aureus SH1000 supernatant was 
loaded onto two ion-exchange columns, interconnected in series: a cation-
exchange column (5 mL-HiTrap SP HP, GE Healthcare) and an anion-
exchange column (5 mL-HiTrap Q HP, GE Healthcare). These columns were 
attached to an Äkta Purifier system (GE Healthcare). The columns were then 
uncoupled and eluted separately using a 0-100% gradient (5 column volumes) 
of lysis buffer B (20 mM MES and 1 M NaCl, pH 5.5) and buffer A (20 mM 
MES and 50 mM NaCl, pH 5.5) as a diluent. All solutions were filter-sterilised 
(0.22 µm Millipore Stericup filter units, Merck) and de-gassed for 30 min prior 
to fractionation. The fractions were collected, filter-sterilised and stored in 1.5 
mL collection tubes at -80oC. Solutions and fractions were filtered using 0.22 
µm Millex-GP Syringe Filter Unit. 
 
2.8.2. SDS-PAGE 
Samples of fractions of SH1000 supernatant, containing 1 X RunBlue LDS 
sample buffer (Expedeon) and 20 mM dithiothreitol (DTT, Expedeon) were 
denatured by heating to 100°C for 5 min prior to separation by SDS-PAGE 
(Sambrook and Russell, 2001). The protein ladder that was used was blue 
prestained protein standard, broad range (11-190 kDa, New England Biolabs). 





2.8.3. Size-exclusion chromatography 
The Äkta Purifier system was also used to perform size-exclusion 
chromatography. A single fraction produced from the ion-exchange 
chromatography was loaded onto a Superdex 75 (16/60) column (GE 
Healthcare) pre-equilibrated with buffer A (20 mM MES and 50 mM NaCl, pH 
5.5), with a flow rate of 0.6 mL/min. Fractions were collected at 3 mL intervals. 
 
2.8.4. Mass spectrometry 
The protein concentration of fractions produced by ion-exchange 
chromatography was determined by the Bradford method (Bradford, 1976). 
Briefly, 1 mL of the Bradford dye (Bio-rad) and 20 µL of each fraction were 
mixed. The absorbance at 595 nm was measured using P300 
nanophotometer (Implen). Bradford dye was used as a blank. Then, aliquots 
of these fractions were sent for mass spectrometry. 
Liquid chromatography-mass spectrometry (LC-MS) was performed by Leeds 
mass spectrometry core facility and the proteins that were detected in each 
fraction were identified. The protocols are described in Appendices and 
supplemental material, 8.4. 
 
 
2.9. Graphs and statistical analysis 
Unless stated otherwise, all graphs were created using GraphPad Prism 7 
(GraphPad Prism version 7.05 for Windows, GraphPad Software, La Jolla 
California USA, www.graphpad.com). Values plotted are means unless 
otherwise indicated and the error bars represent the standard error of mean 
(SEM). 
Statistical analysis was also performed with GraphPad Prism 7 using one-way 
analysis of variance (ANOVA), with the significant difference between groups 
determined by Tukey post-hoc test. The “n” value represents the number of 




value of * p<0.05 was considered statistically significant; * p<0.05, ** p<0.01, 
*** p<0.001. In order to perform statistics, values that were not measurable by 
the assays (below the detection limit) were set to the lowest detection limit 





3. Production of AMPs in keratinocytes in 
response to S. aureus and S. epidermidis 
3.1. Introduction 
The predominant pathogen in AD is S. aureus, found in more than 90% of AD 
patients (Baldry et al., 2018; Chiu et al., 2009; David and Cambridge, 1986). 
In contrast, microbial diversity and especially the presence of S. epidermidis, 
which is ordinarily the most abundant skin commensal, are reduced in AD 
(Nakatsuji et al., 2017; Salava and Lauerma, 2014; Kong et al., 2012; Higaki 
et al., 1999; Otto, 2012; Geoghegan et al., 2018). Although a causative 
relationship between microbial dysbiosis and AD has yet to be proven (Paller 
et al., 2019; Lee et al., 2018), an association between S. aureus colonisation 
and immune system dysregulation in AD has been reported (Di Domenico et 
al., 2018; Tauber et al., 2016; Salava and Lauerma, 2014; Harder et al., 2010; 
Rieg et al., 2005; Harkins et al., 2019). 
Keratinocytes are the main skin cells that produce cytokines and AMPs, 
mainly in response to stimuli, such as bacteria (Zhang and Gallo, 2016; 
Schauber and Gallo, 2008; Schröder, 2010; Suter et al., 2009; Pfalzgraff et 
al., 2018; Yousef et al., 2019). Cytokines are important signalling molecules 
for the skin immune response (Nedoszytko et al., 2014; Coondoo, 2011). The 
IL-8 cytokine is a neutrophil attractant in the epidermis and its levels increase 
in AD (Vlahopoulos et al., 1999; Barker et al., 1991; Jiang et al., 2012; 
Amarbayasgalan et al., 2013). In non-stimulated keratinocytes, IL-8 is usually 
non-detectable. It is not stored in cells but produced and released upon 
stimulation e.g. with staphylococci (Takematsu and Tagami, 1993; 
Mohamadzadeh et al., 1994; Sasaki et al., 2003). Keratinocyte production of 
HBD-2, HBD-3 and LL-37 in AD has been widely studied, due to the potency 
of these AMPs against S. aureus, the most common pathogen in AD and the 
fact that their levels are downregulated in AD. It has been shown that HBD-3 
is more potent against S. aureus compared to HBD-2 and LL-37 (Baldry et al., 
2018; Ong et al., 2002; Midorikawa et al., 2003; Menzies and Kenoyer, 2005; 




Although the exact mechanisms of AMP induction by bacteria have not been 
elucidated, it appears that the induction pathways differ, depending on the 
AMP and even the bacterial species (Steubesand et al., 2009; Chung and 
Dale, 2004; Chung and Dale, 2008). S. epidermidis has been reported to 
induce HBD-2 and HBD-3 expression through TLR2, EGFR and NF-κB 
signaling pathways, whereas S. aureus triggers mainly phosphatidylinositol 3-
kinase and MAPK signaling pathways instead of NF-κB and induces HBD-2 
via IL-1 and HBD-3 via EGFR activation (Sorensen et al., 2005; Lai et al., 
2010; Wanke et al., 2011; Ommori et al., 2013). 
The differentiation stage of keratinocytes may affect their reaction to stimuli. 
Most studies found that HBD-2 is more readily induced in differentiated 
keratinocytes compared to non-differentiated keratinocytes, in contrast to 
HBD-3 (Krisanaprakornkit et al., 2003; Liu et al., 2002; Menzies and Kenoyer, 
2005; Dinulos et al., 2003). However, other studies have reported upregulation 
of both HBD-2 and HBD-3 in differentiated keratinocytes (Harder et al., 2004), 
increased HBD-3 but not HBD-2 expression (Abiko et al., 2003), or no effect 
of the differentiation stage at all (Frye et al., 2001). Other factors may account 
for the different findings in projects, such as different experimental conditions 
(determination of mRNA expression or AMP protein product) or stimulants 
(cytokines, staphylococcal cells or supernatant) (Liu et al., 2002). Although 
differentiated keratinocytes in outermost epidermal layers are the first line 
defence, S. aureus may inhibit terminal differentiation of keratinocytes (Son et 
al., 2014) and skin barrier disruption in AD can increase skin penetration of S. 
aureus and other pathogens towards deeper epidermal layers with nucleated 
keratinocytes (Agrawal and Woodfolk, 2014; Eckert et al., 2002). Therefore, it 
is important to investigate various keratinocyte differentiation stages and the 
interaction of pathogens with host cells from deeper layers as well (Popov et 
al., 2014). 
Keratinocyte monolayers and 3D skin equivalents are both widely used for the 
investigation of skin pathophysiology but have differences in phenotype, cell 
signalling and metabolic functions (Zanoni et al., 2014; Mazzoleni et al., 2009; 
Smalley et al., 2006). A 3D skin equivalent model has a differentiated stratified 
epidermis and dermal fibroblasts and is therefore more similar to human skin 




contrast, 2D keratinocyte monolayers grow in a more controlled environment 
and are more reproducible and easier to manipulate. Growth media can also 
be distributed evenly, allowing a more symmetric cell distribution (Edmondson 
et al., 2014). A reliable model to study keratinocyte response is the HaCaT 
immortalised human keratinocyte cell line, which exhibits lower variability 
compared to primary keratinocytes isolated from human epidermis (Colombo 
et al., 2017). 
A question raised in this project was whether increased S. aureus colonisation 
and microbial dysbiosis, which result in inflammatory responses, can trigger 
AD. In order to investigate differences in the effect of S. aureus and S. 
epidermidis on AMP keratinocyte production and to better understand the role 
of S. aureus in AD pathogenesis, 3D skin equivalent models and keratinocyte 
monolayers were stimulated with staphylococcal cells or supernatants. Most 
previous studies investigated only S. aureus (Midorikawa et al., 2003; Menzies 
and Kenoyer, 2005), or just one S. aureus and one S. epidermidis strain (Lai 
et al., 2010; Holland et al., 2009). However, as bacterial strains even from the 
same species exhibit genotypic and phenotypic differences and may trigger 
different immune responses (Gill et al., 2005; Fux et al., 2005; Sela et al., 
2018), the experiments in this project used a variety of clinical and laboratory 
S. aureus and S. epidermidis strains, including both methicillin susceptible and 
resistant strains. Moreover, most previous studies focused on AMP gene 
expression (Haisma et al., 2013; Wanke et al., 2011). Nevertheless, as 
increased mRNA expression does not necessarily depict increased protein 
production, due to several regulation stages between gene transcription and 
translation of protein (Vogel and Marcotte, 2012; Greenbaum et al., 2003), this 
project evaluated the AMP protein production by ELISA. 
Although AMP levels on lesional AD skin are increased compared to non-
lesional and health skin, they are reduced compared to those seen in other 
inflammatory diseases, such as psoriasis (Méndez-Samperio, 2013). The Th2 
milieu in AD, as opposed to the Th1 axis in psoriasis, may downregulate AMP 
expression (Clausen et al., 2018; Clausen et al., 2016; Hijnen et al., 2013; 
Nomura et al., 2003a; Nomura et al., 2003b). S. aureus can promote Th2 
responses (Mandron et al., 2006) and IL-4 can downregulate gene expression 




et al., 2007; Howell et al., 2006a). Also, addition of IL-4 to keratinocyte 
monolayers stimulated with human serum was shown to reduce HBD-2 




3.2.1. S. aureus cells induce higher HBD-3 production in 3D 
skin equivalent models compared to S. epidermidis 
In order to investigate the effect of S. aureus and S. epidermidis on skin, 3D 
skin equivalent models were exposed to S. aureus USA300 and S. 
epidermidis NCTC6513 live cells. Production of HBD-2 and HBD-3 in the 
culture medium of the skin equivalents was then measured by ELISA2. The 
HBD-2 skin production was induced to higher levels in the presence of S. 
aureus USA300 compared to S. epidermidis NCTC6513 (Figure 3-1a). 
However, the difference was not statistically significant. By contrast, HBD-3 
production was detected only in the presence of S. aureus USA300 (Figure 
3-1b). In addition, the overall HBD-3 concentration produced after stimulation 




                                            
2The skin equivalent experiments were performed by Dr Adewonuola Alase, post-
doctoral researcher in the Wellcome Trust Brenner Building (St. James’s University 








































Figure 3-1: Production of HBD-2 and HBD-3 by skin equivalent models after 
stimulation with S. aureus and S. epidermidis cells 
Skin equivalents were stimulated S. aureus USA300 or S. epidermidis NCTC6513 
cells for 16 h and production of HBD-2 (a) and HBD-3 (b) was measured by ELISA. 
One-way ANOVA was used to determine statistical significance, n=3. Values are 
mean ± SEM, * p<0.05, ns: non-significant. Where the values were below the 
detection limit (PBS and NCTC6513), they were set to 62.5 pg/mL (lowest detection 





3.2.2. Is failure to induce HBD-3 production a general trait of 
S. epidermidis strains? 
The effect of S. aureus and S. epidermidis on keratinocyte AMP production 
detected in skin equivalents was further investigated, using a larger collection 
of staphylococcal strains. As the genome of a single strain cannot be 
representative for the species (Fux et al., 2005), various strains were chosen, 
laboratory and clinical isolates. Therefore, in addition to previously 
characterised laboratory and clinical strains, two other S. epidermidis strains 
were used in this study, which were isolated from healthy subjects and named 
SE3 and SE9. Gram staining and coagulase tests (Materials and methods, 
2.2.2.1) confirmed that these strains were Gram-positive and coagulase-
negative, in accordance with S. epidermidis characteristics (Figure 3-2). To 
further characterise these strains, PCR amplification and DNA sequencing 
was performed on genomic DNA isolated from both strains. Primers specific 
for the rpoB gene were used to confirm these isolates as S. epidermidis 









(a)  (b)  (c)  (d)  
(e)  
Figure 3-2: Gram staining and coagulase test of S. epidermidis SE3 and SE9 
skin isolates 
The Gram-positive S. epidermidis SE3 (a), S. epidermidis SE9 (b) and S. aureus 
SH1000 (c) were stained purple. The Gram-negative Escherichia coli (d) was stained 
red. For the coagulase test (e), the coagulase-negative S. epidermidis NCTC6513 
and the coagulase-positive S. aureus SH1000 were used as controls. [(e) Full strain 
names from left to right: S. aureus SH1000, S. epidermidis NCTC6513, S. 
epidermidis SE3, S. epidermidis SE9] 
 
3.2.3. Induction of AMPs by S. aureus and S. epidermidis 
cells in keratinocyte monolayers  
In order to investigate HBD-3 production in skin equivalent models in more 
detail, further experiments were performed with keratinocyte monolayers. 
Compared to skin equivalent models, keratinocyte monolayers are easier to 
grow in a controlled environment that can be adapted to the needs of the 
experiments. Also, growth media and stimulants can be distributed evenly, 
allowing more consistent results (Edmondson et al., 2014). Monolayers of 
HaCaT cells were cultured in 24-well plates and stimulated independently with 
whole cultures of S. aureus (USA300, SH1000, UAMS-1, WC003 and WC006) 
and S. epidermidis strains (NCTC11047, NCTC6513, SE3, SE9 and 
7765746). In accordance with the results using skin equivalents (Figure 3-1b), 
all S. aureus strains and none of the S. epidermidis strains induced HBD-3 




























































Figure 3-3: Production of HBD-3 by HaCaT cells after stimulation with S. aureus 
and S. epidermidis cells 
HaCaT monolayers were stimulated with staphylococcal cultures for 20 h and HBD-3 
production was measured by ELISA. One-way ANOVA was used to determine 
statistical significance, n=4. Values are mean ± SEM, *** p<0.001. Where the values 
were below the detection limit (DMEM, TSB and the S. epidermidis strains), they were 
set to 62.5 pg/mL (lowest detection limit of the HBD-3 ELISA assay) to allow statistical 
analysis. The full names of the x-axis labels from left to right are: DMEM, TSB, S. 
aureus USA300 (USA), S. aureus SH1000 (SH1000), S. aureus UAMS-1 (UAMS), 
S. aureus WC003 (WC3), S. aureus WC006 (WC6), S. epidermidis NCTC11047 
(N1), S. epidermidis NCTC6513 (N6), S. epidermidis SE3 (SE-3), S. epidermidis SE9 
(SE-9) and S. epidermidis 7765746 (SE-46). 
 
The previous experiment showed that all S. aureus but none of the S. 
epidermidis strains induced HBD-3. The next step was to investigate whether 
S. epidermidis did not actively stimulate HBD-3 production, or whether it was 
too toxic and thereby rendered the HaCaT cells unable to respond to 
stimulation with S. epidermidis cells and produce immune molecules. For this 
reason, the ability of HaCaT cells to respond to stimuli by releasing immune 
mediators after staphylococcal stimulation was determined, by measuring the 
IL-8 HaCaT production after stimulation with S. epidermidis and S. aureus 
cells. As Figure 3-4 shows, there was no significant difference in the IL-8 
production by HaCaT cells, regardless of whether they were stimulated with 
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Figure 3-4: Production of IL-8 by HaCaT cells after stimulation with S. aureus 
and S. epidermidis cells 
HaCaT monolayers were stimulated with staphylococcal cultures for 20 h and IL-8 
production was measured by ELISA. One-way ANOVA was used to determine 
statistical significance, n=3. Values are mean ± SEM, ns: non-significant. Where the 
values were below the detection limit (DMEM and TSB), they were set to 15.6 pg/mL 
(lowest detection limit of the IL-8 ELISA assay) to allow statistical analysis. The full 
names of the x-axis labels are as in Figure 3-3. 
 
In order to investigate whether the different inducing effect of S. aureus and 
S. epidermidis on HBD-3 keratinocyte production applies to other AMPs, this 
project also examined induction of LL-37, as it is a major skin AMP, along with 
HBDs (Kim et al., 2005). Only S. aureus SH1000 and to a lesser extent S. 
epidermidis SE3 induced higher LL-37 production compared to the levels 
present in the controls (Figure 3-5). Therefore, in contrast to the situation with 
HBD-3 production, the inducing effect is neither a general feature of S. aureus 





























































Figure 3-5: Production of LL-37 by HaCaT cells after stimulation with S. aureus 
and S. epidermidis cells 
HaCaT monolayers were stimulated with staphylococcal cultures for 20 h and LL-37 
production was measured by ELISA. One-way ANOVA was used to determine 
statistical significance, n=3. Values are mean ± SEM, * p<0.05, *** p<0.001. The full 
names of the x-axis labels are as in Figure 3-3. 
 
3.2.4. S. aureus supernatant induces higher HBD-3 
production in keratinocyte monolayers compared to S. 
epidermidis 
After investigating the effect of S. aureus and S. epidermidis live cells on 
HaCaT monolayers, it was decided to test whether the S. aureus factor(s) that 
induced AMP production were found in the growth media, in order to further 
plan experimental procedures to investigate these factor(s). Following growth 
of S. aureus and S. epidermidis cultures, bacteria were harvested and their 
supernatant was retained and filter-sterilised. Then, HaCaT monolayers were 
stimulated with filter-sterilised supernatants and HBD-2, HBD-3 and LL-37 
production was measured as before (Figure 3-6). Production of HBD-3 was 
induced at high levels after stimulation with S. aureus supernatants (Figure 
3-6a), similar to the results from the experiments with staphylococcal cultures 




that the S. aureus-inducing factor(s) driving HBD-3 production are present in 
the growth media. The HBD-2 levels were below the limit of detection (data 
not shown), unlike the 3D skin equivalents, where both stimulated and non-
stimulated skin equivalents produced HBD-2 (Figure 3-1a). LL-37 was 
produced at similar levels for non-stimulated HaCaT monolayers and HaCaTs 
stimulated with staphylococcal supernatants (Figure 3-6b). This is in line with 
the results from stimulation of HaCaTs with staphylococcal cultures for all 
strains except S. aureus SH1000 and S. epidermidis SE3 (Figure 3-5), 
suggesting that the inducing factor(s) produced by SH1000 and SE3 are cell-
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Figure 3-6: Production of HBD-3 and LL-37 by HaCaT cells after stimulation 
with S. aureus and S. epidermidis supernatants 
HaCaT monolayers were stimulated with staphylococcal supernatants for 24 h and 
production of HBD-3 (a) and LL-37 (b) was measured by ELISA. One-way ANOVA 
was used to determine statistical significance, n=4 (a), n=3 (b). Values are mean ± 
SEM, * p<0.05, *** p<0.001, ns: non-significant. Where the values were below the 
detection limit [DMEM, TSB and the S. epidermidis strains of graph (a)], they were 
set to 62.5 pg/mL (lowest detection limit of the HBD-3 ELISA assay) to allow statistical 




As the HBD-3 production after stimulation of HaCaTs with S. epidermidis 
supernatants was below the detection limit, a toxicity assay was performed, in 
order to rule out the possibility that S. epidermidis supernatants were more 
toxic than S. aureus, hence causing a reduction in HBD-3 production. The 
results showed that there was no statistically significant difference in the 




















































Figure 3-7: Toxicity of S. aureus and S. epidermidis supernatants towards 
HaCaT cell monolayers 
HaCaT monolayers were stimulated with staphylococcal supernatants for 24 h. 
Luminescence of dead and alive HaCaT cells was determined by Toxilight. Toxicity 
represents the killing of HaCaT cells (ratio of dead HaCaT cells to total HaCaT cells) 
after stimulation. One-way ANOVA was used to determine statistical significance, 
n=4. Values are mean ± SEM, ns: non-significant. The full names of the x-axis labels 
are as in Figure 3-3. 
 
Although the HaCaT cell line is a reliable model to study keratinocyte 
response (Colombo et al., 2017), the ability of S. aureus to induce HBD-3 
production was confirmed in primary keratinocyte monolayers isolated from 
the epidermis of adult skin (Promocell). Keratinocytes were stimulated with 




with HaCaT cells (Figure 3-6a), it was found that production of HBD-3 was 
induced only after stimulation with S. aureus. Although all S. aureus strains 
induced HBD-3, induction mediated by the WC006 strain was not statistically 



























































Figure 3-8: Production of HBD-3 by primary keratinocytes after stimulation with 
S. aureus and S. epidermidis supernatants 
Primary keratinocyte monolayers were stimulated with staphylococcal supernatants 
for 24 h and HBD-3 production was measured by ELISA. One-way ANOVA was used 
to determine statistical significance, n=4. Values are mean ± SEM, *** p<0.001. 
Where the values were below the detection limit (KGM, TSB and the S. epidermidis 
strains), they were set to 62.5 pg/mL (lowest detection limit of the HBD-3 ELISA 
assay) to allow statistical analysis. The full names of the x-axis labels from left to right 
are: KGM, TSB, S. aureus USA300 (USA), S. aureus SH1000 (SH1000), S. aureus 
UAMS-1 (UAMS), S. aureus WC003 (WC3), S. aureus WC006 (WC6), S. epidermidis 
NCTC11047 (N1), S. epidermidis NCTC6513 (N6), S. epidermidis SE3 (SE-3), S. 
epidermidis SE9 (SE-9) and S. epidermidis 7765746 (SE-46). 
 
In addition, there was no statistically significant difference in the toxicity levels 
of S. epidermidis compared to S. aureus and the controls (Figure 3-9), in 






















































Figure 3-9: Toxicity of S. aureus and S. epidermidis supernatants towards 
primary keratinocytes 
Primary keratinocyte monolayers were stimulated with staphylococcal supernatants 
for 24 h. Luminescence of dead and alive keratinocytes was determined by Toxilight. 
Toxicity represents the killing of keratinocytes (ratio of dead keratinocytes to total 
keratinocytes) after stimulation. One-way ANOVA was used to determine statistical 
significance, n=3. Values are mean ± SEM, ns: non-significant. The full names of the 
x-axis labels are as in Figure 3-8. 
 
3.2.5. S. epidermidis does not actively suppress HBD-3 
keratinocyte production 
None of the S. epidermidis strains induced detectable HBD-3 production in 
keratinocytes or showed higher levels of toxicity compared to S. aureus. 
Whilst it was considered likely that this reflected the absence in S. epidermidis 
of the inducing factor(s) present in S. aureus, an alternative possibility was 
that S. epidermidis produces – in addition to the inducing factor(s) – one or 
more factors that inhibit HBD-3 production. In order to test this possibility, 
HaCaT monolayers were stimulated with a combination of S. aureus and S. 
epidermidis supernatants at different ratios. If the assumption about 
production of inhibiting factors by S. epidermidis was true, then combination 




keratinocyte production compared to stimulation by S. aureus supernatant 
only. Despite addition of different concentrations of S. epidermidis 
supernatant, there was no reduction in HBD-3 production by HaCaTs when 
stimulated with S. aureus (Figure 3-10). Therefore, it is unlikely that there is a 
S. epidermidis factor that is actively inhibiting HBD-3 production in 
keratinocytes. 
 




















Figure 3-10: Production of HBD-3 by HaCaT cells after stimulation with 
combinations of S. aureus and S. epidermidis supernatants 
HaCaT monolayers were stimulated with mixtures of S. aureus SH1000 and S. 
epidermidis NCTC6513 supernatants for 24 h. All wells contained the same ratio of 
TSB/DMEM and the same amount of S. aureus supernatant, whereas the 
concentration of S. epidermidis supernatant was increasing. A well with 9 parts of S. 
epidermidis was used as negative control (SE) and a well with just 1 part of S. aureus 
was the positive control (SA). The HBD-3 production was measured by ELISA. One-
way ANOVA was used to determine statistical significance, n=4. Values are mean ± 
SEM, ns: non-significant. Where the values were below the detection limit (DMEM, 
TSB and SE), they were set to 62.5 pg/mL (lowest detection limit of the HBD-3 ELISA 






3.2.6. Some S. aureus strains do not induce HBD-3 in 
keratinocytes 
The 5 S. aureus strains tested in the previous experiments induced HBD-3 
production in keratinocytes (Figure 3-6a). In order to investigate whether this 
trait is universal to all S. aureus strains, HaCaT monolayers were stimulated 
with supernatants from several clinical isolates (Figure 3-11 and Table 3-1). 
The majority of the strains induced HBD-3, in various levels. However, the 
supernatants of 8 S. aureus strains lacked the ability to induce HBD-3 
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Figure 3-11: S. aureus strains have varying ability to induce HBD-3 in 
keratinocytes 
HaCaT monolayers were stimulated with supernatants from S. aureus clinical isolates 











Table 3-1: Supernatants from S. aureus clinical isolates have varying ability to 
induce HBD-3 in keratinocytes 
The supernatants isolated from all strains in Table 3-1a induced HBD-3 production in 
keratinocytes. The supernatants from the strains in Table 3-1b did not exhibit such 
an effect. 
(a) (+) HBD-3 induction  b) (-) HBD-3 induction 
USA300 NRS786 MOS53 MOS208  CS6-EEFIC MOS287 
UAMS-1 851 MOS128 MOS227  602 MOS457 
WC003 860 MOS135 MOS229  1128 MOS148 
WC006 979 MOS153 MOS259  805 MOS283 
NRS65 1076 MOS165 MOS412    
NRS720 1083      
 
One potential explanation for failure of supernatants of these S. aureus strains 
to induce HBD-3 was that these strains produced a toxic component that 
rendered the keratinocytes unable to respond and produce immune 
mediators. Therefore, the toxicity of the supernatants of these S. aureus 
strains towards HaCaT cells was tested (Figure 3-12). The supernatants of S. 
aureus 1128 and 805 showed increased toxicity towards HaCaT cells (Figure 
3-12), suggesting that this might be a contributory factor in the failure of these 





























































Figure 3-12: Toxicity of the S. aureus supernatants that did not induce HBD-3 
in HaCaT cells 
HaCaT monolayers were stimulated with staphylococcal supernatants for 24 h. 
Luminescence of dead and alive HaCaT cells was determined by Toxilight. Toxicity 
represents the killing of HaCaT cells (ratio of dead HaCaT cells to total HaCaT cells) 
after stimulation. One-way ANOVA was used to determine statistical significance, 
n=3. Values are mean ± SEM, * p<0.05, ** p<0.01, ns: non-significant. 
 
The toxicity of these supernatants was confirmed visually by microscopic 
analysis of cultured cells (data not shown); incubation of HaCaT cells with S. 
aureus 1128 and 805 supernatants led to an increased number of detached 
HaCaT cells compared to when HaCaT cultures were incubated with other 
strains. 
The lack of HBD-3 induction associated with these 8 strains (Table 3-1b), 
could imply that they either lack the inducing factor(s) or they do not release 
them into the growth media in sufficient quantities to trigger induction. In order 
to further investigate this, HaCaT monolayers were stimulated with 
staphylococcal cultures from these strains (Figure 3-13). As expected, S. 
aureus SH1000 induced HBD-3 production in HaCaT cells. Also, cells of S. 
aureus MOS283 and MOS287 induced significant HBD-3 production, 




be associated with the cell envelope rather than released into the growth 
media. Moreover, CS6-EEFIC, MOS148 and MOS457 strains also showed 
some HBD-3 induction. However, HBD-3 production was still not induced by 
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Figure 3-13: Production of HBD-3 by HaCaT cells after stimulation with the S. 
aureus cells whose supernatants failed to induce HBD-3 
HaCaT monolayers were stimulated with staphylococcal cultures for 20 h and HBD-3 
production was measured by ELISA. One-way ANOVA was used to determine 
statistical significance, n=4; Values are mean ± SEM, *** p<0.001. Where the values 
were below the detection limit (DMEM and TSB), they were set to 62.5 pg/mL (lowest 
detection limit of the HBD-3 ELISA assay) to allow statistical analysis. 
 
In order to determine if these strains are able to induce production of other 
immune mediators in HaCaT cells, IL-8 induction was determined, essentially 
as described in section 3.2.3 (Figure 3-4). All strains induced IL-8 production 
in HaCaT cells, implying that the lack of induction in these strains is specific 
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Figure 3-14: Production of IL-8 by HaCaT cells after stimulation with the S. 
aureus cells whose supernatants failed to induce HBD-3 
HaCaT monolayers were stimulated with staphylococcal cultures for 20 h and IL-8 
production was measured by ELISA. One-way ANOVA was used to determine 
statistical significance, n=3. Values are mean ± SEM, ns: non-significant. Where the 
values were below the detection limit (DMEM and TSB), they were set to 15.6 pg/mL 
(lowest detection limit of the IL-8 ELISA assay) to allow statistical analysis. 
 
3.2.7. The Th2 cytokine IL-4 may reduce S. aureus-induced 
HBD-3 production in keratinocytes 
The previous experiments showed that S. aureus can induce HBD-3 
production in keratinocytes (Figure 3-6a). HBD-3 is considered to be more 
potent against S. aureus compared to other AMPs (HBD-2, LL-37) (Joly et al., 
2004; Midorikawa et al., 2003; Kisich et al., 2008). AMP expression in AD is 
lower compared to other inflammatory diseases such as psoriasis (Clausen et 
al., 2016) and atopic skin shows increased susceptibility to S. aureus (Hata 
and Gallo, 2008; Ong et al., 2002; Nomura et al., 2003b; Lin et al., 2007). Also, 
AD is characterised by a shift towards the Th2 axis and IL-4 is a key Th2 
cytokine for AD (Brandt and Sivaprasad, 2011; Shiohara, 2011). In order to 




keratinocytes stimulated with S. aureus, HaCaT monolayers were treated with 
IL-4 (Peprotech) for 1 h, before stimulation with filter-sterilised S. aureus 
SH1000 supernatant (Figure 3-15). Production of HBD-3 was reduced to an 
extent when IL-4 concentration increased (Figure 3-15), which suggests that 
an atopic environment could have a direct effect on the ability of S. aureus to 





























































Figure 3-15: Production of HBD-3 by HaCaT cells pretreated with IL-4 and 
stimulated with S. aureus supernatant 
HaCaT monolayers were pre-treated with IL-4 for 1 h and were then stimulated with 
SH1000 supernatant for 24 h. DMEM, TSB and IL-4 were used as negative controls. 
Production of HBD-3 was measured by ELISA (n=1). 
 
In order to further investigate changes of HBD-3 in an atopic environment, Dr 
Anna Berekmeri3 measured both HBD-2 and HBD-3 in the stratum corneum 
of healthy people, patients with psoriasis and AD patients by tape stripping 
(Figure 3-16). She found that the production of HBD-3 (and not HBD-2) was 
                                            
3Dr Anna Berekmeri is a PhD student in the University of Leeds, supervised by Dr 




significantly higher in lesional psoriatic skin compared to lesional AD skin 
(Figure 3-16), suggesting that HBD-3 production in AD is lower compared to 
























































































Figure 3-16: Production of HBD-2 and HBD-3 in lesional psoriatic and lesional 
AD skin 
Production of HBD-2 and HBD-3 was measured by ELISA in tape strip samples from 
the stratum corneum of healthy people, patients with psoriasis and AD patients, 





In order to better understand the role of S. aureus in AD pathogenesis, 
keratinocyte response to S. aureus and S. epidermidis was investigated. 
Although much research has been conducted on the effect of staphylococci 
on AMP keratinocyte production, the results are not always consistent (Wanke 
et al., 2011; Ommori et al., 2013; Lai et al., 2010). Factors that may account 
for the different findings of this project (as well as previous projects) are 
different experimental conditions such as the determination of mRNA 
expression or AMP protein production (Vogel and Marcotte, 2012; Greenbaum 
et al., 2003), stimulants (cytokines, staphylococcal cells or secreted factors) 
(Liu et al., 2002), or the keratinocyte differentiation stage (Krisanaprakornkit 
et al., 2003; Liu et al., 2002). 
 
The effect of S. aureus and S. epidermidis on AMP production in keratinocytes 
To further investigate previous findings, the work in this chapter tested the 
effect of S. aureus and S. epidermidis on the induction of HBD-2, HBD-3 and 
LL-37, which are important skin AMPs that show high potency against S. 
aureus but whose levels do not seem to correspond to the degree of 
inflammation in AD (Hata and Gallo, 2008; Ong et al., 2002; Nomura et al., 
2003b). The results showed that S. aureus and not S. epidermidis triggered 
HBD-3 induction in keratinocyte monolayers and skin equivalents and that the 
HBD-3-inducing factor(s) can usually be found in the S. aureus supernatant 
(Figure 3-1, Figure 3-3, Figure 3-6 and Figure 3-8). In line with these results, 
a previous study detected HBD-3 production in keratinocytes only after 
stimulation with S. aureus cells and supernatant and not S. epidermidis 
(Ommori et al., 2013), while other studies reported significantly higher HBD-3 
expression after exposure of skin equivalents and keratinocyte monolayers to 
S. aureus compared to S. epidermidis (Haisma et al., 2013; Wanke et al., 
2011). It has been shown that stimulation of skin equivalents with S. 
epidermidis cells had a much lower impact on overall gene expression in the 
skin equivalent, whereas S. aureus cells increased the expression of genes 
associated with cytokine production (Holland et al., 2009), supporting the 




explain the different effects of S. epidermidis and S. aureus on the skin 
(Steubesand et al., 2009; Chung and Dale, 2004; Chung and Dale, 2008). 
The skin equivalents produced only low amounts of HBD-2 after stimulation 
with S. aureus live cells and even lower following S. epidermidis induction 
(Figure 3-1). Stimulation of skin equivalents with staphylococci for a longer 
period of time may possibly have induced higher HBD-2 production. 
Nevertheless, the duration of stimulation that was chosen allowed adequate 
time for interactions between staphylococci and skin cells and HBD-3 was still 
induced by S. aureus, consistent with the experiments using keratinocyte 
monolayers (Figure 3-3, Figure 3-6 and Figure 3-8) (Vu et al., 2010; Simanski 
et al., 2016). Production of HBD-2 was undetectable in keratinocyte 
monolayers when stimulated with staphylococcal supernatants, in line with a 
previous study that did not find HBD-2 expression in keratinocytes exposed to 
S. epidermidis and S. aureus supernatants (Wanke et al., 2011). However, 
another study observed production of HBD-2 by keratinocytes exposed to S. 
epidermidis and S. aureus live cells and supernatant from S. epidermidis 
(Ommori et al., 2013). Unlike the work in this chapter, they used primary 
keratinocytes, different staphylococcal strains and different experimental 
conditions (108 CFU and supernatant from a 3-day staphylococcal culture) 
(Ommori et al., 2013). Probably, cells are more able to induce HBD-2 than 
supernatants and HBD-2 production may also be affected by the S. 
epidermidis strain used (Gill et al., 2005; Fux et al., 2005; Sela et al., 2018). 
Regarding LL-37, only cells from S. aureus SH1000 and S. epidermidis SE3 
induced significant LL-37 production (Figure 3-5 and Figure 3-6). Results are 
conflicting, as some researchers report no increase in LL-37 expression upon 
stimulation with S. epidermidis (Lai et al., 2010) or S. aureus (Menzies and 
Kenoyer, 2005), whereas others report upregulation by S. aureus (Midorikawa 
et al., 2003). LL-37 induction may also be influenced by the staphylococcal 
strains used (Gill et al., 2005; Fux et al., 2005; Sela et al., 2018), or by the fact 
that previous studies evaluated gene expression, unlike this project, which 





Even though the findings of this chapter conflict with some previous studies 
that evaluated AMP mRNA expression in keratinocytes stimulated by 
staphylococci (Lai et al., 2010), the results shown herein are based on 
measurement of AMP protein production by ELISA. Increased mRNA 
expression does not necessarily depict increased protein production, due to 
several regulation stages between gene transcription and the translation of 
protein (Vogel and Marcotte, 2012; Greenbaum et al., 2003). Strengthening 
the findings in this chapter, several S. aureus and S. epidermidis strains were 
tested (clinical and laboratory strains, methicillin susceptible and resistant) 
and the staphylococcal effect on HBD-3 production was consistent in 3D skin 
equivalents and monolayers of HaCaTs and primary keratinocytes. As 
different pathways may be implicated in different AMP induction by pathogens 
and commensals (Sorensen et al., 2005; Lai et al., 2010; Wanke et al., 2011; 
Ommori et al., 2013) and S. aureus is a leading cause of skin infections (Tong 
et al., 2015; Kong et al., 2012; Otto, 2013; Bouvet et al., 2017), it seems 
conceivable that the skin may have evolved a S. aureus-specific pathway that 
results in increased HBD-3 production in keratinocytes. Also, HBD-3 is a 
potent AMP against S. aureus and has been found to be associated with the 
control of S. aureus colonisation (Zanger et al., 2010; Haisma et al., 2013; 
Kisich et al., 2008). 
 
S. epidermidis does not actively suppress HBD-3 keratinocyte production 
Further investigation aimed to determine the underlying cause in 
differentiation between the abilities of S. epidermidis and S. aureus to induce 
HBD-3. There was no difference in the survival of keratinocytes (Figure 3-7 
and Figure 3-9) and in their ability to produce immune mediators (Figure 3-4) 
(Jiang et al., 2012) after stimulation with S. aureus and S. epidermidis. Also, 
S. epidermidis supernatant did not reduce the ability of S. aureus to induce 
HBD-3 production in keratinocytes (Figure 3-10), in line with previous research 
(Wanke et al., 2011). It is therefore unlikely that S. epidermidis produces 
factor(s) that can actively inhibit HBD-3 keratinocyte production, which 
suggests that S. epidermidis does not trigger HBD-3 response in keratinocytes 




selectively express HBD-3 upon exposure to S. aureus by detecting 
components unique to this bacterium. 
 
Is the induction of HBD-3 in keratinocytes a universal trait of S. aureus? 
The work in this chapter also investigated whether the ability to induce HBD-3 
production in keratinocytes is universal to all S. aureus strains. In addition to 
the 5 S. aureus strains that were initially tested (Figure 3-6), 26 S. aureus 
clinical isolates were screened (Figure 3-11 and Table 3-1). Supernatants 
from all but 8 of these S. aureus strains induced HBD-3 production in 
keratinocytes (Figure 3-11 and Table 3-1). When the ability of cells from these 
8 strains to induce HBD-3 in keratinocytes was examined, it was found that 
cells of MOS283 and MOS287 induced significant HBD-3 production, whereas 
cells of CS6-EEFIC, MOS148 and MOS457 strains also showed some HBD-3 
induction (Figure 3-13), suggesting that the HBD-3-inducing factor(s) they 
produce may predominantly be associated with the cell envelope rather than 
released into the growth media. Therefore, HBD-3 production was not induced 
by 3 out of 30 clinical isolates screened in total (Figure 3-13). The total amount 
of proteins-toxins produced may possibly vary among S. aureus strains, which 
would indicate that some strains are more toxic and keratinocytes may be 
unable to respond and produce immune mediators. Although supernatants 
from two of the strains that did not induce HBD-3 (1128 and 805) were found 
to be toxic for keratinocytes (Figure 3-12), production of other immune 
mediators by HaCaTs (such as IL-8) in the presence of these strains was not 
impaired (Figure 3-14). Previous work has found that S. aureus serine 
proteases can induce IL-8 through NF-κB activation (Rudack et al., 2009), 
whereas other researchers reported that proteases, such as recombinant S. 
aureus superantigen-like protein, can degrade recombinant IL-8 (Tang et al., 
2019). The results of the experiment in this chapter suggest that either the 
proteases produced by S. aureus strains may degrade HBD-3 but not IL-8, or 
that these strains activate IL-8 through a pathway different to the HBD-3 
induction pathway. Indeed, it has been reported that expression of IL-8 is 
mediated by NF-κB (Dejean et al., 2012; Roebuck, 1999; Mukaida et al., 1994; 




whereas S. aureus HBD-3 induction is mediated through phosphatidylinositol 
3-kinase and MAPK, independently of NF-κB (Wanke et al., 2011). 
 
S. aureus HBD-3-inducing factor(s) are released into the supernatant 
The finding that S. aureus HBD-3-inducing factor(s) were present in the 
supernatant of the majority of S. aureus strains (Figure 3-6, Figure 3-8 and 
Figure 3-11) is important in order to plan further experimental procedures and 
facilitate the research towards the identification of these factor(s). It is not 
known yet whether the HBD-3-inducing factor(s) are intracellular and are 
released from the cells upon spontaneous lysis; cell-bound, which may be 
shed extracellularly during the growth cycle; or actively secreted into the 
supernatant. However, as washed S. aureus cells and filter-sterilised 
supernatant both induced HBD-3 keratinocyte production (Figure 3-1, Figure 
3-6 and Figure 3-8), it may be hypothesised that these factor(s) are surface-
associated that may be released into the supernatant and be recognised by 
keratinocytes. For instance, IsaB is a S. aureus protein which was found to be 
both secreted and surface-associated (Mackey-Lawrence et al., 2009). 
 
The effect of IL-4 on the HBD-3 production in keratinocytes stimulated with S. 
aureus 
S. aureus can promote Th2 responses (Mandron et al., 2006) and IL-4 can 
downregulate gene expression of HBD-2 and HBD-3 in keratinocytes, induced 
by other cytokines (Albanesi et al., 2007; Howell et al., 2006a). Addition of IL-4 
to keratinocyte monolayers stimulated with human serum was shown to 
reduce HBD-2 protein production (Alase et al., 2012). This project found that 
HBD-3 production in response to S. aureus-inducing factor(s) was reduced 
when IL-4 concentration increased in keratinocytes (Figure 3-15). Although 
more research is required in order to optimise the conditions of the experiment 
(e.g. concentrations of IL-4 and S. aureus supernatant and incubation times), 
this experiment indicates that the elevated IL-4 cytokine production of the 
atopic environment (Matsunaga and Yamauchi, 2016; Gandhi et al., 2017) can 




response to S. aureus. This supports the importance of HBD-3 in skin defence 
against S. aureus, as AD is characterised by a failure to effectively counter S. 
aureus infection (Baldry et al., 2018; Chiu et al., 2009; David and Cambridge, 
1986) and the AMP levels in AD do not seem to correspond to the degree of 
inflammation (Hata and Gallo, 2008; Ong et al., 2002; Nomura et al., 2003b; 
Lin et al., 2007). The inadequate immune response in AD may be caused by 
absence of induction of HBD-3 by S. aureus or by inability of the immune 
system to initiate effective HBD-3 production. 
Previous research found higher HBD-2 levels in psoriatic skin compared to 
AD skin and assumed that this might account for the difference in inflammation 
levels between psoriasis and AD (Jansen et al., 2009). However, Dr 
Berekmeri found that the production of HBD-3 (and not HBD-2) was 
significantly higher in lesional psoriatic skin compared to lesional AD skin 
(Figure 3-16). This finding (Figure 3-16), along with the result of the 
experiment of this project (Figure 3-15) and the fact that HBD-3 is more potent 
against S. aureus than HBD-2 (Schibli et al., 2002; Dhople et al., 2006; Harder 
et al., 2001; Jung et al., 2011), suggests a key role for HBD-3 in AD dysbiosis 
and a possible justification of the fact that there is less infection in psoriasis 
compared to AD (Nowicka and Grywalska, 2018; Christophers and Henseler, 
1987; Elfatoiki et al., 2016). 
 
In conclusion, this chapter has identified a clear difference in the effect of S. 
epidermidis and S. aureus on the induction of HBD-3 in keratinocytes. Taking 
into account the fact that S. aureus is a leading cause of skin infections (Tong 
et al., 2015; Bouvet et al., 2017) and that HBD-3 is found to be more potent 
against S. aureus compared to other AMPs (Jung et al., 2011; Ouhara et al., 
2008), it is suggested that the skin may have evolved an HBD-3 pathway 
specific to S. aureus, while S. aureus may develop mechanisms to protect 
itself from this HBD-3 response. In order to further investigate the difference 
in the interaction of S. epidermidis and S. aureus with keratinocytes and 
explain why some S. aureus strains induce low or no HBD-3 in keratinocytes, 
the following chapter of the project will investigate the HBD-3-inducing 




4. Nature of the S. aureus HBD-3-inducing 
factor(s) 
4.1. Introduction 
Findings described in the previous chapter indicate that there are one or more 
factors produced by S. aureus that induce HBD-3 production in keratinocytes. 
This chapter describes further investigations into these HBD-3-inducing S. 
aureus factor(s), by examining the effect of the Agr system on the expression 
of these factor(s), their heat-stability and whether they contain a 
proteinaceous component. Further approaches to isolate and identify these 
factor(s) were also attempted. 
The S. aureus secretome refers to all proteins secreted by staphylococcal 
cells in the extracellular environment and represents about 30% of its 
proteome (Mukherjee and Mani, 2013; Agrawal et al., 2010). Various studies 
have tried to identify the role of S. aureus secreted proteins, as they play an 
important role in its virulence and affect the host responses to S. aureus 
colonisation (Kusch and Engelmann, 2014; Koppenol-Raab et al., 2017; 
Ravipaty and Reilly, 2010). As the S. aureus Agr system is a major regulator 
that controls the expression of several genes encoding surface-associated 
and secreted virulence factors (Wang and Tom, 2016; Boles and Horswill, 
2008), it was hypothesised that it may also regulate the HBD-3-inducing 
factor(s). The Agr system can regulate the resistance of S. aureus to AMPs, 
e.g. through the expression of proteases that degrade AMPs (Joo and Otto, 
2015; Lai et al., 2007). The expression of agr in S. aureus is influenced by the 
RNA polymerase factor SigB, which is itself activated by phosphoserine 
phosphatase RsbU. Signals that promote activation of RsbU and therefore 
SigB in S. aureus have not been fully elucidated but one trigger is believed to 
be environmental stress (Lauderdale et al., 2009; Pane-Farre et al., 2009; 
Pförtner et al., 2014). The SigB protein was found to modulate agr expression, 
downregulate the production of virulence factors such as proteases (Karlsson-
Kanth et al., 2006) and promote biofilm formation and intracellular growth 
(Tuchscherr et al., 2015). However, the exact effects of SigB on production of 




2014). Mutations of sigB gene in S. aureus SH1000 and USA300 strains were 
found to upregulate the Agr system, leading to increased virulence and 
reduced biofilm formation (Lauderdale et al., 2009; Savage et al., 2013a). In 
addition, mutations in agr have resulted in strains with an increased ability to 
evade the host’s immune system, due to increased expression of surface 
proteins, enhanced biofilm formation and decreased expression of secreted 




4.2.1. The effect of S. aureus Agr system on the induction of 
HBD-3 in keratinocytes 
As the S. aureus Agr system is a major regulator of the expression of virulence 
factors (Wang and Tom, 2016), it was hypothesised that it might also regulate 
the S. aureus factor(s) that induce HBD-3 production in keratinocytes. In order 
to investigate this, HaCaT cells were stimulated with supernatants from 
mutants of S. aureus SH1000 and USA300 strains exhibiting altered Agr 
function (Table 4-1 and Figure 4-1). Production of HBD-3 was reduced 
noticeably when HaCaT cells were stimulated with supernatants from strains 
exhibiting increased Agr activity (WV1 and NE1109) compared to the parental 
strains. However, the difference was statistically significant for WV1 only 
(Figure 4-1). Conversely, when HaCaT cells were exposed to supernatants 
from the agr-defective mutant NE1532, HBD-3 production was significantly 
higher compared to the parental strain USA300 (Savage et al., 2013a; BEI 
Resources, c2019). However, HBD-3 induction by the agr-defective variant of 
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Figure 4-1: Production of HBD-3 by HaCaT cells stimulated with supernatants 
from S. aureus strains with altered Agr activity 
HaCaT monolayers were stimulated with supernatants from S. aureus strains with 
altered Agr function for 24 h and HBD-3 production was measured by ELISA. 
One-way ANOVA was used to determine statistical significance, n=3. Values are 
mean ± SEM, * p<0.05, *** p<0.001, ns: non-significant. Where the values were 
below the detection limit (DMEM, TSB and WV1), they were set to 62.5 pg/mL (lowest 
detection limit of the HBD-3 ELISA assay) to allow statistical analysis. 
 
The failure of S. aureus WV1 supernatant to induce HBD-3 was further 
explored. In order to investigate whether cells of S. aureus WV1 can induce 
HBD-3 production in keratinocytes, HaCaT monolayers were stimulated with 
whole cultures from S. aureus WV1 and SH1000 (Figure 4-2). Although S. 
aureus SH1000 cells induced HBD-3 production in HaCaT cells as expected, 
WV1 cells did not (Figure 4-2). 
Failure of the WV1 strain to induce HBD-3 could be attributable to the 
increased toxicity of this strain, thereby either killing keratinocytes, or 
rendering them unable to respond to stimulation and produce immune 
mediators. Therefore, the toxicity of S. aureus WV1 supernatant towards 
HaCaT cells was compared with SH1000 and was found to be significantly 
increased (Figure 4-3). The toxicity of the WV1 supernatant was confirmed 




number of detached HaCaT cells compared to challenge with SH1000 






























Figure 4-2: Production of HBD-3 by HaCaT cells stimulated with S. aureus WV1 
cells 
HaCaT monolayers were stimulated with cultures from S. aureus WV1 and SH1000 
for 20 h and HBD-3 production was measured by ELISA. One-way ANOVA was used 
to determine statistical significance, n=4; Values are mean ± SEM, *** p<0.001. 
Where the values were below the detection limit (DMEM and TSB), they were set to 































Figure 4-3: Toxicity of S. aureus WV1 supernatant, which did not induce HBD-
3 in HaCaT cells 
HaCaT monolayers were stimulated with supernatants from S. aureus WV1 and 
SH1000 for 24 h. Luminescence of dead and alive HaCaT cells was determined by 
Toxilight. Toxicity represents the killing of HaCaT cells (ratio of dead HaCaT cells to 
total HaCaT cells) after stimulation. One-way ANOVA was used to determine 
statistical significance, n=3. Values are mean ± SEM, *** p<0.001, ns: non-significant. 
 
In order to determine whether WV1 is able to induce production of other 
immune mediators in HaCaT cells, IL-8 induction was determined, as 
described in section 3.2.3 (Figure 4-4). The results showed that WV1 strain 
induced IL-8 production in HaCaT cells, implying that the lack of induction in 
this strain is specific to HBD-3 (Figure 4-4). These results indicate that, even 
though HaCaT cells are not completely killed by staphylococci and are able to 
respond (Figure 4-4), the levels of staphylococcal toxicity (Figure 4-3) may still 































Figure 4-4: Production of IL-8 by HaCaT cells stimulated with WV1 cells 
HaCaT monolayers were stimulated with cultures from S. aureus WV1 and SH1000 
for 20 h and IL-8 production was measured by ELISA. One-way ANOVA was used to 
determine statistical significance, n=3; Values are mean ± SEM, ns: non-significant. 
Where the values were below the detection limit (DMEM and TSB), they were set to 
15.6 pg/mL (lowest detection limit of the IL-8 ELISA assay) to allow statistical 
analysis. 
 
The agr expression is associated with production of virulence factors, 
including proteases (Wang and Tom, 2016; Boles and Horswill, 2008). 
Therefore, WV1 strain shows a highly-proteolytic phenotype (Savage et al., 
2013b). In addition to the elevated toxicity of WV1, it seemed plausible that 
the apparent lack of HBD-3 induction of this strain might in part result from this 
proteolytic activity destroying either the HBD-3-inducing factor(s) (if 
proteinaceous) or the produced HBD-3. To test this, HBD-3 keratinocyte 
production was determined in the presence of a protease inhibitor cocktail 
(PIC, Sigma-Aldrich), to block proteolytic activity (Liu et al., 2010). 
First, HaCaT monolayers were pre-treated with PIC and then stimulated with 
supernatants from S. aureus SH1000 and WV1. There was again no 
detectable HBD-3 production by the HaCaT cells stimulated with S. aureus 
WV1, regardless of the concentration of PIC added (Figure 4-5). The positive 




PIC concentration, indicating that the PIC was not toxic to HaCaT cells (Figure 
4-5). 
Since pre-incubation of HaCaTs with PIC before stimulation with S. aureus 
WV1 supernatant did not result in an increase in HBD-3 production (Figure 
4-5), an alternative approach was attempted. Staphylococcal cultures were 
grown overnight and were then incubated in the presence of PIC for 1 h. Then, 
HaCaT cells were stimulated with the supernatants from these cultures 
(Figure 4-6). No detectable HBD-3 was induced by S. aureus WV1, regardless 































































Figure 4-5: Production of HBD-3 by PIC-treated HaCaT cells stimulated with S. 
aureus supernatants 
HaCaT monolayers were either left untreated (PIC -) or treated with 1 mg/mL PIC at 
final dilution 1:800 (1.25 μg/mL, PIC +), 1:400 (2.5 μg/mL, PIC ++) or 1:200 (5 μg/mL, 
PIC +++) in DMEM, according to the manufacturer’s recommendation. Then, these 
HaCaT monolayers were stimulated with filter-sterilised supernatants from S. aureus 
SH1000 and WV1 for 24 h. Production of HBD-3 was measured by ELISA. One-way 
ANOVA was used to determine statistical significance, n=3. Values are mean ± SEM, 
*** p<0.001, ns: non-significant. Where the values were below the detection limit 
(DMEM, TSB, PIC +++ and the WV1 strains), they were set to 62.5 pg/mL (lowest 



































































Figure 4-6: Production of HBD-3 by HaCaT cells stimulated with supernatants 
from PIC-treated S. aureus cultures 
Cultures of S. aureus WV1 and SH1000 were grown for 17 h. Then, 1 mg/mL PIC 
was added to the cultures at final dilution 1:800 (1.25 μg/mL, PIC +), 1:400 (2.5 
μg/mL, PIC ++) or 1:200 (5 μg/mL, PIC +++) in TSB, according to the manufacturer’s 
recommendation and the cultures were incubated at 37oC for 1 h, with vigorous 
aeration. HaCaT monolayers were stimulated with filter-sterilised supernatants from 
these cultures for 24 h. Production of HBD-3 was measured by ELISA. One-way 
ANOVA was used to determine statistical significance, n=3. Values are mean ± SEM, 
*** p<0.001, ns: non-significant. Where the values were below the detection limit 
(DMEM, TSB, PIC +++ and the WV1 strains), they were set to 62.5 pg/mL (lowest 
detection limit of the HBD-3 ELISA assay) to allow statistical analysis. 
 
4.2.2. The HBD-3-inducing S. aureus factor(s) are 
proteinaceous 
The next step was to investigate the nature of the HBD-3-inducing S. aureus 
factor(s). In order to examine whether these factor(s) are proteinaceous, 
Proteinase K (PrK), an enzyme with proteolytic activity, was used (Ebeling et 
al., 1974). 
First, the possibility that PrK could directly degrade HBD-3 was studied. 
HaCaT cells were stimulated with S. aureus SH1000 supernatant for 24 h and 
then PrK was added to the wells for a further 1 h of incubation (SH1000 + PrK) 




negative control. The HBD-3 levels did not show significant reduction following 
addition of PrK, indicating that PrK did not degrade the HBD-3 that was 















































Figure 4-7: The effect of PrK upon HBD-3 stability 
HaCaT cells were stimulated with S. aureus SH1000 supernatant for 24 h and then 
heat-denatured PrK (SH1000 + PrK heat) and non-heated PrK (SH1000 + PrK) was 
added for 1 h incubation. Production of HBD-3 was measured by ELISA. One-way 
ANOVA was used to determine statistical significance, n=5. Values are mean ± SEM, 
*** p<0.001, ns: non-significant. Where the values were below the detection limit 
(DMEM and all TSB controls), they were set to 62.5 pg/mL (lowest detection limit of 
the HBD-3 ELISA assay) to allow statistical analysis. 
 
Moreover, toxicity of PrK towards HaCaT cells was investigated. The toxicity 
assay showed that PrK (TSB-PrK) was not toxic for the HaCaT cells (Figure 
4-8). SH1000 supernatant that was heated at 100oC for 10 min was also tested 
(SH1000 heat) to examine whether components in the supernatant may 
exhibit altered toxicity upon heat treatment. However, heated S. aureus 
supernatant did not show altered toxicity towards keratinocytes compared to 





































Figure 4-8: Toxicity of heated S. aureus supernatant and PrK towards HaCaT 
cells 
HaCaT monolayers were stimulated for 24 h with S. aureus SH1000 supernatant, 
unheated (SH1000) or heated (SH1000 heat). Luminescence of dead and alive 
HaCaT cells was determined by Toxilight. Toxicity represents the killing of HaCaT 
cells (ratio of dead HaCaT cells to total HaCaT cells) after stimulation. One-way 
ANOVA was used to determine statistical significance, n=3. Values are mean ± SEM, 
ns: non-significant. 
 
The above experiments showed that PrK did not degrade HBD-3 (Figure 4-7) 
and was not toxic towards HaCaT cells (Figure 4-8). HaCaT cells were 
stimulated with S. aureus SH1000 supernatant that was either pre-incubated 
with PrK or heated, in order to determine whether the HBD-3-inducing 
factor(s) contain a protein component and examine their heat-stability (Figure 
4-9). 
The results (Figure 4-9) showed that HBD-3 was undetectable when HaCaT 
cells were stimulated with SH1000 supernatant that was preincubated with 
PrK (SA-PrK). When supernatant without PrK was heated to 100°C for 10 min 
(SA-heat), HBD-3 was still produced, albeit at significantly reduced levels 
compared to when using a non-heated supernatant, suggesting that heat is 




inactivation of PrK at 100°C was confirmed, as SH1000 supernatant 
preincubated with heat-inactivated PrK (SA + PrK-heat) induced similar 
HBD-3 levels to the control (SA) (Figure 4-9) (Tirumurugaan et al., 2015). 
Taken together, these results suggest that the HBD-3-inducing factor(s) 
produced by S. aureus are of a proteinaceous nature and heat-stable to some 
extent, as heating to 100oC only reduced the HBD-3 production by ~ 40%, 















































































Figure 4-9: Production of HBD-3 by HaCaT cells after stimulation with S. aureus 
supernatant heated or treated with PrK 
HaCaT monolayers were stimulated for 24 h with SH1000 supernatant only (SA), with 
heated supernatant (SA-heat) and with supernatant preincubated with heated PrK 
(SA + PrK-heat) or non-heated PrK (SA-PrK). As controls, an aliquot of SA-PrK was 
heated at 100oC for 10 min [(SA+PrK)-heat] and SA was incubated at 37oC for 1 h 
(SA37). Production of HBD-3 was measured by ELISA. One-way ANOVA was used 
to determine statistical significance, n=5. Values are mean ± SEM, *** p<0.001, ns: 
non-significant. Where the values were below the detection limit [DMEM, all TSB 
controls, SA-PrK and (SA+PrK)-heat], they were set to 62.5 pg/mL (lowest detection 





4.2.3. Fractionation of S. aureus supernatant with a view to 
identifying the HBD-3-inducing factor(s) 
 Ion-exchange chromatography of S. aureus supernatant 
Given that the HBD-3-inducing factor(s) produced by S. aureus seem to be 
either protein(s) or oligopeptide(s), standard protein purification techniques 
were deployed in order to separate HBD-3-inducing factor(s) from other 
proteins present in the supernatant and allow further identification. Liquid 
chromatography can separate proteins found in a mixture based on their 
charge (ion-exchange) or their size (size-exclusion) (Coskun, 2016) and has 
been used to isolate S. aureus proteins such as SdrE (Prachi, 2013), 
α-hemolysin (Fiaschi et al., 2016) and S. aureus heme transporters (Abe et 
al., 2012). Ion-exchange chromatography was performed using an Äkta 
Purifier system (Materials and methods, 2.8.1), in order to separate 
staphylococcal supernatant proteins by their charge and reduce the number 
of candidate proteins responsible for the HBD-3 induction in keratinocytes. In 
order to capture the majority of proteins in the supernatant, two columns 
interconnected in series were used: an anion-exchange column, which binds 
to proteins with a net negative charge, and a cation-exchange column, which 
binds to proteins with a net positive charge. The columns were then uncoupled 
and eluted separately with linear gradients of NaCl. 
Collected fractions were filter-sterilised and added to HaCaT monolayers to 
test their ability to induce HBD-3 production (Figure 4-10). The buffers A (20 
mM MES and 50 mM NaCl, pH 5.5) and B (20 mM MES and 1 M NaCl, pH 
5.5) that were used during fractionation, DMEM and TSB were the controls. 
In the first experiment, every other fraction was collected, to reduce the 
number of samples. Fractions from both anion-exchange and cation-
exchange columns induced HBD-3 in HaCaT cells (Figure 4-10, graphs a and 
b). In order to verify the results, a second chromatography experiment was 
performed. Unfortunately, the elution of the cation-exchange column failed, so 
only the anion-exchange column produced fractions (Figure 4-10, graph c). 
The peak HBD-3-inducing fractions from both exchange columns (Figure 
4-10, graphs a and c) were analysed by LC-MS, in order to identify the proteins 




showed stronger HBD-3 induction by fractions from the anion-exchange 
column, in contrast to the first experiment (Figure 4-10, graphs d and e). The 
peak fractions from both columns (Figure 4-10, graphs d and e) were also 
analysed by LC-MS (see below). A fourth repeat showed higher HBD-3 
induction by fractions from the cation-exchange column, whereas several 
fractions from the anion-exchange column induced lower levels of HBD-3 
(Figure 4-10, graphs f and g). The peak fractions from the fourth experiment, 
along with the peak fraction from the anion-exchange column of the first 
fractionation (Figure 4-10, graph b) were later analysed by a newly developed 










































































































































































































































































































































































































Figure 4-10: Production of HBD-3 by HaCaT cells when exposed to fractions 
from the ion-exchange chromatography 
HaCaT monolayers were stimulated for 24 h with the fractions from the cation-
exchange (a, d, f) and the anion-exchange (b, c, e, g) chromatography experiments 
and HBD-3 production was measured by ELISA. Peaks in red represent the fractions 
analysed with the initial LC-MS method and peaks in green are the samples analysed 




 Size-exclusion chromatography 
Fractions from Figure 4-10 that induced HBD-3 production in keratinocytes 
were analysed by SDS-PAGE. The fractions produced multiple bands, 
indicating the presence of numerous proteins in each fraction (data not 
shown). Size-exclusion chromatography of the HBD-3-inducing fraction 9 was 
performed (Figure 4-10, graph a), in an attempt to separate the proteins by 
size and hence further isolate the protein(s) inducing HBD-3 production. 
However, none of the fractions produced from the size-exclusion experiment 
induced HBD-3 production in HaCaT cells (data not shown), suggesting that 
the protein concentration in these fractions may not have been high enough 
to induce HBD-3. 
 
 Mass spectrometry 
Following recovery of fractions containing the S. aureus HBD-3-inducing 
factor(s), the next step towards identification was to perform LC-MS (Materials 
and methods, 2.8.4). Mass spectrometry can detect peptide sequences in a 
mixture and match them to known proteins from a database (Pitt, 2009). The 
peak HBD-3-inducing fractions from two experiments from the cation-
exchange column (Figure 4-10, graphs a and d) and two experiments from the 
anion-exchange column (Figure 4-10, graphs c and e) were analysed. The 
LC-MS assay was performed by the mass spectrometry group at the 
University of Leeds, UK and data were provided as predicted peptide 
sequences. As S. epidermidis did not induce HBD-3 production in 
keratinocytes (Figure 3-6 and Figure 3-8), it was assumed that S. aureus 
proteins with counterparts in S. epidermidis would be less likely to be 
implicated in HBD-3 production. Comparison of the similarity of the S. aureus 
proteins detected by LC-MS with S. epidermidis proteins was performed with 
the NCBI genomic database using the BLAST algorithm (Table 4-2 and Table 
4-3) (Altschul et al., 1990; Altschul et al., 1997). Among the S. aureus proteins 
detected in these four fractions, only the IsaB protein was found in both 
fractions from the cation-exchange column (Table 4-2) and the SdrD protein 






Table 4-2: LC-MS detected candidate HBD-3-inducing proteins in the peak fractions produced from the cation-exchange chromatography 
The following proteins were detected in fractions 9 and 10 from the cation-exchange column (Figure 4-10, graphs a and d). (Cover: percentage of 
peptide coverage of the total protein sequence; Pept: number of peptides that match the protein in the description; SE: percentage of similarity to S. 
epidermidis proteins; ns: no significant similarity to S. epidermidis proteins found) 





Description SE (%) 
Q79ZW0|ISAB_STAAW 68 49 Immunodominant staphylococcal antigen B 43 
Q2FZK7|ATL_STAA8 15 15 Bifunctional autolysin 67 
Q99VJ0|NUC_STAAM 34 7 Thermonuclease 47 
A6QG31|ISDA_STAAE 35 7 Iron-regulated surface determinant protein A 25 
Q6GDN2|OATA_STAAR 13 6 O-acetyltransferase OatA 66 
Q7A150|ISDE_STAAW 23 5 High-affinity heme uptake system protein IsdE 25 
Q2G2B2|SASG_STAA8 3 3 Surface protein G 59 
       





Description SE (%) 
tr|A0A1E5JB95|A0A1E5JB95_STAAU 81 45 Glycerophosphoryl diester phosphodiesterase family protein 70 
tr|A0A1D4ILC4|A0A1D4ILC4_STAAU 18 13 Cell division protein FtsI [Peptidoglycan synthetase]/Transpeptidase, 
Penicillin binding protein transpeptidase domain 
85 
tr|A0A1R2DD87|A0A1R2DD87_STAAU 33 8 Uncharacterised protein 62 
tr|A0A181GRB0|A0A181GRB0_STAAU 36 7 Immunodominant antigen B 43 
tr|A0A0E1AE62|A0A0E1AE62_STAAU 25 4 Secretory antigen SsaA 80 
tr|A0A0H2WWP4|A0A0H2WWP4_STAAC 22 4 Uncharacterised protein 57 







Table 4-3: LC-MS detected candidate HBD-3-inducing proteins in the peak fractions produced from the anion-exchange chromatography 
The following proteins were detected in fractions 7 and 10 from the anion-exchange column (Figure 4-10, graphs c and e). (Cover: percentage of 
peptide coverage of the total protein sequence; Pept: number of peptides that match the protein in the description; SE: percentage of similarity to S. 
epidermidis proteins; ns: no significant similarity to S. epidermidis proteins found) 
fraction 7 from the anion-exchange column (graph c)  
Accession Cover (%) Pept (%) Description SE (%) 
Q5HFV0|DBH_STAAC 70 5 DNA-binding protein HU 99 
O86488|SDRD_STAAE 6 8 Serine-aspartate repeat-containing protein D 49 
Q2YWS3|G6PI_STAAB 15 6 Glucose-6-phosphate isomerase 93 
      
fraction 10 from the anion-exchange column (graph e)  
Accession Cover (%) Pept (%) Description SE (%) 
P13916|GLCA_SOYBN 5 7 Beta-conglycinin, α chain 35 
P19594|2SS_SOYBN 18 5 2S albumin ns 
O86488|SDRD_STAAE 3 3 Serine-aspartate repeat-containing protein D 49 
tr|A0A1D4RZS0|A0A1D4RZS0_STAAU 5 3 LPXTG-motif cell wall anchor domain-containing protein 81 
99 
 
 S. aureus USA300 mutant strains from NTML 
Upon identification of several candidate proteins for HBD-3 induction from the 
LC-MS analysis (Table 4-2 and Table 4-3), a search was performed in the 
NTML. This library consists of S. aureus USA300 strains, in which 
approximately 2,000 non-essential individual genes have been disrupted by 
the insertion of the mariner transposon bursa aurealis (Bose et al., 2013; BEI 
Resources, c2019). S. aureus USA300 strains that carry mutations which 
inactivate the genes equivalent to the candidate proteins identified by LC-MS 
were chosen in order to test whether any of these mutations may affect the 
ability of the S. aureus strain to induce HBD-3. Not all the detected proteins 
had corresponding S. aureus USA300 mutants in the NTML. The strains from 
the NTML that were tested are shown in Table 4-4. 
Supernatants from these USA300 mutants were added to HaCaT monolayers 
and HBD-3 production was measured (Figure 4-11). There was no statistically 
significant difference in the induction of HBD-3 by S. aureus mutants 
compared to the wild-type strain, although HaCaT cells stimulated with NE460 
and NE987 strains showed some reduction in their HBD-3 production (Figure 
4-11). This suggests that either none of these proteins are implicated in the 
HBD-3 induction, or maybe the mutations were not sufficient to effectively 
inhibit the activity of the corresponding protein. These strains have insertional 
mutations, which would be expected to block the expression of a functional 
gene product (Bose et al., 2013; BEI Resources, c2019); however, sometimes 
the insertion may result in an altered protein, which may retain characteristics 
of the functional protein. Another possibility is that the synergistic effect of two 










Table 4-4: S. aureus USA300 variants from the NTML that carry mutations 
which inactivate the genes corresponding to the proteins detected by LC-MS 
(Bose et al., 2013; BEI Resources, c2019) 






NE24 secretory antigen precursor SsaA (ssaA) SAUSA300_2503 
NE33 
LPXTG-motif cell wall surface anchor family 
protein 
SAUSA300_2589 
NE67 immunodominant antigen B (isaB) SAUSA300_2573 
NE460 autolysin (atl) SAUSA300_0955 
NE710 thermonuclease precursor SAUSA300_0776 
NE778 
glycerophosphoryl diester phosphodiesterase 
(glpQ) 
SAUSA300_0862 
NE925 superantigen-like protein 7 SAUSA300_0401 
NE987 secretory antigen precursor SsaA (ssaA) SAUSA300_2249 
NE1035 secretory antigen precursor SsaA (ssaA) SAUSA300_2253 
NE1241 thermonuclease (nuc) SAUSA300_1222 
NE1289 SdrD protein (sdrD) SAUSA300_0547 
NE1408 






































S. aureus USA300 mutants
ns
 
Figure 4-11: Production of HBD-3 by HaCaT cells stimulated with supernatants 
from S. aureus USA300 mutants from NMTL 
HaCaT monolayers were stimulated with supernatants from S. aureus USA300 
wild-type and mutants for 24 h and HBD-3 production was measured by ELISA. One-
way ANOVA was used to determine statistical significance, n=4. Values are mean ± 
SEM, ns: non-significant. Where the values were below the detection limit (DMEM 
and TSB), they were set to 62.5 pg/mL (lowest detection limit of the HBD-3 ELISA 
assay) to allow statistical analysis. The full names of the x-axis labels from left to right 
are: DMEM, TSB, S. aureus USA300 (USA), NE24 (1), NE33 (2), NE67 (3), NE460 
(4), NE710 (5), NE778 (6), NE925 (7), NE987 (8), NE1035 (9), NE1241 (10), NE1289 
(11), NE1408 (12) and NE1544 (13) (Table 4-4). 
 
As the experiment with the S. aureus USA300 mutants did not confirm any of 
the LC-MS candidate proteins, a different approach was taken. Although the 
HBD-3-inducing protein(s) could be any of the proteins identified by LC-MS, 
or even proteins not detected by LC-MS, the IsaB protein was selected for 
further investigation, as it was detected in both fractions from the cation-
exchange column (Table 4-2) and the SdrD protein, which was detected in 





 The SdrD protein 
A purified or recombinant SdrD protein product was not available for purchase, 
therefore the SdrD protein needed to be produced in the laboratory. 
Lactococcal wild-type strains, strains with an empty vector (pMG36e) and with 
a vector containing the sdrD insert were cultured (Materials and methods, 2.7) 
(Askarian et al., 2017). Then, HaCaT monolayers were stimulated with 
cultures (~ 107 CFU) and filter-sterilised supernatants (at a final dilution ratio 
of 1:50 in DMEM) from lactococcal strains. Cultures and filter-sterilised 
supernatants from S. aureus SH1000 were used as positive control. Cultures 
from lactococci with an empty vector were used as a negative control, in 
addition to DMEM, TSB and M17 broth. There was no HBD-3 induction by 
lactococcal cells or supernatant, whereas the S. aureus SH1000 displayed 
induction in both cases, as expected (data not shown). 
 
 The IsaB protein 
In order to investigate the effect of IsaB protein on keratinocytes (Materials 
and methods, 2.7), HaCaT monolayers were stimulated with heated IsaB 
(MyBiosource), as well as increasing concentrations of non-heated IsaB. As 
shown in Figure 4-12, HBD-3 production increased in HaCaT cells when 
stimulated with increasing concentrations of IsaB. Moreover, heat did not 
ablate the ability of IsaB to induce HBD-3 production, indicating that IsaB is 
heat-stable (Figure 4-12). This experiment suggests that IsaB may be a factor 





















































Figure 4-12: Production of HBD-3 by HaCaT cells stimulated with IsaB 
recombinant protein 
HaCaT cells were stimulated for 24 h with increasing concentrations of IsaB protein 
from 10 μg/mL up to 50 μg/mL and with 50 μg/mL IsaB heated at 100oC for 10 min. 
S. aureus SH1000 supernatants heated (100oC for 10 min) and non-heated were 
used as positive controls. Production of HBD-3 was measured by ELISA (n=1). 
 
 S-Trap micro ultra-high recovery protocol mass spectrometry 
An improved LC-MS method, which can identify proteins in the supernatant 
with higher sensitivity, was subsequently tested to determine if any of the 
components that could not be detected originally may be involved in HBD-3 
induction (Appendices and supplemental material, 8.4). The peak fractions 
from the rest of the ion-exchange chromatography experiments were analysed 
by this method (Figure 4-10, graphs b, f and g) to confirm if the previously 
suggested candidates also appeared in these experiments. This improved 
method detected more proteins and more peptides from each protein (Table 
4-5 and Table 4-6) compared to the previous method (Table 4-2 and Table 
4-3). Similar to the results from the previous LC-MS analysis (Table 4-2 and 
Table 4-3), the IsaB protein was detected in the fraction from the cation-
exchange column and the SdrD protein was detected in both fractions from 
the anion-exchange column (Table 4-5 and Table 4-6). Unfortunately, the 







Table 4-5: New S-Trap LC-MS detected candidate HBD-3-inducing proteins in the peak fractions produced from the anion-exchange 
chromatography 
The following proteins were detected in fractions 9 from the anion-exchange column (Figure 4-10, graphs b and g). (Cover: percentage of peptide 
coverage of the total protein sequence; Pept: number of peptides that match the protein in the description; SE: percentage of similarity to S. 
epidermidis proteins; ns: no significant similarity to S. epidermidis proteins found) 
fraction 9 from the anion-exchange column (graph b) 
Accession Cover (%) Pept (%) Description SE (%) 
tr|A0A2T8C9R7|A0A2T8C9R7_STAAU 42 30 YSIRK-type signal peptide-containing protein 27 
tr|A0A0H3K9U6|A0A0H3K9U6_STAAE 64 19 Ferrichrome ABC transporter lipoprotein 70 
Q2G296|FTHS_STAA8 53 17 Formate-tetrahydrofolate ligase 92 
O86488|SDRD_STAAE 63 77 Serine-aspartate repeat-containing protein D 49 
tr|A0A0H3KH34|A0A0H3KH34_STAAE 74 19 Glutamyl-aminopeptidase 80 
A6QFI1|CDR_STAAE 39 13 Coenzyme A disulfide reductase 76 
tr|A0A0E1AIM5|A0A0E1AIM5_STAAU 79 15 Purine nucleoside phosphorylase DeoD-type 93 
P64415|HUTH_STAAM 33 11 Histidine ammonia-lyase 84 
Q5HCV3|PANB_STAAC 57 12 3-methyl-2-oxobutanoate hydroxymethyltransferase 80 
tr|G0XY21|G0XY21_STAA8 22 8 Clumping factor A (Fragment) 89 
tr|X5DSE7|X5DSE7_STAAU 71 8 6 7-dimethyl-8-ribityllumazine synthase 88 
Q6GGT8|DBH_STAAR 64 7 DNA-binding protein HU 99 
tr|A1KDX6|A1KDX6_STAAU 31 7 Immunoglobulin G binding protein A (Fragment) 37 
tr|Q2FY66|Q2FY66_STAA8 17 7 Glucose-6-phosphate 1-dehydrogenase 90 
tr|A0A1D4J4D7|A0A1D4J4D7_STAAU 39 7 γ-hemolysin component B 59 
tr|A0A0Z0KFX7|A0A0Z0KFX7_STAAU 36 6 Putative heme-dependent peroxidase 82 
tr|X5E0Y0|X5E0Y0_STAAU 24 6 GTP cyclohydrolase FolE2 90 
Q6GI89|SYW_STAAR 24 6 Tryptophan-tRNA ligase 90 








Table 4-5 (Continued) 
fraction 9 from the anion-exchange column (graph b) 
Accession Cover (%) Pept (%) Description SE (%) 
tr|A0A0D1G9L3|A0A0D1G9L3_STAAU 14 5 Adenylosuccinate lyase 92 
Q6GAU3|FABH_STAAS 22 4 3-oxoacyl-[acyl-carrier-protein] synthase 3 91 
tr|A0A0H3KAB2|A0A0H3KAB2_STAAE 20 4 Amino-acid ABC transporter amino-acid-binding protein 82 
tr|A0A122N575|A0A122N575_STAAU 12 4 2 3-bisphosphoglycerate-independent phosphoglycerate mutase 91 
tr|A0A2I7Y801|A0A2I7Y801_STAAU 48 37 Hydrolase 74 
Q6GHY9|DLDH_STAAR 16 3 Dihydrolipoyl dehydrogenase 96 
tr|A0A2T9ULH0|A0A2T9ULH0_STAEP 26 3 Glucose-6-phosphate isomerase (Fragment) 100 
tr|A0A0H3JW11|A0A0H3JW11_STAAW 17 3 Uncharacterised protein 73 
tr|A0A0H2XHK0|A0A0H2XHK0_STAA3 12 3 Iron compound ABC transporter-binding protein SirA 35 
     
fraction 9 from the anion-exchange column (graph g) 
Accession Cover (%) Pept (%) Description SE (%) 
tr|A1KDX8|A1KDX8_STAAU 57 25 Immunoglobulin G binding protein A (Fragment) 40 
tr|A0A0H3K9U6|A0A0H3K9U6_STAAE 29 10 Ferrichrome ABC transporter lipoprotein 70 
tr|A0A0E1VN13|A0A0E1VN13_STAA3 41 9 γ-hemolysin component B 59 
tr|A0A2I7Y801|A0A2I7Y801_STAAU 27 18 Fibrinogen-binding protein with hydrolase activity 74 
tr|A0A0H2XGG1|A0A0H2XGG1_STAA3 20 8 6-phosphogluconate dehydrogenase decarboxylating 91 
tr|A0A133PX21|A0A133PX21_STAAU 31 7 Glycerophosphodiester phosphodiesterase 43 
tr|T1YE75|T1YE75_STAAU 41 6 Uncharacterised protein 43 
O86488|SDRD_STAAE 29 25 Serine-aspartate repeat-containing protein D 49 
tr|A0A2T8C9F8|A0A2T8C9F8_STAAU 56 3 Purine-nucleoside phosphorylase (Fragment) 97 
Q2FJ56|Y569_STAA3 17 3 Putative heme-dependent peroxidase 82 








Table 4-6: New S-Trap LC-MS detected candidate HBD-3-inducing proteins in the peak fraction produced from the cation-exchange 
chromatography 
The following proteins were detected in fraction 9 from the cation-exchange column (Figure 4-10, graph f). (Cover: percentage of peptide coverage 
of the total protein sequence; Pept: number of peptides that match the protein in the description; SE: percentage of similarity to S. epidermidis 
proteins; ns: no significant similarity to S. epidermidis proteins found) 
fraction 9 from the cation-exchange column (graph f) 
Accession Cover (%) Pept (%) Description SE (%) 
tr|A0A0H3JUJ6|A0A0H3JUJ6_STAAM 77 41 Glycerophosphoryl diester phosphodiesterase 70 
tr|A0A142G9F1|A0A142G9F1_STAAU 30 28 N-acetylmuramoyl-L-alanine amidase 59 
Q7A377|ISAB_STAAN 68 26 Immunodominant staphylococcal antigen B 43 
tr|A0A0E1VN13|A0A0E1VN13_STAA3 59 18 γ-hemolysin component B 59 
tr|Q2G0X9|Q2G0X9_STAA8 63 12 Uncharacterised protein ns 
tr|A0A0D1HN79|A0A0D1HN79_STAAU 61 12 Heme ABC transporter substrate-binding protein 25 
tr|A1KDX8|A1KDX8_STAAU 45 11 Immunoglobulin G binding protein A (Fragment) 40 
tr|A0A0U1MGQ8|A0A0U1MGQ8_STAAU 62 11 Uncharacterised protein 62 
tr|A0A1D4CL80|A0A1D4CL80_STAAU 27 11 Lipoteichoic acid synthase 90 
A7X659|SBI_STAA1 31 11 Immunoglobulin-binding protein Sbi 40 
Q5HEI1|PHLC_STAAC 71 16 Phospholipase C 53 
tr|A0A0H3KAM8|A0A0H3KAM8_STAAE 16 7 O-acetyltransferase OatA 66 
tr|A0A2D1PJH6|A0A2D1PJH6_STAAU 44 7 Serine protease (Fragment) 35 
tr|A0A0H2WXE4|A0A0H2WXE4_STAAC 10 7 Cell wall surface anchor family protein 52 
tr|A0A0E1VIY6|A0A0E1VIY6_STAA3 39 6 Uncharacterised protein 55 
tr|A0A0H2WZ01|A0A0H2WZ01_STAAC 16 6 Uncharacterised protein ns 
tr|A0A0E1VLD0|A0A0E1VLD0_STAA3 42 9 Thermonuclease 42 









Table 4-6 (Continued) 
fraction 9 from the cation-exchange column (graph f) 
Accession Cover (%) Pept (%) Description SE (%) 
tr|A0A1D4IBN5|A0A1D4IBN5_STAAU 27 4 Iron compound ABC uptake transporter substrate-binding 
protein 
75 
P52078|Y997_STAA8 21 4 Uncharacterised protein 77 
Q5HJ48|LIP2_STAAC 30 14 Lipase 2 47 
tr|A0A0D1JP07|A0A0D1JP07_STAAU 25 8 Leucotoxin LukD ns 
tr|A0A1D5AAC1|A0A1D5AAC1_STAAU 47 3 α/β hydrolase 69 
tr|A0A0E1VJY8|A0A0E1VJY8_STAA3 27 3 Uncharacterised protein 76 





Although only IsaB was detected in all fractions from the cation-exchange 
column (Table 4-2 and Table 4-6) and SdrD was detected in all fractions from 
the anion-exchange column (Table 4-3 and Table 4-5), some proteins also 
appeared in two or more fractions (Table 4-7). Even though none of the 
proteins detected by LC-MS can be excluded from the search, proteins that 
appear in several fractions that induced HBD-3 may be more likely to be 
implicated in the production of HBD-3 in keratinocytes. 
 
Table 4-7: Proteins detected by LC-MS that are appear in two or more fractions 
of S. aureus supernatant 
Protein Fractions Table 
Thermonuclease 
fractions 9 from cation-exchange 
column (graphs a and f) 
Table 4-2 
and 
Table 4-6 O-acetyltransferase 
   
Glycerophosphodiester 
phosphodiesterase 
fraction 10 from cation-exchange 
column (graph d) and fraction 9 






Ferrichrome ABC transporter 
lipoprotein 
fractions 9 from anion-exchange 











Amino-acid ABC transporter 
amino-acid-binding protein fraction 9 from anion-exchange 
column (graph b) and fraction 9 










Immunoglobulin G binding 
protein A 
fractions 9 from anion-exchange 
column (graphs b and g) and 
fraction 9 from cation-exchange 
column (graph f) 
Table 4-5 
and 






The work in the previous chapter of this thesis, as well as previous research, 
found that S. aureus supernatant contains factor(s) that can induce production 
of HBD-3 in keratinocytes (Figure 3-1, Figure 3-3, Figure 3-6 and Figure 3-8) 
(Menzies and Kenoyer, 2005; Midorikawa et al., 2003). The aim of this chapter 
was to further investigate and identify the S. aureus HBD-3-inducing factor(s), 
in order to examine the existence and expression patterns of these factor(s) 
in S. epidermidis and S. aureus that do not induce HBD-3 and to better 
understand the differential effect of staphylococci on HBD-3 production in 
keratinocytes and the role of S. aureus in AD pathogenesis. Other studies 
have also underlined that the investigation of S. aureus virulence factors, 
responsible for host inflammation, may help elucidate the role of S. aureus in 
pathogenesis and aggravation of AD (Cho et al., 2009; Ezepchuk et al., 1996; 
Herz et al., 1998). Although the HBD-3-inducing factor(s) could not be 
identified within the time-frame of this project, the available data suggest the 
involvement of heat-stable protein(s). Moreover, steps were taken towards 
detection of candidate proteins and approaches were proposed for further 
investigation of these S. aureus factor(s). 
 
The effect of the S. aureus Agr system on the induction of HBD-3 in 
keratinocytes 
Previous research has reported that upregulation of the Agr system leads to 
increased virulence (Lauderdale et al., 2009; Savage et al., 2013a) and 
conversely strains with an inactivation of agr show increased biofilm formation 
and decreased expression of secreted virulence factors (Boles and Horswill, 
2008; Savage et al., 2013a). By contrast, this chapter showed that the strains 
with increased Agr activity (WV1 and NE1109) induced lower HBD-3, whereas 
the agr mutant (NE1532) induced higher HBD-3 compared to the parental 
strains (Figure 4-1), suggesting that reduced HBD-3 production may be 
associated with Agr upregulation. 
Fibrinogen-binding proteins participate in S. aureus biofilm formation but can 




2010; Shinji et al., 2011; McCourt et al., 2014; Reginald et al., 2011). Also, 
extracellular proteases have been shown to cleave virulence molecules in 
order to achieve autoregulation of the strain’s own virulence. Therefore, 
virulence factors such as γ-hemolysin and PSMs may be more abundant in 
protease-null strains (e.g. those that have decreased Agr activity), increasing 
the likelihood that they would induce HBD-3 production in keratinocytes more 
than proteolytic strains (Kolar et al., 2013; Lindsay and Foster, 1999), 
supporting the findings in this work (Figure 4-1) (Savage et al., 2013a; Bose 
et al., 2013; BEI Resources, c2019). These results suggest that HBD-3-
inducing factor(s) may be produced during the initial phases of S. aureus 
colonisation, before activation of the Agr system. Subsequently, activation of 
the Agr system would then change the bacterial global gene-expression profile 
and possibly downregulate expression of the HBD-3-inducing factor(s) or 
upregulate factors that degrade HBD-3 or HBD-3-inducing factor(s). 
The sigB mutation of S. aureus WV1 results in increased Agr activity and a 
highly proteolytic secretome profile (Savage et al., 2013b; Wang and Tom, 
2016; Boles and Horswill, 2008). Indeed, its supernatant was found to be toxic 
for keratinocytes (Figure 4-3) and WV1 strain did not induce HBD-3 production 
in keratinocytes (Figure 4-2), even after the addition of PIC (Figure 4-5 and 
Figure 4-6). Possibly the proteases of WV1 were not deactivated by the PIC. 
Nevertheless, although WV1 cultures did not induce HBD-3 (Figure 4-2), they 
induced IL-8 (Figure 4-4), suggesting that either WV1 proteases may degrade 
HBD-3 but not IL-8, or that these strains activate IL-8 through a pathway 
different to the HBD-3 one. Recognition patterns of keratinocytes may activate 
different immune molecules through different pathways (Dejean et al., 2012). 
Indeed, previous researchers reported that S. aureus serine proteases can 
induce IL-8 (Rudack et al., 2009) and that the expression of IL-8 is mediated 
by NF-κB (Dejean et al., 2012; Roebuck, 1999; Mukaida et al., 1994; Huang 
and McCance, 2002) or EGFR (Frankart et al., 2012; Lan et al., 2013), 
whereas S. aureus HBD-3 induction is mediated through phosphatidylinositol 
3-kinase and MAPK, independently of NF-κB (Wanke et al., 2011). Alternative 
suggestions to test this idea in future work would be to stimulate keratinocytes 
with mixtures of S. aureus SH1000 and WV1 supernatant, in order to 




factor(s), or to perform in vitro stability assays of HBD-3 in the presence of 
WV1 supernatant in order to define whether WV1 proteases can directly 
degrade HBD-3. Analysis of HBD-3 mRNA expression by real-time reverse-
transcription PCR and protein levels by ELISA or Western Blot, from both 
cytoplasmic and media fractions (Warters et al., 2009; Mekki et al., 2018), 
would then elucidate if the gene encoding HBD-3 is induced, if the protein is 
translated, or if it is subsequently degraded.  
 
The HBD-3-inducing S. aureus factor(s) are heat-stable and proteinaceous 
The fact that PrK completely abolished HBD-3 induction implies the existence 
of an essential proteinaceous component, responsible for this HBD-3 
induction (Figure 4-9) (Daniel et al., 1996; Pinto et al., 1991; Soltis et al., 1979; 
Ebeling et al., 1974). Heating S. aureus supernatant showed only modest 
reduction in its ability to induce HBD-3 (Figure 4-9), indicating that at least one 
of the HBD-3-inducing factors is heat-stable, consistent with previous studies 
(Menzies and Kenoyer, 2005; Midorikawa et al., 2003). 
 
Fractionation and characterisation of S. aureus supernatant 
The LC-MS method identified proteins in the peak HBD-3-inducing fractions 
that were produced by ion-exchange chromatography (Table 4-2 and Table 
4-3). The fact that none of the NTML strains with single transposon mutations 
tested (Table 4-4) showed a significant reduction in their HBD-3 induction (BEI 
Resources, c2019; Bose et al., 2013), suggests that either: none of these 
proteins can induce HBD-3; the mutations did not completely inhibit the activity 
of the corresponding protein; or HBD-3 induction in keratinocytes is a result of 
the synergistic effect of two or more proteins (Figure 4-11). 
The IsaB protein that was detected in all fractions from the cation-exchange 
column (Table 4-2 and Table 4-6) and the SdrD protein that was detected in 
all fractions from the anion-exchange column (Table 4-3 and Table 4-5) were 
further analysed. The IsaB protein can be both secreted and cell-bound, which 
is in line with the finding of this thesis that live cells and filter-sterilised 




(Figure 3-1, Figure 3-6 and Figure 3-8) (Mackey-Lawrence et al., 2009). The 
IsaB protein is induced under various conditions, such as in the presence of 
human serum, under anaerobic conditions and during infections (Mackey-
Lawrence and Jefferson, 2013). IsaB binds nucleic acids but its role in S. 
aureus virulence has not yet been elucidated (Mackey-Lawrence et al., 2009; 
Liu, P.-F. et al., 2015; Mackey-Lawrence and Jefferson, 2013; Fuchs et al., 
2007). The SdrD protein, which belongs to the family of microbial surface 
components recognising adhesive matrix molecules (MSCRAMMs), is a 
cell-bound adhesive protein that can bind to extracellular host proteins (e.g. 
fibronectin, collagen) (Liu, H. et al., 2015), human squamous cells and 
keratinocytes in vitro (Askarian et al., 2016) and can increase virulence and 
survival of S. aureus (Askarian et al., 2017). Genetic variability of sdrD among 
S. aureus strains has been reported (Ajayi et al., 2018). 
Lactococcus lactis strains expressing sdrD did not induce HBD-3 in 
keratinocytes (section 4.2.3.5). Recombinant IsaB protein induced HBD-3 
only in concentrations above 20 μg/mL, which is substantially higher than the 
concentration of other S. aureus proteins released into the supernatant (e.g. 
α-hemolysin up to ~ 30 ng/mL and staphylococcal enterotoxin H up to ~ 700 
ng/mL) (Su and Wong, 1996; Omoe et al., 2002; Monecke et al., 2014). HBD-3 
was induced by IsaB in a dose-dependent manner and heat only had a modest 
effect on reducing its activity (Figure 4-12). 
In addition to IsaB and SdrD, other proteins also appeared in two or more 
fractions (Table 4-7). Some proteins (e.g. amino-acid ABC transporter) were 
detected in fractions from both cation-exchange and anion-exchange columns 
(Table 4-7). Proteins are large molecules and although each protein has a 
defined isoelectric point, individual sites of the protein may have different 
charges that could allow them to potentially bind to both cation-exchange and 
anion-exchange columns, depending on the charge of the site of the protein 
that comes in contact with the column (He et al., 2002; Shire, 2015). 
As S. aureus PSMs play a role in its virulence (Wang et al., 2007; Cheung et 
al., 2014), it was speculated that these proteins might induce HBD-3 in 
keratinocytes. However, no PSMs were detected by LC-MS. The fractions 




Virulence factors detected by LC-MS worth investigating include the pore-
forming proteins leukocidin D and γ-hemolysin (Nocadello et al., 2016; 
Vandenesch et al., 2012), the immunoglobulin-binding protein A (Falugi et al., 
2013) and the fibrinogen-binding clumping factor A (Higgins et al., 2006), 
which are major S. aureus virulence factors, often implicated in skin and 
systemic infections (Herman-Bausier et al., 2018; Kong et al., 2016). Although 
many of the proteins identified in the staphylococcal supernatant are known 
to be involved in functions such as nutrient uptake, they can still play a role in 
S. aureus virulence. For instance, iron ABC uptake transporters are required 
to obtain iron, which is necessary for bacterial growth, as well as for 
expression of virulence factors (Dale et al., 2004; Speziali et al., 2006). 
Proteins of unknown function that were detected (uncharacterised proteins) 
are also worth studying (Table 4-2, Table 4-5 and Table 4-6). 
Although testing the ability of IsaB and SdrD proteins to induce HBD-3 in 
keratinocytes is a sensible approach towards the identification of the S. aureus 
HBD-3-inducing factor(s), the experiments performed are not definitive. Even 
though the expression of genes cloned into the pMG36e vector is constitutive 
(Van de Guchte et al., 1989; Kim et al., 2009), it is not known if and in what 
concentration the SdrD protein is produced by lactococci and whether other 
lactococcal proteins expressed may affect the SdrD production. Purifying the 
SdrD protein might be preferable in order to test its effect on HBD-3 induction. 
With regards to the IsaB protein, as there were no reports in the literature 
regarding the physiologic concentration of IsaB produced by S. aureus, the 
IsaB concentrations used in this project were similar to the concentrations 
used in previous studies (Liu, P.-F. et al., 2015). Although it is unlikely that S. 
aureus produces IsaB in such high concentrations as those tested, the 
percentage of activity of the IsaB protein is unknown; therefore, the 
concentrations used might not correspond to the actual concentration of a 
fully-active protein. More research is required in order to optimise the 
experimental conditions. Moreover, it is possible that the synergistic action of 
IsaB with another S. aureus compound or with host molecules may increase 
the effect of IsaB on HBD-3 induction. Previous research has shown a 
synergistic effect of S. aureus peptidoglycan with lipopolysaccharide on the 




lipoteichoic acid on the activation of NF-κB in macrophages (Schwandner et 
al., 1999). 
 
In conclusion, the aim of this chapter, which was to further investigate and 
identify the S. aureus factor(s) that induce HBD-3 production in keratinocytes, 
was only partially achieved. Progress was made, as the results obtained 
showed that the HBD-3-inducing factor(s) are heat-stable and most likely 
proteinaceous. Candidate proteins were detected but further confirmation of 





5. Defining conditions to rectify staphylococcal 
dysbiosis: a preliminary evaluation of 
differing growth requirements for S. aureus 
and S. epidermidis 
5.1. Introduction 
Skin microbial dysbiosis has been found to be associated with AD (Salava and 
Lauerma, 2014; McPherson, 2016). The previous chapters (chapters 3 and 4) 
investigated the different response of keratinocytes to S. epidermidis and S. 
aureus, focusing on the AMP production by keratinocytes stimulated with 
staphylococci, since AMPs are an important skin defence mechanism against 
pathogens such as S. aureus (Midorikawa et al., 2003; Nakatsuji et al., 2017; 
Kong et al., 2012). Antibiotics prescribed in AD fail to restore skin microbial 
balance, as they act not only against pathogens but also against skin 
commensals (such as S. epidermidis), ultimately leading to reduced microbial 
diversity and increased S. aureus recolonisation (Kobayashi et al., 2015; 
Friedman and Goldman, 2011; Gilani et al., 2005; SanMiguel et al., 2017). 
This chapter sought to identify compounds that favour S. epidermidis, which 
is the most abundant skin commensal (Otto, 2009; Otto, 2012), or inhibit S. 
aureus, which is a leading cause of skin infections and is increased in the skin 
of the majority of AD patients (Tong et al., 2015; Kong et al., 2012; Otto, 2013; 
Bouvet et al., 2017; Baldry et al., 2018). This aim of this work was to contribute 
to the development of techniques that restore the microbial skin balance and 
improve the skin defence against pathogens. 
Despite the molecular and genetic similarities between S. epidermidis and S. 
aureus (Ghebremedhin et al., 2008; Méric et al., 2015), both organisms 
display quite different phenotypes on human skin. S. epidermidis is the most 
abundant skin commensal (Otto, 2009; Otto, 2012) and usually causes 
infection only in immunocompromised people (Dong and Speer, 2014; 
Sabaté-Brescó et al., 2017). In contrast, S. aureus is much less abundant on 




than 90% of AD patients (Cogen et al., 2008; Danby, 2017; Abeck and 
Mempel, 1998; Baldry et al., 2018). 
Known phenotypic differences between S. aureus and S. epidermidis are 
reflected mainly in their virulence. Although S. epidermidis carries genes 
encoding virulence factors such as PSMs, expression of cytolytic factors is 
lower compared to S. aureus (Cheung et al., 2010). Also, the most prominent 
virulence factor of S. epidermidis is biofilm formation (Sabaté-Brescó et al., 
2017), whereas S. aureus displays a more aggressive profile, with increased 
expression of highly cytolytic virulence factors that trigger the immune 
response, such as superantigens (Bröker et al., 2016). The coa and vWbp 
genes, which are responsible for the coagulase-positive nature of S. aureus 
strains, have also been implicated in its pathogenicity (McAdow et al., 2012; 
Cheng et al., 2010), therefore also providing an explanation for the apparent 
lower virulence associated with coagulase-negative species (Von Eiff et al., 
2002; Becker et al., 2014). Differences between the S. epidermidis and S. 
aureus Agr system, which plays a role in their virulence (Traber et al., 2008; 
Boles and Horswill, 2008), have also been reported (Vuong et al., 2003). Gene 
transfer between staphylococci and other bacteria may be the reason of S. 
aureus genes encoding virulence factors such as enterotoxins, not found in S. 
epidermidis, although phenotypic differences between the two species have 
not yet been fully elucidated (Gill et al., 2005). In addition, genes encoding 
factors that enhance the host immune system are expressed more in S. 
epidermidis, such as δ-toxin, which can increase the potency of host AMPs 
(Cogen et al., 2010a). 
Although a causative relationship between the microbial dysbiosis and AD has 
not been proven so far (Paller et al., 2019; Lee et al., 2018), skin microbial 
balance is associated with AD pathogenesis (Salava and Lauerma, 2014). 
Imbalance of skin barrier components disrupts the skin barrier integrity and 
increases the susceptibility to pathogens (Agrawal and Woodfolk, 2014; 
Berdyshev et al., 2018; Imokawa and Ishida, 2014). Previous researchers 
reported imbalance of skin lipids in AD (Proksch et al., 2003; Gupta et al., 
2007), including the presence of shorter chain length fatty acids and 
ceramides (Janssens et al., 2012; Park et al., 2012), an increase in cholesterol 




increase in sphingomyelin can favour S. aureus, whereas decreased 
sphingosine, which is potent against S. aureus, is associated with increased 
S. aureus colonisation (Imokawa and Ishida, 2014; Brauweiler et al., 2014). 
Application of mixtures with the right proportion of ceramides, cholesterol and 
free fatty acids was found to improve the skin barrier integrity (Yang et al., 
1995; Imokawa et al., 1989). In addition, application of a formula containing 
one or two ceramides and a fatty acid (behenic acid) on ex vivo skin 
preparations was found to improve the structure of stratum corneum (Berkers 
et al., 2018).  
As S. aureus is the most common pathogen in AD (Baldry et al., 2018), the 
effect of fatty acids on S. aureus growth has been tested. Sphingosine, 
dihydrosphingosine, cis-6-hexadecenoic acid, lauric, capric and myristic acids 
have been shown to decrease S. aureus growth (Takigawa et al., 2005; 
Fischer et al., 2012; Bibel et al., 1992; Drake et al., 2008; Dayan and Wertz, 
2011; Kelsey et al., 2006). The mode of action of fatty acids against S. aureus 
is primarily via membrane disruption. A secondary mode of action has been 
reported, whereby incorporation of these fatty acids into the S. aureus 
membrane can enhance host immune response (Parsons et al., 2012; Nguyen 
et al., 2016). 
In the acidic pH of normal skin, ceramide production is optimal (pH 4.5-5.5) 
(Panther and Jacob, 2015; Rippke et al., 2002; Rippke et al., 2004) and 
colonisation of pathogens such as S. aureus and Streptococcus pyogenes is 
reduced (Grice and Segre, 2011; Whiting et al., 1996; Panther and Jacob, 
2015). Use of moisturisers with specific acidity can improve the pH of the skin 
and the skin flora and reduce AD flares (Rippke et al., 2002; Lee et al., 2016; 
Rippke et al., 2004). 
Creams containing oligosaccharides were found to increase S. epidermidis 
growth but they also increased S. aureus colonisation (Nodake et al., 2015; 
Hunt et al., 2012). This indicates the need to evaluate the effect of compounds 
and conditions against both S. aureus and S. epidermidis, in order to develop 
therapeutic schemes that target specifically S. aureus rather than the normal 




greater extent than S. epidermidis, due to differences in operon regulation 
(Moran et al., 2017). 
A previous study focused on external skin application of S. epidermidis, rather 
than compounds that favour the growth of skin commensals. Although they 
reported improvement in skin barrier integrity, a direct association with 
increase of S. epidermidis growth could not be proven (Nodake et al., 2015). 
Moreover, another study noticed inhibition of S. aureus colonisation and 
improvement of skin microbial balance after application of commensal 
Staphylococcus hominis strains from healthy people on AD lesional skin 
(Nakatsuji et al., 2017). 
Although previous research has examined the effect of various compounds 
and conditions on staphylococcal growth, most studies focused on the 
investigation of a single compound (Moran et al., 2017), or a single 
staphylococcal species (Kelsey et al., 2006) and the studies were performed 
mainly in vivo in healthy subjects or AD patients (Janssens et al., 2012; Di 
Nardo et al., 1998), or ex vivo in skin models (Berkers et al., 2018). This 
chapter involves the investigation of the growth conditions, phenotypic 
characterisation and susceptibility to various compounds for two S. aureus 
(USA300 and CS6-EEFIC) and two S. epidermidis strains (NCTC11047 and 
NCTC6513), in order to identify compounds that favour the growth of S. 
epidermidis over S. aureus. Defining conditions that rectify staphylococcal 
dysbiosis is a potential way to address the question as to whether dysbiosis 
drives AD. If AD resolves by rectifying dysbiosis, this would suggest that skin 




5.2.1. Characterisation of strain susceptibility to host 
molecules – MIC determination 
In order to investigate the differing susceptibility of S. aureus and S. 




(USA300 and CS6-EEFIC) and 2 S. epidermidis (NCTC11047 and 
NCTC6513) strains to a small panel of compounds were tested using broth 
microdilutions and determination of MICs. Arachidonic, linoleic and γ-linolenic 
acids were chosen, as they are essential skin barrier components. Cis-UCA, 
was also chosen, as it is found in the stratum corneum, plays an important 
role in AD and can reduce S. aureus colonisation (Berbis et al., 1990; 
Horrobin, 1993; Kaneko et al., 2008; Miajlovic et al., 2010; Peltonen et al., 
2014; Ong, 2012). 
The results of the MIC determination experiments were consistent and 
showed no difference in the susceptibility of the staphylococcal strains to any 
of the molecules tested (Table 5-1). Therefore, it is unlikely that imbalance in 
any of these components would be the main cause of skin imbalance between 
S. aureus and S. epidermidis populations. 
 
Table 5-1: MIC determination of S. aureus and S. epidermidis strains to lipid 
mediators 
The susceptibility of four staphylococcal strains against a panel of molecules was 













Arachidonic acid 64 64 64-128 128 
Cis-UCA > 256 > 256 > 256 > 256 
Linoleic acid > 512 > 512 > 512 > 512 
γ-linolenic acid 64 64 64 64 
 
5.2.2. Phenotypic characterisation 
Slant cultures of S. aureus USA300, S. aureus CS6-EEFIC, S. epidermidis 
NCTC11047 and S. epidermidis NCTC6513 were sent to Biolog for 
phenotypic microarray analysis, in order to identify the factors favouring or 
restricting the growth of S. epidermidis and S. aureus (Biolog Inc, c2019). 
Biolog investigated the metabolic pathways of the four staphylococcal strains 




sensitivity to various sources (carbon, nitrogen, phosphorus, sulfur) and 
antimicrobials with different mechanisms of action. If the phenotype was 
strongly positive in a well, the cells respired actively, reducing a tetrazolium 
dye to display a strong colour. If the phenotype was weak or negative, 
respiration was slowed or halted and the result was a reduction in colour. The 
redox assay provided both amplification and precise quantitation of 
phenotypes. Incubation and recording of phenotypic data were performed 
automatically by the OmniLog instrument. To compare the phenotypes of two 
cell lines, one was recorded as a red tracing and one as a green tracing. These 
graphs were then overlaid by the bioinformatic software to detect differences. 
Areas of overlap were coloured yellow, whereas differences were highlighted 
as patches of red or green (Figure 5-1). The OmniLog PM software in 
conjunction with the OmniLog PM system and phenotype microarray panels 
was used by Biolog in order to analyse the data, export them in a variety of 
raw and processed forms, and generate reports (Biolog Inc, c2019). 
 
 
Figure 5-1: Comparison of the phenotypes of two cell lines 
In order to compare the phenotypes of two cell lines, one is recorded as a red tracing 
and one as a green tracing. These graphs can then be overlaid and the areas of 
overlap are coloured yellow (Biolog Inc, c2019). 
 
The phenotype microarray panels that were tested are available on Biolog 
website (Biolog Inc, c2019). The preliminary results from the phenotypic assay 
are shown in Appendices and supplemental material, 8.5. The compounds 








Table 5-2: Compounds that favour S. epidermidis growth according to the 
phenotypic characterisation 
The following compounds were found to favour the growth of both S. epidermidis 
strains tested over both S. aureus strains. The underlined compounds were 
purchased to verify the results from the phenotypic characterisation with MICs. 
Compounds that favour S. epidermidis growth over S. aureus 
L-alanine D-alanine Met-Asp Leu-Met 
D-aspartic acid L-citrulline Ala-Ala Ala-Arg 
L-homoserine Leu-Ala Val-Leu Leu-Leu 
Ala-Phe Phe-Ala Leu-Pro Leu-Asp 
Met-Leu Ala-Lys Met-Met Gly-Phe 
Ala-Leu Ala-Pro Ala-Met Paromomycin 
Ala-Thr Arg-Ala Sodium m-arsenite Boric acid 
Asp-Leu Gly-Leu   
 
In order to verify these results, broth microdilutions and determination of MICs 
were performed for the underlined compounds of Table 5-2, using the four 
staphylococcal strains (S. aureus USA300, S. aureus CS6-EEFIC, S. 
epidermidis NCTC11047 and S. epidermidis NCTC6513). The culture medium 
that was used by Biolog was prepared, according to the information that was 
available on the website. This formula contained 100 mM NaCl, 30 mM 
triethanolamine HCI (pH 7.1), 5 mM NH4Cl, 2 mM NaH2PO4, 0.25 mM Na2SO4, 
0.05 mM MgCl2, 1 mM KCl and 0.01% (v/v) tetrazolium violet. Where a 
nitrogen source was tested, NH4Cl was omitted from the medium. However, 
media prepared in the laboratory failed to show staphylococcal growth. As an 
alternative, MHB-II was used and several concentrations were tested 
(Appendices and supplemental material, 8.5). Unfortunately, there was no 








The aim of this chapter was to investigate differences in S. aureus and S. 
epidermidis growth conditions (Otto, 2009; Laborel-Préneron et al., 2015; 
Kong et al., 2012; Otto, 2012; Nowicka and Grywalska, 2018). The ultimate 
goal was to identify compounds that can contribute to improvement of the skin 
microbial balance and skin barrier integrity, which are dysregulated in AD 
(Leung and Bieber, 2003; Hata and Gallo, 2008; Wollina, 2017; Salava and 
Lauerma, 2014) and evaluate whether restoration of the skin flora can improve 
AD. Although the phenotypic characterisation identified compounds that 
favour the growth of S. epidermidis over S. aureus, subsequent laboratory 
experiments were unable to reproduce these differences in susceptibility of S. 
aureus and S. epidermidis to host molecules and amino-acids. The fact that 
these results could not be reproduced under similar but not identical 
experimental conditions indicates the phenotypic similarities of S. aureus and 
S. epidermidis and the need for deeper investigation of differences in gene 
regulation. 
 
Staphylococcal susceptibility to host molecules 
The susceptibility of S. aureus and S. epidermidis to skin lipids and cis-UCA 
was tested using broth microdilutions and determination of MICs. Although it 
has been reported that cis-UCA can reduce S. aureus colonisation (Kaneko 
et al., 2008; Miajlovic et al., 2010), previous work failed to show the killing 
capacity of cis-UCA against S. aureus (Rinaldi et al., 2006). Regarding skin 
lipids, the susceptibility of S. aureus to cis-9, cis-12 linoleic acid and trans-10, 
cis-12 conjugated (bio-converted) linoleic acid has been tested, with MIC 
values ranging between 50-100 μg/mL unlike this thesis, which found MIC 
values > 512 μg/mL. However, these experiments used TSB for bacterial 
growth, which does not conform to CLSI standards (Cockerill et al., 2012) and 
ethanol as a solvent, which may be toxic for staphylococci (Kelsey et al., 
2006). In this thesis, sterile water was used as a solvent and MHB-II was used 
for bacterial growth, in accordance with the CLSI standards (Cockerill et al., 
2012), which strengthens the validity of the results. Other work has shown that 




aureus, when the compound is dissolved in DMSO and Luria-Bertani media is 
used (Young Shin et al., 2005), which is again not in line with the CLSI 
standards (Cockerill et al., 2012). Although the experimental conditions, the 
form of the compound and its solvent, as well as the S. aureus strain used 
may affect the outcome, it seems that these compounds are not candidates 
for selective S. aureus killing, as both S. aureus and S. epidermidis showed 
similar resistance to skin lipids and cis-UCA (Table 5-1).  
. 
Phenotypic characterisation 
Given that the compounds tested with broth microdilutions and determination 
of MICs did not show any difference in S. aureus versus S. epidermidis growth, 
a phenotypic assay was performed, which identified compounds that may 
show preferential growth of S. epidermidis over S. aureus (Table 5-2) (Biolog 
Inc, c2019). Most of these compounds were amino-acids (Table 5-2). Previous 
analyses of staphylococcal susceptibility to amino-acids is limited. One study 
reported that alanine can increase susceptibility of S. aureus to nisin (Chen et 
al., 2012). Another study found that L-aspartic acid and L-cysteine inhibited S. 
aureus biofilm formation (Yang et al., 2015). The medium used by Biolog was 
not sufficient for growth in subsequent tests, as further information such as 
the pH of the medium, temperature, incubation times, concentrations of the 
tested compounds and solvents used were not available. Therefore, different 
growth media were used but the results could not be reproduced. This may in 
part be attributed to the similarity of the S. aureus and S. epidermidis genome 
(Méric et al., 2015; Ghebremedhin et al., 2008), which results in many 
common phenotypic characteristics, such as growth conditions and suggests 
the need for investigation of the conditions that differently affect 
staphylococcal gene expression, colonisation and virulence.  
 
Suggestions for further research 
Enhancement or inhibition of staphylococcal growth by a compound may be 
optimal under specific conditions. It may be preferable to perform growth 




staphylococcal growth over time. Also, testing various conditions such as 
different pH, temperatures or concentrations of a compound may be useful in 
order to identify whether molecules such as skin lipids or compounds identified 
by phenotypic characterisation can enhance S. epidermidis growth. Using 
minimal media might also show a more profound difference between S. 
epidermidis and S. aureus growth in the presence of these compounds. As 
the killing potency of compounds can be affected by time and concentration 
(Knapp and Melly, 1986), another suggestion is to perform competition 
assays, in which both S. epidermidis and S. aureus are exposed together to a 
compound and use appropriate controls in order to evaluate staphylococcal 
growth with and without the presence of the compound. This experiment could 
also test whether a compound can increase the ability of one strain to 
dominate over the other. 
Also, if there are indications that a compound has a beneficial effect for S. 
epidermidis or an inhibitory effect for S. aureus, it may be preferable to test 
this effect on 3D skin equivalent models that mimic healthy and AD skin, which 
could provide further information regarding staphylococcal growth and skin 
barrier integrity. The use of 3D skin equivalent models in order to study the 
effect of skin microbiome on the skin barrier has been proposed in the past 
and has several benefits (Popov et al., 2014; Rademacher et al., 2018). A skin 
equivalent is a simulation of the skin structure, with a differentiated and 
stratified epidermal layer. The environment can be easily modified according 
to study objectives and no major ethical issues arise (Rademacher et al., 
2018). Previous research has also used skin equivalents in order to study the 
colonisation and interaction of S. epidermidis with skin (Holland et al., 2008), 
as well as the effect of S. aureus virulence factors on skin molecules, such as 
tight junction proteins (Popov et al., 2014; Basler et al., 2017). 
 
In conclusion, there is a lot of ongoing research on methods to restore skin 
microbial balance and skin barrier integrity and improve AD. Some 
researchers investigated compounds such as skin lipids (Fischer et al., 2012; 
Takigawa et al., 2005), or conditions such as the pH (Lee et al., 2016), 




2015) to enhance skin commensal bacteria. This project took into account the 
fact that S. epidermidis and S. aureus have many similarities (Méric et al., 
2015) and the need to selectively enhance S. epidermidis and inhibit S. aureus 
growth and investigated compounds that favour S. epidermidis over S. aureus 
with phenotypic characterisation and MIC determination. Although 
compounds that favour S. epidermidis over S. aureus growth under some 
conditions in vitro were detected, further research is needed in order to 
confirm their effect and further test them in vivo. Defining conditions that rectify 
staphylococcal dysbiosis may help elucidate whether dysbiosis drives AD. If 
AD improves by restoring the skin microbial balance, this would suggest that 





A diverse array of factors has been implicated in the pathogenesis of AD, 
including genetic predisposition, environmental factors, skin barrier integrity, 
immune response and the skin microbiome (McPherson, 2016; Thomsen, 
2014). However, it has not yet been established whether any of these factors 
is the driving cause of AD and which factors might be secondary causes or 
indeed consequences of AD (McPherson, 2016; Salava and Lauerma, 2014; 
Thomsen, 2014). A deeper understanding of the association of these factors 
with AD, including the role of microbial dysbiosis in the immune response and 
inflammation of the skin, will contribute to the development of more targeted 
and effective treatments. 
This project investigated the differential effect of S. aureus and S. epidermidis 
on keratinocytes, in order to clarify how the skin reacts to commensals and 
bacteria commonly involved in infection (Otto, 2009; Otto, 2012; Bouvet et al., 
2017). It also attempted to identify compounds that favour the growth of S. 
epidermidis over S. aureus, based on the assumption that enhancing skin 
commensals and rectifying the skin microbial balance could improve AD, 
which would indicate that the skin microbiome might be a key factor in AD 
pathogenesis. 
The results of the thesis showed a clear difference in the effect of S. aureus 
and S. epidermidis on HBD-3 production in keratinocytes, as HBD-3 was 
uniquely induced by S. aureus (Figure 3-1, Figure 3-3, Figure 3-6 and Figure 
3-8). By contrast, induction of HBD-2 and LL-37 was similar for S. epidermidis 
and S. aureus (Figure 3-1, Figure 3-5 and Figure 3-6). The normal skin flora 
consists mainly of S. epidermidis (Prescott et al., 2017; Otto, 2009; Otto, 
2012), whereas S. aureus is a leading cause of skin infections (Tong et al., 
2015; Kong et al., 2012; Otto, 2013; Bouvet et al., 2017). HBD-3 is considered 
to be more potent against S. aureus compared to other AMPs (Joly et al., 
2004; Midorikawa et al., 2003; Kisich et al., 2008). It therefore appears that 
the skin has evolved not only an effective strategy for defending itself against 
S. aureus (HBD-3 production), but also a means of triggering this response 
specifically to non-commensal staphylococci by detecting a cell component 




Identifying the S. aureus factor(s) that induce HBD-3 production in 
keratinocytes is of great importance in order to further investigate the 
mechanism of the different skin response to commensals and bacteria 
commonly involved in infection, such as S. aureus (Tong et al., 2015; Kong et 
al., 2012; Otto, 2013; Bouvet et al., 2017). Moreover, given the fact that S. 
aureus is the most common pathogen in AD (Baldry et al., 2018), it will help 
to explain the changes and defects of the pathways that result in reduced 
HBD-3 production in AD and to better understand why many AD patients 
inadequately control S. aureus infections. This knowledge could in turn 
contribute to the development of approaches to restore these defects and 
amplify HBD-3 expression, with a view to increasing skin defence and 
reducing infection. 
All S. epidermidis strains tested failed to induce HBD-3 (Figure 3-3, Figure 3-6 
and Figure 3-8). Results presented showed that S. epidermidis is unlikely to 
produce factor(s) that actively inhibit HBD-3 keratinocyte production (Figure 
3-10), further pointing to the existence of S. aureus-specific HBD-3-inducing 
factor(s). It is not yet known whether there are one or more S. aureus factors 
that induce HBD-3 in keratinocytes. This project found that there is at least 
one essential proteinaceous factor that acts as an inducer of HBD-3 
production (Figure 4-9) and detected candidate inducer proteins in the S. 
aureus supernatant using LC-MS (Table 4-2, Table 4-3, Table 4-5 and Table 
4-6). Further tests to identify the HBD-3-inducing proteins were promising but 
not conclusive and more research is required in order to identify the S. aureus 
HBD-3-inducing factor(s). The ion-exchange chromatography successfully 
produced fractions of S. aureus supernatant. The improved LC-MS method 
that was utilised in the latter stages of the project should assist in this 
endeavour, since it proved capable of identifying a considerably greater 
number of proteins in the fractions tested. However, this also created the need 
to reduce the number of proteins contained in each fraction, e.g. by optimising 
the experimental conditions and increasing the protein concentration in the 
fractions to allow a second fractionation step, or by heating the S. aureus 
supernatant before fractionation to remove heat-unstable proteins, since the 




This project also found that the S. aureus agr mutant strain (NE1532) induced 
higher HBD-3 in keratinocytes, whereas S. aureus strains with increased Agr 
activity (WV1 and NE1109) induced lower HBD-3 compared to the parental 
strains (Figure 4-1). These results suggest that HBD-3 may be mainly 
expressed during the initial colonisation stage of S. aureus, when the Agr 
system is inactive, whereas subsequent Agr activation, which increases the 
expression of host-damaging factors (Wang and Tom, 2016; Boles and 
Horswill, 2008), may possibly downregulate the expression of HBD-3-inducing 
factors or activate factors that degrade HBD-3 or the HBD-3-inducing 
factor(s). This observation proposes that the skin may have developed a 
means of activating the potent anti-S. aureus HBD-3 (Joly et al., 2004; 
Midorikawa et al., 2003; Kisich et al., 2008) in response to S. aureus 
components produced in the early stages of staphylococcal colonisation 
(Wang and Tom, 2016; Jenkins et al., 2015), to prevent further skin damage. 
It may be suggested that subsequent activation of the S. aureus Agr system 
after establishment of colonisation (Le and Otto, 2015), can possibly 
downregulate the HBD-3-inducing factor(s), to allow the bacterium to counter 
this HBD-3 response, evade the skin defence and spread to other host sites. 
In order to investigate whether the ability to induce HBD-3 production in 
keratinocytes is universal to all S. aureus strains, 30 clinical isolates were 
screened in total. Τhe majority of S. aureus strains induced production of 
HBD-3 in keratinocytes (Figure 3-6 and Figure 3-11), though 3 out of 30 
clinical strains tested (1128, 805 and 602) did not (Figure 3-13). The S. aureus 
CS6-EEFIC strain induced very low HBD-3 compared to the rest of the strains 
(Figure 3-13). Failure to induce is probably due to the absence of the HBD-3-
inducing factor(s) but could potentially also result from the degradation of 
HBD-3. These strains are all successful AD isolates (O'Neill et al., 2004; 
O'Neill et al., 2007a; O'Neill et al., 2007b). Previous research speculated that 
their success could be attributed to their toxin profile and antibiotic resistance 
(Stobberingh et al., 2012; O'Neill et al., 2007a; O'Neill et al., 2007b). However, 
the results presented in this thesis suggest that these strains are successful 
AD clones due to their ability to evade the main anti-S. aureus HBD-3 
response in the skin (Figure 3-13 and Figure 3-14) (Dejean et al., 2012; 




considerable proportion failed to induce (4 out of a total of 9 AD isolates 
tested) (Figure 3-11). Such strains are expected to be more likely to cause 
AD, since they can evade important host immune mechanisms (HBD-3 
production). 
Expression of HBD-3 is generally increased in AD compared to healthy skin 
but the increase is lower compared to other inflammatory diseases (e.g. 
psoriasis), due to increased Th2 cytokine levels (Clausen et al., 2018; Harder 
et al., 2010; Clausen et al., 2016; Jin et al., 2014; Schonthaler et al., 2013). 
Previous research has found that other AMPs (HBD-2, psoriasin) are 
increased in lesional AD skin compared to healthy skin, whereas HBD-3 is 
found mainly in non-lesional AD skin (Clausen et al., 2018). Moreover, 
keratinocytes of AD patients have shown reduced ability to mobilise HBD-3 
upon S. aureus stimulation compared to keratinocytes from healthy skin 
(Kisich et al., 2008). These findings suggest that HBD-3 may play an important 
role in AD, with reduced HBD-3 resulting in increased disease severity. This 
project found that HBD-3 production in response to S. aureus HBD-3-inducing 
factor(s) was reduced when IL-4 concentration increased in keratinocytes 
(Figure 3-15). Although this is a preliminary observation which requires further 
research, it is in line with the findings of this thesis regarding the role of HBD-3 
in skin defence against S. aureus, as AD is characterised by failure to 
effectively counter S. aureus infection (Baldry et al., 2018; Chiu et al., 2009; 
David and Cambridge, 1986) and the AMP levels in AD do not seem to 
correspond to the degree of inflammation (Hata and Gallo, 2008; Ong et al., 
2002; Nomura et al., 2003b; Lin et al., 2007). The inadequate immune 
response in AD may be caused by the absence of induction of HBD-3 by S. 
aureus or by the inability of the immune system to initiate effective HBD-3 
expression. 
This thesis proposed two approaches in order to correct dysbiosis, restore the 
normal skin flora and improve the skin defence against pathogens. The first 
approach refers to amplifying the host immune response and mainly the 
HBD-3 response against S. aureus, as analysed above. The second approach 
refers to favouring the growth of skin commensals. Phenotypic 
characterisation (Morandi et al., 2009) is a sensible method in order to study 




skin commensal (Prescott et al., 2017; Otto, 2009; Otto, 2012) and S. aureus, 
which is commonly implicated in skin infections (Tong et al., 2015; Kong et al., 
2012; Otto, 2013; Bouvet et al., 2017) and identify compounds that favour 
colonisation of S. epidermidis over S. aureus (Table 5-2). This could contribute 
to the development of therapeutic techniques that enhance the growth of skin 
commensals and restore the skin microbial flora. 
Overall, the data in this thesis have shown that S. aureus and S. epidermidis 
have different effects on the production of HBD-3 by keratinocytes and 
suggest that the skin may have developed mechanisms to selectively express 
HBD-3 upon exposure to S. aureus by detecting components unique to this 
bacterium. This may indicate the skin’s ability to selectively initiate immune 
response against non-commensals by detecting specific components. 
After identification of the HBD-3-inducing factor(s) of S. aureus, exogenous 
introduction of the encoding gene(s) to S. epidermidis would further confirm 
the function. Another suggestion for future research is the construction of S. 
aureus mutant strains with deletion of the gene encoding the HBD-3-inducing 
factor(s) or development of an inhibitor of the protein product(s) (Bae and 
Schneewind, 2006; Wright and Nair, 2012). This will help to examine whether 
more than one molecule can induce HBD-3 and if there is a main 
HBD-3-inducing factor along with other secondary factors. Pathways of HBD-3 
induction by external pathogens have been described (Sorensen et al., 2005; 
Lai et al., 2010; Wanke et al., 2011). Identification of the S. aureus 
HBD-3-inducing factor(s) and expression patterns may help to define whether 
S. aureus strains that do not induce HBD-3: do not produce the corresponding 
factor(s); produce factors that may degrade HBD-3 or the HBD-3-inducing 
factor(s) in order to evade the host’s immune system; or are too toxic and 
render keratinocytes unable to respond. This may explain why some S. aureus 
strains are more likely to be implicated in AD and other inflammatory diseases 
(Moriwaki et al., 2019) and why the skin reacts differently to commensal 
bacteria, such as S. epidermidis. 
The skin microbiome plays an important role in skin defence (Prescott et al., 
2017; Zipperer et al., 2016; Nakatsuji et al., 2017; Hannigan and Grice, 2013). 




if restoration of the skin flora can improve the symptoms, then this will further 
verify the key role of the skin microbiome in skin defence and AD 
pathogenesis. This will help to develop more effective therapeutic approaches 
for AD, such as cream preparations containing analogues of the 
HBD-3-inducing factor(s) in order to boost the HBD-3 production and the skin 
immune response, or compounds that favour the growth of skin commensals 
(S. epidermidis) at the expense of S. aureus, in order to enhance skin 
microbial balance and avoid the overuse of antibiotics and the side-effects of 
current treatments (Nowicki et al., 2015; Megna et al., 2016; Hong et al., 
2011). The ultimate aim is to improve the quality of life of patients suffering 
from AD (McPherson, 2016) and potentially other diseases characterised by 
skin microbial imbalance, such as immunodeficiencies and diabetes mellitus 
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8. Appendices and supplemental material 
8.1. Suppliers of the products used in the study 
Supplier Location 
Appleton Woods Birmingham B38 8SE, UK 
Beckman-Coulter Genomics Bishop's Stortford CM22 6TA, UK 
BEI Resources Manassas 20110-2209 Virginia, USA 
Berthold Technologies Harpenden AL5 4UT, UK 
Bibby Scientific Stone ST15 0SA, UK 
Biolegend London NW5 1LB, UK 
Biolog, Inc Hayward 94545 California, USA 
Bio-rad Watford WD17 1ET, UK 
Camlab Cambridge CB24 5WE, UK 
Delta-Lab Barcelona 08191, Spain 
EdgeBio San Jose 95131 California, USA 
Eppendorf Stevenage SG1 2FP, UK 
Eurofins Ebersberg 85560, Germany 
Expedeon 
GE Healthcare 
Cambridge CB24 5QE, UK 
Amersham HP7 9NA, UK 
Hycult Biotech Cambridge CB23 8SQ, UK 
Implen Munich 81829, Germany 
Lonza Castleford WF10 2JT, UK 
Merck Watford WD18 8YH, UK 
MyBiosource San Diego 92195-3308 California, USA 
New England Biolabs Hitchin SG4 0TY, UK 
Oxoid Basingstoke RG24 8PW, UK 
Peprotech London W6 8LL, UK 
Pro Lab Diagnostics Birkenhead CH62 3QL, UK 
Promega Fitchburg 53711 Wisconsin, USA 
PromoCell Heidelberg 69126, Germany 
Public Health England Salisbury SP4 0JG, UK 
Qiagen Manchester M15 6SH, UK 
Sapphire Manchester M15 6SH, UK 
Sarstedt Leicester LE4 1AW, UK 
Sigma-Aldrich Gillingham SP8 4XT, UK 
Terumo Prescot L34 9GT, UK 
Thermo-Fisher Scientific Paisley PA4 9RF, UK 




8.2. Gram staining, pastorex test and MIC 
determination 
8.2.1. Gram staining 
During Gram staining (Pro Lab Diagnostics), a drop of sterile water was placed 
on a slide with a sterile loop. A single staphylococcal colony from a TSA plate 
was picked up with the loop and stirred in the drop of water. The slide was 
air-dried, passed several times through a flame (heat fixation) and then placed 
on a staining tray. Initially, the fixed smear was flooded with crystal violet 
solution for 1 min. The slide was rinsed with tap water and was then flooded 
with iodine solution. After 1 min, it was rinsed again with water. Acetone 
(Sigma-Aldrich) was poured on the slide and after 2-3 s it was rinsed with 
water. Then, the slide was flooded with carbol fuchsin solution for 30 s, rinsed 
with water and dried on absorbent paper. Finally, the slide was examined 
under a microscope using oil-immersion (Sigma-Aldrich). Gram-positive 
bacteria retain the crystal violet dye, whereas Gram-negative bacteria are 
stained red (Matheson, 1999). 
 
8.2.2. Pastorex test 
The manufacturer’s protocol was followed (Bio-rad). Briefly, one drop of latex 
test and one of negative control latex reagent were applied onto an 
agglutination card. A single colony of the test culture on a loop was mixed into 
each of the drops. Catalase-positive colonies can be discriminated by this 
method as they form aggregates in the latex test (Bio-rad). 
 
8.2.3. Broth microdilutions and MIC determination 
The MIC protocol was followed according to the CLSI guidelines (Cockerill et 
al., 2012). Briefly, a doubling dilution series of the compound to be tested was 
prepared. The most concentrated stock was at 10X the final required 
concentration. Then, 10 μL was added to wells of a flat-bottomed 96-well plate 




determined using OD625 nm. Cells were diluted in MHB-II to achieve a cell 
number of ~ 5 x 105 CFU/mL. Then, 90 μL of the diluted culture was added to 
each compound-containing well. The edge of the plate was sealed with 
parafilm and the plate was incubated at 37°C with agitation on a Heidolph 
Inkubator 1000 for 16-18 h. MICs were determined by evaluation of turbidity 
of the wells with constantly increasing concentration of the tested compound. 
 
 
8.3. Oligonucleotide primers used in this study 
Primers for verification of staphylococcal strains 
before phenotypic characterisation 
Primer Sequence (5' → 3') Comments 
F3, S. aureus rpoB 
forward 
AGTCTATCACACCTCAACAA 
~ 600 bp amplicon 
from S. aureus 
(Aubry-Damon et al., 
1998) 
F4, S. aureus rpoB 
reverse 
TAATAGCCGCACCAGAATCA 




~ 250 bp amplicon 
from S. epidermidis 
(Work conducted by 
Dr Liam Sharkey) 






8.4. Liquid chromatography-mass spectrometry 
8.4.1. Initial LC-MS – Protein Identification (PTM mapping) 
In-solution digestion 
Dithiothreitol was added to a final concentration of 10 mM and heated to 56°C 
for 30 min with shaking. The Eppendorf was left to cool before adding 
Primers for verification of S. epidermidis skin-isolated strains 
Primer Sequence (5' → 3') Comments 




~ 600 bp amplicon 
from S. epidermidis 
(Eurofins) 








iodoacetic acid to a final concentration of 55 mM and incubated at room 
temperature in the dark for 30 min with shaking. Trypsin solution (20 ng/µL in 
25 mM ammonium bicarbonate) was added to a 1:50 ratio (protease:total 
protein content). The samples were incubated at 37°C with shaking for 18 h. 
The digest reaction was stopped by adding 5 µL of 1% formic acid. 
 
Sep-Pak C18 Purification 
The Sep-Pak column was equilibrated with 1 mL acetonitrile followed by 1 mL 
0.1% trifluoroacetic acid. Then, 500 µL 0.1% trifluoroacetic acid was added to 
the peptide digest, this mix was passed through the column. The column was 
washed with 1 mL 0.1% trifluoroacetic acid. Peptides were then eluted from 
the column with 500 µL 50% acetonitrol, 50% water, 0.1% formic acid. The 
eluant was dried by vacuum centrifugation. The peptides were reconstituted 
in 20 µL 0.1% aqueous trifluoroacetic acid.  
 
Liquid chromatography-mass spectrometry 
Liquid chromatograph separation of the peptide mixtures was performed on 
an ACQUITY M-Class UPLC (Waters UK, Manchester). Firstly, 1 µL of each 
sample was loaded onto a Symmetry C18 trap column (180 µM i.d. * 20 mm) 
and washed with 1% acetonitrile/0.1% formic acid for 5 min at 5 µL/min. After 
valve switching, the peptides were then separated on a HSS T3 C18, 75 µm 
i.d. x 150 mm analytical column (Waters UK, Manchester) by gradient elution 
of 1-60% solvent B in A over 30 min. at 0.3 µL/min. Solvent A was 0.1% formic 
acid in water, solvent B was 0.1% formic acid in acetonitrile. 
The column eluant was directly interfaced to a Xevo G2-XS Q-TOF mass 
spectrometer via a Z-spray nanoflow electrospray source. The MS was 
operated in positive TOF mode using a capillary voltage of 3.0 kV, cone 
voltage of 40 V, source offset of 80 V, backing pressure of 3.58 mbar and a 
trap bias of 2 V. The source temperature was 80°C. Argon was used as the 
buffer gas at a pressure of 8.6 × 10-3 mbar in the trap and transfer regions. 
Mass calibration was performed using [Glu]-fibrinopeptide (GFP) at a 




with a 1 s lock spray scan taken every 30 s during acquisition. Ten scans were 
averaged to determine the lock mass correction factor. Data acquisition was 
using data dependent analysis with a 0.2 s scan MS over m/z 350-2000 being 
followed by five 0.5 s MS/MS taken of the five most intense ions in the MS 
spectrum. CE applied was dependent upon charge state and mass of the ion 
selected. Dynamic exclusion of 60 s was used. Data processing was 
performed using the MassLynx v4.1 suite of software supplied with the mass 
spectrometer. Peptide MS/MS data were processed with PEAKS Studio 
(Bioinformatic Solutions Inc, Waterloo, Ontario, Canada) and searched 
against the Uniprot database for Staphylococcus aureus. 
Carbamiodomethylation was selected as a fixed modification, variable 
modifiacations were set for oxidation of methionine and deamidation of 
glutamine and asparagine. MS mass tolerance was 15 ppm, and fragment ion 
mass tolerance was 0.05 Da. The false discovery rate was set to 1% and only 
proteins with 3 or more unique peptides were reported. 
 
8.4.2. Improved sensitivity LC-MS 
Protein Digest Method: S-Trap micro ultra-high recovery protocol 
First, 12.5 µL SDS solubilisation buffer (10% SDS, 100 mM triethylammonium 
bicarbonate TEAB, pH 7.55) was added to 12.5 µL lysate sample. To reduce 
the proteins DTT was added to a final concentration of 20 mM then incubated 
for 10 min at 95°C. Samples were allowed to cool to room temperature before 
adding iodoacetamide to a final concentration of 40 mM and incubated for 30 
min at 20°C to alkylate the proteins. 4 µL of 12% phosphoric acid were then 
added to aid protein trap binding. 165 µL S-trap protein binding buffer (90% 
aqueous methanol containing a final concentration of 100 mM TEAB, pH 7.1) 
was added to the S-Trap micro column. 1 µg trypsin was added to the acidified 
sample and immediately mixed by pipetting up and down. The acidified lysate 
plus trypsin was immediately transferred to S-Trap binding buffer within the 
spin again by mixing up and down. The micro column was placed in a 2 mL 
tube for flowthrough and centrifuged at 4,000 x g until the sample had passed 




the protein-trapping matrix of the spin column. The captured protein was 
washed by adding 150 µL S-Trap protein binding buffer, before being 
centrifuged at 4,000 x g for 1 min. This was step was repeated three times 
whilst rotating the S-Trap micro column 180oC between centrifugations. 0.5 
µg of trypsin in 25 µL of 50 mM TEAB, pH 8 to the top of the protein trap. The 
column was capped loosely and incubated in a clean 1.5 mL tube for 1 h at 
47°C without shaking. Peptides were eluted with 40 µL each of 50 mM TEAB 
added to the trypsin solution and then centrifuged at 4,000 x g. Further elution 
rounds added 40 µL 0.2% aqueous formic acid, then 35 µL 50% acetonitrile, 
0.2% formic acid. Peptides were dried down and resuspended in 0.1% 
trifluoroacetic acid for MS analysis. 
 
Liquid chromatography-mass spectrometry 
Liquid chromatography separation of the peptide mixtures was performed on 
an ACQUITY M-Class UPLC (Waters UK, Manchester). Initially, 1 µL of each 
sample was loaded onto a Symmetry C18 trap column (180 µM i.d. * 20mm) 
and washed with 1% acetonitrile/0.1% formic acid for 5 min at 5 µL/min. After 
valve switching, the peptides were then separated on a HSS T3 C18, 75 µm 
i.d. x 150 mm analytical column (Waters UK, Manchester) by gradient elution 
of 1-60% solvent B in A over 30 min. at 0.3 µL/min. Solvent A was 0.1% formic 
acid in water, solvent B was 0.1% formic acid in acetonitrile. The column 
eluant was directly interfaced to a quadrupole orthogonal time of flight mass 
spectrometer (Xevo QTOF G2-XS, Waters UK, Manchester) via a Z-spray 
nanoflow electrospray source. The MS was operated in positive TOF mode 
using a capillary voltage of 3.0 kV, cone voltage of 40 V, source offset of 80 
V. The source temperature was 80°C. Mass calibration was performed using 
[Glu]-fibrinopeptide (GFP) at a concentration of 250 fmolµL. GFP was also 
used as a lock mass calibrant with a 1 s lock spray scan taken every 30 s 
during acquisition. Ten scans were averaged to determine the lock mass 
correction factor. Data acquisition was using data dependent analysis with a 
0.2 s scan MS over m/z 350-2000 being followed by five 0.5 s MS/MS (m/z 
50-2000) taken of the four most intense ions in the MS spectrum. CE applied 




exclusion of 60 s was used. Data processing was performed using the 
MassLynx v4.1 suite of software supplied with the mass spectrometer. Peptide 
MS/MS data were processed with PEAKS Studio (Bioinformatic Solutions Inc, 
Waterloo, Ontario, Canada) and searched against the Uniprot database, with 
entries confined to Staphylococcus aureus. Carbamiodomethylation was 
selected as a fixed modification, variable modifiacations were set for oxidation 
of methionine and deamidation of glutamine and asparagine. MS mass 
tolerance was 20 ppm, and fragment ion mass tolerance was 0.05 Da. The 
false discovery rate was set to 1% and only proteins with 3 or more unique 
peptides were reported. 
 
 
8.5. Phenotypic characterisation 
8.5.1. Susceptibility determination of S. aureus and S. 
epidermidis 
The susceptibility of the four staphylococcal strains (S. aureus USA300 and 
CS6-EEFIC and S. epidermidis NCTC11047 and NCTC6513) for the 
compounds identified by Biolog was examined using broth microdilutions and 
MIC determination. These compounds were tested in a 2-fold series of 
dilutions, starting from the highest concentration in which each compound is 
soluble, as shown below. 
Compound Final concentration range 
D-alanine 50 mg/mL - 1.5625 mg/mL 
L-alanine 50 mg/mL - 1.5625 mg/mL 
L-citrulline 50 mg/mL - 1.5625 mg/mL 
L-homoserine 50 mg/mL - 25 mg/mL 
Phe-Ala 50 mg/mL - 25 mg/mL 
Leu-Ala 50 mg/mL - 6.25 mg/mL 
Ala-Phe 5 mg/mL - 0.0049 mg/mL 





8.5.2. Phenotypic characterisation: preliminary results 
The data presented were produced during the phenotypic characterisation of 
S. aureus USA300, S. aureus CS6-EEFIC, S. epidermidis NCTC11047 and 




























C) S. aureus CS6-EEFIC (green) versus S. aureus USA300 (red) 
 
 
 
